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CHAPTER 1: INTRODUCTION 
It has been said that vaccination is one of the most effective medical discoveries ever (1). 
Some estimates show that each year vaccination prevents 2.5 million deaths worldwide (2). The 
success of vaccines is most profoundly illustrated in a recent study, which showed dramatic 
decreases or complete elimination of common infectious diseases in the post-vaccine era that 
induced a great burden in the pre-vaccine era (Figure 1.1) (3). Some diseases have been 
completely eliminated, such as polio and smallpox, and others have seen >90% reduction in 
morbidity, including measles, hepatitis, and chickenpox. 
The birth of vaccination began in the late 1700s when Edward Jenner used pustules from 
cows with cowpox to protect humans from the closely related smallpox (2). Cowpox induced 
disease in humans, albeit not nearly as severe as smallpox and more importantly protected 
humans from getting smallpox. Vaccines have evolved greatly since then. Later, it became 
common practice to inactivate microorganisms that caused a disease and inject them into humans 
to induce an effective immune response. Although these vaccines were effective, they exhibited 
high reactogenicity and inflammation at the injection site (4). Recent breakthroughs in 
vaccinology have allowed for development of a new generation of vaccines. These 
breakthroughs include viral propagation in cell culture, the use of recombinant expression 
systems to produce large quantities of antigen, and the utilization of novel adjuvants and delivery 
systems to amplify the immune response (5-7). These new generation vaccines are also enabling 
the delicate balance between safety and efficacy. In other words, the primary objective of any 
vaccine going to market today is to increase the immunogenicity without compromising safety.  
A well-studied strategy to augment the immunogenicity of vaccines while maintaining 
safety is to encapsulate pathogen-specific antigens into biodegradable delivery vehicles. This 
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helps ensure that the antigen interacts with cells internalizing the delivery vehicle. In particular, 
synthetic biodegradable polymers, such as polyanhydrides, have shown to be promising 
candidates as both vaccine adjuvants and as vehicles to deliver antigen to immune cells (8-11). 
This is because micro- or nanoparticles synthesized from these polymers serve as antigen carriers 
that stabilize their payload, while providing a controlled release for sustained antigen persistence 
(12). Simultaneously they present molecular patterns that enhance the adjuvanticity and enable 
immunomodulation (13).  
An alternative method to enhance the immunogenicity of vaccines is to actively target 
antigen presenting cells (APCs). Current vaccines on the market do not target cells (13). 
However, many active targeting techniques under development rely on targeting pattern 
recognition receptors (PRRs), such as C-type lectin receptors or Toll-like receptors (14). PRRs 
are an important part of the innate immune systems that recognize conserved molecules from 
pathogens called pathogen-associated molecular patterns (PAMPs) (14). They are convenient to 
target because they are usually expressed on the surface or in the endosome of APCs and other 
immune cells, such as macrophages, B cells, and T cells. This makes them easily reachable with 
appropriately designed delivery systems (15; 16). Indeed, there have been numerous studies to 
determine the signaling pathways and outcomes of targeting PRRs (17; 18).  
The overall goal of this thesis is to integrate active targeting of CLRs with the 
polyanhydride nanovaccine delivery platform to enable the design of targeted nanovaccines 
against respiratory pathogens, in particular, influenza A virus.  
1.1 References 
1. Jones KS. 2008. Biomaterials as vaccine adjuvants. Biotechnology progress 24:807-14 
2. De Gregorio E, Rappuoli R. 2014. From empiricism to rational design: a personal perspective 
of the evolution of vaccine development. Nature reviews. Immunology 14:505-14 
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4. Bachmann MF, Jennings GT. 2010. Vaccine delivery: a matter of size, geometry, kinetics and 
molecular patterns. Nature reviews. Immunology 10:787-96 
5. Wong SS, Webby RJ. 2013. Traditional and new influenza vaccines. Clinical microbiology 
reviews 26:476-92 
6. Ulmer JB, Valley U, Rappuoli R. 2006. Vaccine manufacturing: challenges and solutions. 
Nature biotechnology 24:1377-83 
7. Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM. 2006. Expression and 
purification of an influenza hemagglutinin--one step closer to a recombinant protein-based 
influenza vaccine. Vaccine 24:2176-85 
8. Kipper MJ, Shen E, Determan A, Narasimhan B. 2002. Design of an injectable system based 
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10. Huntimer L, Wilson Welder JH, Ross K, Carrillo-Conde B, Pruisner L, et al. 2013. Single 
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promotes high titer and avid antibody responses. Journal of biomedical materials research. 
Part B, Applied biomaterials 101:91-8 
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platform for vaccine delivery. Advanced healthcare materials 2:369-78 
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selective expression of TLR3 in dendritic cells. Journal of immunology 164:5998-6004 
17. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. 2007. Dendritic-cell immunotherapy: 
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1.2 Figures 
 
Figure 1.1 Vaccines have contributed to a dramatic reduction of some of society’s worst 
diseases. Reprinted from (3). 
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CHAPTER 2: LITERATURE REVIEW  
This chapter summarizes the major advancements made in the fields of polymeric 
vaccine delivery systems (Section 2.1) and targeted delivery systems (Section 2.2). This review 
summarizes the wide array of polymers that have been used as delivery vehicles, including 
polyesters, polyanhydrides, natural based polymers, and liposomes. A number of techniques 
have been used to actively target drugs and vaccines to cells or tissues, and these are 
comprehensively reviewed herein. The chapter concludes with a discussion on the influenza 
virus and the design of novel vaccines against influenza (Section 2.3). New generations of 
influenza vaccines are on the horizon and they often utilize delivery systems as well as active 
targeting mechanisms to provide enhanced protection from the virus. 
2.1 Polymeric Vaccine Delivery Systems 
2.1.1 Introduction 
Biodegradable micro- and nanoparticles for vaccine delivery can be synthesized from a 
number of building blocks including proteins, polysaccharides, or synthetic polymers (1). They 
can function effectively as vehicles to deliver antigen and their unique properties can also impart 
adjuvant-like characteristics that enhance the resulting immune response. 
The in vivo performance of nanomedicines is a function of their hydrophobicity, surface 
modification, surface charge, and particle size (2). Hydrophobicity has two important roles. It 
influences the rate of payload release from the nanoparticles and it affects the in vivo circulation 
time of the nanoparticles. Biodegradable delivery vehicles that are hydrophobic inhibit water 
from penetrating into the polymer matrix, thus slowing down degradation and payload release. It 
has also been suggested that hydrophobicity is a “danger signal” to immune cells (3). However, 
hydrophobic particles are known to be rapidly opsonized and cleared by mononuclear phagocytic 
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cells (2). As a result, particles used for drug delivery requiring long circulation times generally 
have their surfaces conjugated with a more hydrophilic moiety, such as polyethylene glycol (4). 
Surface modification can be used to design particles to target a specific receptor on a cell, while 
surface charge can help particles interact with oppositely charge cellular membranes. It is well 
known that a positive surface charge is preferable as it is often shown to increase nanoparticle 
internalization (5). Nanoparticles with sizes below 1000nm have important properties for drug 
and vaccine delivery. They can penetrate capillaries and tissue gaps to reach their target organs. 
In particular, particles between 20-100nm have been shown to be optimal for entering the 
lymphatic system (6). They are subcellular in size, can be readily internalized, and still provide 
controlled release of drugs or antigen that ensure stability and improved utility (7).  
Drugs and antigens are either bound to the surface of delivery vehicles or encapsulated 
inside the vehicle (2). Both non-covalent adsorption and covalent attachment of drugs to the 
surface of vehicles have been reported (8-10). These systems have been shown to present 
particulate antigen to B cells, thus amplifying the humoral immune response. However, this 
approach has important limitations when compared to delivery vehicles that encapsulate 
antigens. First, the antigen is subjected to environmental conditions, which makes it susceptible 
to degradation. Second, the delivery vehicle releases its payload all at once, whereas 
encapsulated antigens tend to release their payload more gradually as the delivery vehicle 
degrades. A sustained release of antigen has been shown to be optimal to prime adaptive immune 
responses (11; 12). 
There are a number of techniques to characterize nano-based delivery vehicles. These 
include imaging techniques, such as scanning or transmission electron microscopy, which 
characterize the morphology and size of the delivery vehicle (13). Zeta potential experiments can 
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be used to measure the average surface charge of the delivery vehicle by analyzing the mobility 
of charged particles in response to an electric potential (14). Particle size and size distribution 
can be determined by dynamic light scattering, which analyzes the light scattered by the 
Brownian motion of the particles (14).  
Current research has shown that nanomedicines have the potential to serve as an excellent 
platform for the development of next generation vaccines (15; 16). In particular, several classes 
of nanomedicines derived from polyesters, polyanhydrides, natural polymers, and liposomes, are 
already in various stages of preclinical and clinical trials for both vaccine and drug delivery. 
These different polymeric chemistries are reviewed next. 
2.1.2 Polyesters 
Biodegradable polyesters first rose to prominence for biomedical applications in the early 
1970’s when researchers successfully demonstrated that these polymers were ideal for sutures 
and fibers (17). These aliphatic polyesters are thermoplastic and can be easily formed into a 
number of shapes. Early research demonstrated that polyesters exhibited great biocompatibility, 
low toxicity, and had predictable degradation rates leading to their approval by the U.S. Food 
and Drug Administration (FDA) for therapeutic uses in humans (18). These beneficial properties 
have been exploited since to make polyesters among the most attractive biomaterials for drug 
and vaccine delivery. 
Biodegradable polyesters are composed of lactic acid or glycolic acid monomers and 
copolymers thereof (i.e., poly(lactic-co-glycolic acid) or PLGA) (Table 2.1). Poly(lactic acid) 
(PLA) has a chiral α-carbon that in stereochemical terms is described as D or L and the 
enantiomer type can greatly affect the properties of the polymer.(19). Poly L-lactic acid is more 
crystalline while poly D-lactic acid has disordered polymer chains and so it is amorphous (19). 
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Poly(glycolic acid) (PGA) has no methyl groups and is also crystalline (Table 2.1). PLGA 
usually has an equal mixture of D- and L- lactic acid enantiomers (19). The polymers are 
synthesized using a ring-opening melt condensation reaction of lactide and glycolide cyclic 
dimers. Polymerization proceeds for 2-6 hours at 175°C in the presence of organotin catalysts 
(17). It is known that environmental humidity and the amount of free acid impurities in the melt 
significantly affect polymer synthesis (17). Both need to be at low levels to achieve high 
molecular weight polymers. Today, PLA, PGA, and various PLGA copolymers can be purchased 
commercially with a variety of molecular weights.  
In aqueous solutions, polyesters degrade by the hydrolysis of their ester linkages (Figure 
2.1) (20). This forms monomeric lactic acid or glycolic acid that can be safely metabolized 
through the Krebs cycle. Crystallinity and water uptake are important factors that influence the 
degradation rate. The methyl groups on PLA make it more hydrophobic than PGA, meaning they 
absorb less water (19). As a result PLA homopolymers have a slower degradation rate than 
PLGA or PGA. Generally increasing the GA content in PLGA increases the degradation rate of 
the copolymer. The one exception is 50:50 PLGA, which degrades the fastest. Polyesters also 
degrade more slowly in basic solutions compared to acidic solutions because their degradation is 
acid-catalyzed (21).  Polyesters are also known to undergo bulk erosion, in which the rate of 
hydration of water molecules diffusing into the polymer matrix is faster than polymer hydrolysis 
or solubilization (Figure 2.2) (20). This bulk erosion behavior makes PLGA erosion more 
unpredictable than surface eroding polymers. 
Polyesters are soluble in several solvents, including acetone, chlorinated solvents, and 
tetrahydrofuran, resulting in a number of methods to synthesize nano- or microparticles (19; 22). 
The most common technique to prepare polyester particles is the single emulsion solvent 
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evaporation technique (23). Polymer is dissolved in a volatile organic solvent while the drug or 
antigen usually has to be dispersed because it does not dissolve in organic solvents. This solution 
is emulsified in a large volume of water with the presence of a surfactant, such as polyvinyl 
alcohol or polysorbate-80 (13). The organic solvent is then evaporated inducing particle 
formation, upon which the particles are collected through centrifugation. Water-soluble drugs or 
antigens that don’t disperse well in organic solvents can be encapsulated into polyester 
nanoparticles through a double emulsion process (13). Here the polymer is again dissolved in the 
organic solvent; however, the antigen is dissolved in water and the two are mixed using rapid 
stirring to create an emulsion. This solution is then added to a large volume of water that 
contains a surfactant and is continuously emulsified. Evaporating the organic solvent results in 
nanoparticles. 
PLGA nanoparticles are efficiently internalized by phagocytic cells and deliver their 
payload to the lysosomal compartments of cells, through pathways independent of clathrin-
coated endocytosis (24; 25). Some researchers have reported that PLGA nanoparticles were 
efficient at escaping the endosome and making it to the cytoplasm (26). Similarly another study 
showed that ovalbumin (OVA) loaded PLGA particles stimulated dendritic cells to produce IL-2 
and led to sustained MHC presentation as compared to soluble antigen (27). This could 
potentially lead to better T cell responses in vaccine development. PLGA delivery systems have 
the capability to co-encapsulate antigen with other adjuvants so that both are internalized by the 
same cells (28). Polyesters have also been used to encapsulate nucleic acids and protect them 
from nucleases (29). However, due to their negative charge, nucleic acids do not disperse readily 
in the organic solvents during nanoparticle synthesis and so they are often complexed with 
cationic polymers to improve encapsulation efficiency. In one such study, researchers complexed 
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a cationic polymer with siRNA to enhance the encapsulation efficiency from 43% to 79% (30). 
Lastly, in addition to human vaccines, PLGA nanoparticles have been explored as oral delivery 
devices for fish (31).  
Perhaps the most significant detriment to PLGA-based delivery devices is that when they 
degrade, their acidic degradation products can be trapped in the polymer matrix, reducing the 
local pH of the medium to as low as 3 (32). This can result in hydrolysis of the encapsulated 
payload, particularly proteins (32; 33). Degraded proteins in vivo can have detrimental effects, 
including loss of activity or function. The acidic microenvironment has been alleviated by 
incorporating basic inorganic salts into the particles, such as magnesium hydroxide or sodium 
bicarbonate (32; 33). PLGA particles also tend to exhibit a burst release in the early stage of 
incubation with aqueous solutions. This is believed to be due to surface adsorbed or poorly 
encapsulated protein. 
Poly(ε-caprolactone) (PCL) is another aliphatic polyester that has been investigated for 
drug delivery applications (Table 2.1) (34). Unlike PLA or PGA, is has a very low glass 
transition temperature of about -60°C and a low melting point of 63°C. This makes melt 
encapsulation a feasible technique to form biomedical devices encapsulating proteins (35). In 
contrast, PLA, PGA, and their copolymers have glass transition temperatures that are above 
room temperature and melting points above 100°C (18). PCL degrades very slowly in water and 
is used for long-term drug delivery usually in excess of one year (36). This slow degradation can 
be advantageous as PCL degradation does not generate a locally acidic environment unlike 
PLGA degradation. If faster degradation rates are needed, PCL is sometimes formulated as a 
blend with PLGA and then synthesized to form nanoparticles (36). 
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2.1.3 Polyanhydrides 
The study of polyanhydrides as a platform for drug delivery originated in the early 1980’s 
by Langer and co-workers (37). The presence of a hydrophobic backbone together with water-
labile anhydride linkages enables great control over degradation kinetics and subsequently drug 
release. This has stimulated over three decades of research on the use of these surface-erodible 
polymers for drug and vaccine delivery. 
An anhydride polymer is composed of multiple monomer dicarboxylic acids (Figure 2.1) 
(38). The physical properties of each monomer are unique and they impart their characteristics 
on the resulting polymer. Aliphatic diacids and aromatic diacids are commonly used monomers 
to synthesize polyanhydrides. Aliphatic polyanhydrides consist of a straight or branched chain of 
saturated carbon atoms that make up the backbone of the polymer (Table 2.1). These 
homopolymers are highly crystalline, upwards of 60% for poly(sebacic anhydride) (PSA), and 
have melting points ranging from 50-90°C (39; 40). Polyanhydrides are generally eliminated 
from the body over a period of several weeks after in vivo injection (41). Their degradation 
products, which are dicarboxylic acids, are non-toxic and easily metabolized by the body (Figure 
2.1). Polymerization with aromatic diacids results in melting points greater than 100°C, 
insolubility in most organic solvents, and slow degradation rates that can last over a year due to 
the increased hydrophobicity associated with the aromatic rings (38). Adding methyl groups to 
the backbone of an aromatic diacid decreases the melting point of the corresponding 
homopolymers (41). Aromatic-based anhydrides in vivo have also proven to be safe and non-
toxic; however, their degradation products are not metabolized and are excreted instead (41). 
There are numerous other families of diacids, including branched diacids, unsaturated diacids 
and fatty acid-derived diacids, but they are less commonly utilized in drug delivery.  
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Synthesizing anhydride polymers is most commonly performed through melt 
polycondensation. Melt polycondensation generates high molecular weight polymers (up to 100 
kDa). The dicarboxylic acids are acetylated by refluxing in excess acetic anhydride and melted at 
180°C for 2-3 hours with a high vacuum to remove the condensation product and push the 
polymerization forward (38). Other synthesis routes include dehydrochlorination, dehydrative 
coupling, and ring opening polymerization (38). The physical properties of these polymers can 
be further tailored by copolymerizing different types of monomer diacids (42). Typically, 
aliphatic and aromatic diacids are copolymerized together to adjust drug release times or 
hydrophobicity. 
When exposed to water, polyanhydrides undergo hydrolysis of their anhydride bonds 
(Figure 2.1). One of the advantages of polyanhydrides is that they are surface-eroding polymers, 
enabling more predictable release kinetics (Figure 2.2). This occurs because the polymeric chains 
at the interface of the polymer and water break down and release the drug before water can 
penetrate into the polymeric matrix (40; 43). This degradation is controlled by a number of 
factors. For example, aromatic homopolymers degrade several orders of magnitude slower than 
aliphatic homopolymers (41; 44). As a dry powder, these aromatic polymers have been able to 
retain their original molecular weight for over a year, while aliphatic polymers have exhibited 
significant degradation during this time (37). Generally, in aqueous solutions hydrophobic 
polymers degrade more slowly than less hydrophobic polymers because there is reduced water 
permeability into the polymeric matrix (43). Additionally, semicrystalline polymers degrade 
more slowly than amorphous polymers. The pH of the solution can greatly affect polymer 
degradation. Polyanhydride degradation is base-catalyzed and their degradation rates increase 
with higher pH. Copolymer degradation is more complex. In a random A-B copolymer there are 
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three bond types, A-A, B-B, and A-B, and the degradation rates of all three bonds need not be 
equal. This leads to the formation of microphases and non-homogeneous degradation (38). 
Degradation products resulting in the formation of dicarboxylic acids lowers the local pH. 
However, unlike polyester degradation, this decrease in pH is milder (45).  
Polyanhydrides have been utilized as implantable and injectable vehicles for drug 
delivery. Implantable systems consist of a wafer made by mixing the drug with the polymer 
powder and forming the wafer through compression molding or melt compression. The most 
well-known polyanhydride system, the Gliadel
®
 wafer, is a compression-molded wafer (46). The 
Gliadel
®
 wafer is an FDA-approved implant, consisting of a copolymer of sebacic acid (SA) and 
1,3-bis(p-carboxyphenoxy)propane (CPP). It is post-surgically implanted into the brain of 
patients with malignant glioma, where it degrades and releases a chemotherapeutic, carmustine, 
to inhibit tumor growth (47).  
Nanoparticles and microparticles based on polyanhydrides have been synthesized using a 
number of techniques including spray drying, solvent extraction, or cryogenic atomization 
(Figure 2.3) (48; 49). Solvent extraction can involve the use of a single emulsion or a double 
emulsion. In single emulsion systems, such as the solid/oil/oil (s/o/o) method, the drug and 
polymer are dissolved in a solvent and then dispersed in a non-solvent, precipitating the micro- 
or nanoparticles (Figure 2.3) (40; 49). Other nanoprecipitation techniques involve double 
emulsions, such as the water/oil/water (w/o/w), and water/oil/oil (w/o/o) emulsions. These are 
used when a drug is poorly soluble in the oil solvent. The drug is first dissolved in water, while 
the polymer is still dissolved in a solvent. The two are emulsified through vigorous mixing and 
the particles are precipitated after exposure to the non-solvent, which is either water or oil. The 
s/o/o method is convenient because it provides high encapsulation efficiencies and avoids a 
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water/oil interface that can cause protein migration and unfolding (48; 49). Spray drying involves 
using a volatile solvent to dissolve the polymer and drug (Figure 2.3). The solution is atomized 
through a spray dryer with a stream of hot air. This induces the solvent to evaporate leaving 
behind precipitated particles. An alternative method to make particles is through cryogenic 
atomization. In this method, the polymer and drug are dissolved in a solvent and pumped through 
an ultrasonic nozzle into a bath of liquid nitrogen that is on top of frozen ethanol (49). The 
ethanol slowly thaws and as the frozen particles fall into it, the solvent diffuses into the ethanol, 
inducing precipitation of the particles. 
Polyanhydride micro- and nanoparticles enhance protein stability and have been shown to 
release biologically and functionally active protein antigens that maintain their primary, 
secondary, and tertiary structure (45; 50-53). Recent studies from our laboratory demonstrated 
that the pneumococcal surface protein A, the hemagglutinin protein from the H5 influenza virus, 
and gp41 from the HIV virus were stably released from polyanhydride nanoparticles, 
demonstrating their value as a viable delivery platform for vaccines (54-56). These studies also 
demonstrated that the chemistry of polyanhydrides can be tailored to provide a sustained release 
of antigen. Vaccine formulations based on such nanoparticles allow for providing prolonged 
exposure of antigen without needing more administrations.  
In addition to stabilizing protein antigens, polyanhydride delivery vehicles have shown 
the ability to adjuvant the immune response to antigen (57). Several studies have shown 
enhancement of both cellular and humoral immune responses in a single dose, 
immunomodulation, and dose sparing using polyanhydride nanovaccines (53; 58-62). 
Additionally, the internalization by innate immune cells of hydrophobic polyanhydride 
formulations was enhanced because the surface patterns of the hydrophobic chemistries 
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mimicked PAMPs and triggered danger signals to APCs (63). The majority of these particles 
were localized in the endosomal regions of the cell, which is an important pathway for antigen 
loading on to major histocompatibility complex II molecules.  
2.1.4 Natural polymers and polysaccharides 
Natural polymers have been extensively studied as candidates for enhancing the delivery 
of drugs and vaccines. They are derived from plants, animals, and microbes (2). Typically they 
are biodegradable and have higher biocompatibility than synthetic polymers (7). Two of the most 
prominent natural polymers used to make nanoparticles or microparticles are chitosan and 
gelatin. 
Chitosan is a linear polysaccharide with long polymer chains (50-200 kDa) (Table 2.1) 
(64). It is produced commercially by the deacetylation of chitin, which is a natural biomaterial 
from the shells of crustaceans and insects. This polymer is composed of β-(1-4) linkages of 
glucosamine and N-acetyl glucosamine and has nitrogen groups on its polymer backbone making 
it cationic (64). These nitrogen moieties impart important properties to chitosan that have 
contributed to its success in drug delivery. Chitosan is non-toxic, stable, easily sterilized, and 
biodegradable, making it a strong candidate for the controlled release of vaccines (65). 
Chitosan is water soluble only at low pH, but it can be methylated to form a derivative 
called N-trimethyl chitosan (TMC), which has a positive charge regardless of pH and is more 
stable in aqueous solutions (66). Particles are most commonly synthesized through coacervation, 
ionic gelation, or spray drying. The coacervation technique takes advantage of chitosan being 
insoluble in alkaline solutions. Here the dissolved solution is passed through a compressed air 
nozzle to form droplets and precipitated into an alkaline solution (67; 68). Following purification 
through centrifugation or filtration, the particles can be hardened using a crosslinking reagent, 
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such as gluteraldehyde, to control release rate. Spray drying chitosan particles is very similar to 
that of polyanhydrides except that the polymer is dissolved in acetic acid (Figure 2.3) (67). The 
solution is atomized in hot air leading to the formation of small droplets that evaporate and 
inducing particle formation. In ionic gelation, the chitosan and antigen are dissolved in acidic 
solution and it is added dropwise to a polyanionic solution (66). The two oppositely charged 
chemicals complex and precipitate. Due to a lack of covalent bonds, these particles usually have 
poor mechanical strength and rapidly release their encapsulated payload (67). 
A major advantage of chitosan-based nanoparticles is that they are mucoadhesive, 
making them an excellent candidate for intranasal immunizations (68). Mucins in the intranasal 
mucosal tissue are negatively charged and the strong electrostatic interactions between mucins 
and the positively charged chitosan particles help increase the retention time of the particles and 
encapsulated antigen (69). It has also been suggested that chitosan has the capacity to loosen the 
tight junctions formed by epithelial cells, allowing the particles to more easily cross epithelial 
barriers making for enhanced drug delivery (67). Chitosan particles and chitosan-coated particles 
administered intranasally to mice have induced both systemic and local immune responses (70; 
71). For example, one study compared the immune responses of antigen encapsulated in PLGA 
nanoparticles coated in chitosan or chitosan nanoparticles to that of soluble antigen upon 
intranasal administration to mice (66). The antigen released from the chitosan nanoparticles had 
the longest retention time as measured by the in vivo fluorescence intensity of dye-conjugated 
antigen and also generated the highest serum antibody titers and IgA titers. Other studies have 
also used chitosan-coated particles for nasal administration. PCL particles were coated in 
chitosan and delivered intranasally to mice in order to induce an immune response against 
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influenza (72). One shortcoming of chitosan is that its molecular weight is extremely variable 
and hard to control. 
Another important natural polymer used in drug delivery is gelatin. Gelatin is a 
polyampholyte and has both positively charged and negatively charged functional groups (73). It 
also has hydrophilic components that lead to swelling when these particles are incubated in 
aqueous solutions, enabling easier diffusion and release of antigen. However, the swelling and 
release rate can be controlled by crosslinking with glutaraldehyde (74). In a study using 
microspheres, gelatin particles with 0.06% glutaraldehyde released 64% of its payload in 30 
minutes. When the amount of glutaraldehyde was increased to 0.18%, the release rate was 37% 
of the payload in the same time (75). Even so, these are relatively high release rates, which is a 
limitation in using gelatin based drug formulations for drug and vaccine delivery applications. 
Gelatin is a protein-based polymer derived from the hydrolysis of collagen from either 
bovine or swine origin (76). The hydrolysis is either base-catalyzed or acid-catalyzed, which in 
turn affects the functional groups that are present. The diversity of functional groups available 
makes gelatin a good candidate for surface functionalization (77). It also has low antigenicity, is 
biodegradable, and has been well studied for drug delivery (78; 79). In addition to diffusion and 
erosion, gelatin particles can be broken down by proteases (78). One study showed that only 
about 10% of doxorubicin loaded into gelatin nanoparticles were released in 72 hours when 
incubated in saline solution, but upon adding proteases this release rate was immediately 
increased several-fold (80).  
2.1.5 Liposomes 
Liposome-based vehicles have been clinically approved for drug delivery. Astellas 
Pharmaceutical Corporation has designed a liposome-based formulation to increase the solubility 
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and targeting of the anti-fungal drug amphotericin B (81). Other manufacturers use liposomes to 
limit the non-specific toxicity of anti-cancer drugs such as doxorubicin and daunorubicin (81). In 
terms of vaccine delivery, liposomes are now being utilized in clinical trials. One example is the 
cationic liposome, CAF01, which is used as a delivery vehicle with a tuberculosis (TB) antigen 
in a TB vaccine (82; 83). This liposome is formed with a synthetic cationic lipid along with a 
synthetic lipid derived from the cell wall of Mycobacterium tuberculosis to adjuvant the immune 
response. This vaccine induced a strong Th1-mediated immune response (82; 83). 
Liposomes are bilayered vesicles that form spontaneously when lipids are incubated in 
aqueous solutions (Figure 2.4) (84). Their release kinetics as well as their ability to adsorb or 
encapsulate antigen depend greatly on their composition, charge, and size.  Liposome formation 
is most affected by the geometry of the individual lipid monomers. Typically, the lipid monomer 
is composed of a large hydrophilic head group followed by long double hydrocarbon chains (85). 
Hydrocarbon chains that are saturated and long exhibit more van der Waals forces with 
neighboring chains leading to more rigid liposomes. Unsaturated or short hydrocarbon chains 
give the liposome more fluid like properties. Liposome fluidity can also be altered by 
incorporating sterols, such as cholesterol, into the liposome membrane (86). This fluidity can 
affect the immune response. Investigators have found that more rigid liposomes can form long 
term depots and do not disperse as readily from the site of injection as more fluid liposomes, 
resulting in more robust immune responses (81).  
Liposomes are most commonly made with the neutral lipid monomer, 
phosphatidylcholine, while incorporating smaller amounts of cationic or anionic lipid monomers 
in the membrane bilayer to get a charged delivery vehicle (86). Several studies have shown that 
cationic liposomes are more immunostimulatory than anionic liposomes (87; 88). All liposomes 
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have an aqueous core that allows encapsulation of drugs, proteins, or DNA (Figure 2.4). A 
disadvantage of liposomes is their stability. In vivo, their release times have been reported to 
range from minutes to hours depending on the composition (85). Methods have been developed 
to obtain lyophilized liposomes to prevent their degradation and release of antigen in aqueous 
solutions during storage (85). This necessitates the use of excipients, including cryoprotective 
agents, such as trehalose. Additionally upon in vivo administration, liposomes have been shown 
to be rapidly consumed by the mononuclear phagocyte system (MPS) because studies have 
shown that nearly 80% of the dose is adsorbed by the MPS within 30 minutes of intravenous 
administration (85). 
2.2 Targeted Delivery of Vaccines
*
 
2.2.1 Introduction 
Vaccines that can direct their action to a specific target on antigen presenting cells 
(APCs) can overcome the lack of immunogenicity associated with subunit vaccines. This 
“rational design” approach involves targeting specific receptors that have the ability to trigger 
immune activating and signaling events or to induce enhanced cellular internalization and 
processing of antigen. Pattern recognition receptors (PRRs) make excellent targets in the rational 
design of vaccines as they play an integral role in the innate host defense by recognizing 
conserved pathogen associated molecular patterns (PAMPs). Targeted vaccines can provide 
several advantages, including cost effectiveness, dose sparing, immune modulation, and less 
toxicity than alternative systems. Dose sparing and cost effectiveness correlate with each other in 
that vaccines that target PRRs have the capability to induce robust immune responses using less 
antigen than conventional vaccines. Rationally designed antigens can be targeted to specific 
                                                     
*
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receptors or tailored to induce specific cytokine profiles that modulate the immune response (89). 
Vaccines that target APCs cells while avoiding a systemic response could also reduce toxicity to 
the host.  
2.2.2 Types of PRRs 
2.2.2.1 C-Type Lectin Receptors (CLRs) 
Most CLRs are membrane bound proteins that contain one or more carbohydrate 
recognition domains (CRDs) for binding to carbohydrates. With over 60 types of receptors, 
CLRs represent a diverse receptor family that have been shown to mediate host biological events 
and contribute to the innate immune response (90). CLRs are often associated with a Ca
2+
 
dependent mechanism of binding; however, some CLRs such as Dectin-1 have been shown to 
bind its carbohydrate ligand independent of Ca
2+
.  
The macrophage mannose receptor (MMR) has eight CRDs located sequentially on one 
polypeptide chain and it is most efficient at recognizing single or low order mannose moieties 
that are present on yeast, fungi, viruses, and many bacteria including Mycobacterium 
tuberculosis and Streptococcus pneumoniae (Figure 2.5) (91). The MMR is most commonly 
expressed on immature DCs, tissue macrophages, and some epithelial cells, whereas circulating 
monocytes have very low levels of expression (Table 2.2) (92). It acts as an endocytic receptor 
that internalizes its ligand through coated pits. One specific example of its role in the immune 
response is the induction of maturation in human peripheral blood mononuclear cells, leading to 
a strong Th17 adaptive response, by mannan derived from Candida albicans (93). By blocking 
MMR expression on DCs with siRNA, T cell activation was inhibited, preventing CD4
+
 cells 
from producing IL-17 and IFN-γ. There is increasing evidence to support that the MMR has a 
“dual role” as an important PRR for the innate immune system and in homeostasis by the 
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clearance of endogenous ligands. For example, it has been shown that the blood of MMR-
deficient mice showed delayed clearance of lysosomal enzymes that contained mannose side 
chains (94).  
A soluble C-type lectin that is closely related to the MMR is the mannose binding lectin 
(MBL). Each single polypeptide chain has one CRD, but usually three chains come together to 
form a collagen helix resulting in a single structure with three CRDs at its tip. These structures 
can further form multimers containing different numbers of structural subunits (95). Like the 
MMR, the MBL has specificity for mannose, N-acetylglucosamine (GlcNAc), and fucose. Each 
CRD binds with relatively low affinity and so ultimately it is the clustering of multiple CRDs 
that gives the MBL a strong avidity. The MBL, along with other soluble lectins, such as ficolin, 
have been shown to bind to bacterial peptidoglycan and fungal derived β-glucans (96). This 
induces the binding of MBL-associated serine proteases (MASPs) to promote the activation of 
the lectin pathway of the complement system (96; 97).  
Similarly to the MMR, DEC-205 is another CLR used for targeting. It does not have a 
signaling motif on its cytoplasmic tail; however, there are two separate motifs that are believed 
to influence endocytosis and intracellular trafficking (Figure 2.5) (98). This includes a tyrosine-
based motif as well as a triacidic cluster in contrast to the MMR that only has the tyrosine-based 
motif. It is believed that this triacidic cluster explains why DEC-205 transports its ligand to late 
endosomes whereas the MMR trafficking is mostly restricted to early endosomes (99). As a 
result targeting through DEC-205 is more efficient at presenting antigen than through the MMR 
(99). In humans, DEC-205 is also readily expressed on DCs, particularly on myeloid DCs, 
moderate levels in B cells and low levels on T cells as well as natural killer cells (100). Unlike 
the MMR where DC expression is down-regulated upon maturation, DEC-205 expression is 
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generally up-regulated, which seems to imply that it has an important function in mature DCs 
(Table 2.2) (101). Ligands taken up by DEC-205 mediated endocytosis have been shown not 
only to present antigen on MHC class II, but also on MHC class I, including cross presentation 
of antigen (102).   
The dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-
SIGN) is a CLR expressed on immature DCs in peripheral tissues, such as the skin, gut, and 
lung, and its expression is down-regulated upon maturation (Table 2.2) (103). As a PRR it is 
mostly known for recognizing high mannose structures on surface glycoproteins of bacteria, 
fungi, and viruses including gp120 on HIV and glycoprotein E on the Dengue virus (104). DC-
SIGN has one CRD that is used for antigen recognition, cell transport across epithelial barriers 
and for interacting with other cells such as neutrophils. Studies have shown that the single 
polypeptide chains of DC-SIGN form tetramers with each other thus allowing each structure to 
present four CRDs (Figure 2.5) (105). DC-SIGN has a cytoplasmic tail consisting of three 
motifs, which include the tyrosine-based motif, a triacidic cluster, and a dileucine motif. Azad 
and co-workers inserted point mutations into each of the motifs individually to determine their 
function (106). They found that mutating the triacidic cluster reduced the surface expression of 
DC-SIGN most significantly and it also had a 90% reduction in the phagocytosis of 
mannosylated-coated beads. Cells with the mutated dileucine motif had a small defect in 
phagocytosis and tended to retain antigen on its surface suggesting a role in internalization (106). 
Mutations to the tyrosine motif had little effect on DC-SIGN expression or function. The overall 
conclusion was that these triacidic motifs are essential for DC-SIGN surface expression and that 
they play an important role in the uptake of antigen to the late endosome for fusion with the 
lysosome. 
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Dectin-1 is a proven phagocytic PRR for fungal β-glucans and it is expressed 
predominantly on DCs, macrophages, and neutrophils (Table 2.2). In particular, it is expressed 
on splenic macrophages, Kupffer cells, and macrophages in the lamina propria of the gut villi 
(107). The cytoplasmic tail of Dectin-1 is unique to CLRs in that it has an immunoreceptor 
tyrosine-based activation motif (ITAM) that allows it to transduce signals into the cell and 
mediate internalization (108). Researchers have shown that Dectin-1 acts as a powerful PRR that 
can induce the innate immune system through Syk kinase signaling (Figure 2.5). This results in 
the production of reactive oxygen species and inflammasome formation.  Additionally, it has 
been shown that Dectin-1 influences the adaptive immune response by inducing the secretion of 
IL-1β and IL-23p19, which polarizes the T cell response to that of a TH17-mediated response 
(109).  
2.2.2.2 Toll-like Receptor (TLRs) 
TLRs are essential PRRs of the innate immune system and while they are not as diverse 
as their CLR counterparts, they remain a highly conserved class of receptors across multiple 
species. A total of 10 TLRs have been identified in humans and 12 in mice (110). Their main 
function is in signal transduction to induce the release of inflammatory cytokines or Type 1 
interferons that can stimulate the adaptive response. TLRs are transmembrane proteins expressed 
on the surface of the plasma membrane or within endosomes. Many TLRs that recognize 
PAMPS are located on the plasma membrane, while those that recognize nucleic acids are 
expressed on the surface of endosomes (111). Intracellularly, each TLR has a single 
Toll/interleukin-1 receptor (TIR) domain similar to that of the IL-1 receptor that allows for 
downstream signaling. The extracellular portion contains leucine-rich repeats shaped like a 
horseshoe (Figure 2.5). Monocytes and myeloid DCs express TLR2 and TLR4 while 
plasmacytoid DCs are known for expressing TLR7 and TLR9 in higher abundance. They are 
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expressed at very low levels in B cells; however it has been found that TLR9 and TLR10 are up-
regulated following triggering of the B cell receptor (112). Additionally TLRs are expressed on 
memory B cells (112). There is evidence showing that TLR2 is highly expressed on activated 
human T cells and memory T cells, suggesting a role as a co-stimulatory receptor of T cells and a 
role in the maintenance of memory T cells (113). At the same time, activated and memory T 
cells failed to respond to TLR4, TLR3, or TLR9 ligands.  
The most notorious TLR is TLR4, because it is triggered by gram negative bacterial 
lipopolysaccharide (LPS). LPS induces a pro-inflammatory response through a receptor complex 
composed of MD-2 and TLR4, ultimately triggering the MyD88 dependent pathway and the 
activation of NFκB or the TRAM adaptor and activating interferon response factor 3 (IRF3) 
(Figure 2.5) (114). There are numerous studies citing the importance of TLR4 activation in 
generating a protective immune response against pathogens (115-117). At the same time 
overstimulation of TLR4 can have adverse consequences and potentially lead to sepsis. In 
particular, fever and seizures have been reported with the pertussis whole cell vaccine because it 
triggers TLR4 (116). Other TLR4 agonists include the vaccine adjuvant, monophosphoryl lipid 
A, and a number of heat shock proteins (118; 119).  
TLR2 is important in the host response against gram positive bacteria and yeast because 
it binds a wide array of peptidoglycans, zymosan, and lipopeptides. It is unique in that it doesn’t 
form homodimers with itself, but instead forms heteromers with either TLR1 or TLR6 in order to 
initiate a signaling cascade (120). TLR2 signals through the MyD88 adaptor protein only when 
the Mal and MyD88 adaptor proteins bind to the TIR domains on the heterodimer (Figure 2.5).  
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Flagellin, originating from the filaments on the flagella of proteobacteria, binds to each 
TLR5 and triggers the assembly of a homodimer allowing for MyD88-dependent signaling 
through the TIR domains (Figure 2.5) (121). Specifically TLR5 binds to conserved regions on 
the flagellin that are essential to the bacteria’s ability to form a filament. This suggests that the 
TLR is well adapted to withstand mutations from the flagellin (122).  
Unlike TLR4, TLR2 or TLR5, TLR3 and TLR 9 are endosomal TLRs (Figure 2.5). TLR3 
recognizes double stranded (ds) RNA and thus plays an important role in the immune response 
against viruses, while TLR9 responds to unmethylated DNA, which is generally bacterial DNA 
(Table 2.2). Poly(I:C) is typically the standard dsRNA immunostimulant that interacts with 
TLR3, but it has been demonstrated to be slightly toxic and so modified versions that have 
reduced toxicity, such as, poly(ICLC) are often used (123).  It has been determined that this 
receptor interacts with the sugar and phosphate backbones rather than the nucleotides of the 
dsRNA, which is why it is not specific for sequences (124; 125). The focus of current research is 
to utilize TLR3 and TLR9 ligands to induce more balanced immune responses in order to reduce 
Th2-dependent pathways (126).  
2.2.2.3 RIG-I Like Receptors (RLRs) 
There are three types of RLRs which include RIG-I, MDA5, and LGP2 and all are 
cytosolic PRRs (127). RIG-I and MDA5 have been shown to recognize RNA from different 
viruses and can initiate important host defense mechanisms against RNA viruses (128). This 
contrasts with LGP2, which has no signaling domains, but has been shown to be both a positive 
and negative regulator of RIG-I and MDA5 (129). 
RIG-I has two caspase activation recruitment domains (CARD) which are the signaling 
domains of the receptor, and they activate the transcription factors NF-κB, AP-1, and IRF3 
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(Figure 2.5) (127). These act in concert to induce production of Type 1 interferons. RIG-I 
predominantly recognizes short ssRNA and dsRNA sequences if they contain a triphosphate at 
the 5’ end of the molecule and binds to longer dsRNA molecules up to several hundred base 
pairs long (130). Additionally RIG-I is indirectly the receptor for the adjuvant poly(dA:dT) when 
the DNA sequence is converted to RNA with a 5’-triphosphate through RNA polymerase III 
(131). Initially RIG-I has a closed conformational structure where the two CARD domains are 
folded along the helicase. This prevents the CARD domains from accidently triggering 
downstream signaling. A conformational change occurs upon dsRNA binding to the CTD and 
helicase which is dependent on ATP hydrolysis (127; 132). MDA5 has a similar structure and 
signaling profile as RIG-I, but it primarily binds to long dsRNA molecules, including Poly(I:C) 
(133). 
2.2.2.4 NOD Like Receptors (NLRs) 
The NOD family is a diverse set of cytosolic receptors that specialize in recognizing 
PAMPs against intracellular bacterial pathogens. They are able to bind to flagellin, 
peptidoglycans, or bacterial toxins, while others detect intracellular potassium levels to 
determine if there was a loss of host membrane activity (Table 2.2) (134). There are 23 NLRs in 
humans and 34 in mice and they are mostly expressed on macrophages and neutrophils (135). 
There is also significant expression on epithelial cells and on specialized cells, such as Paneth 
cells in the gut, where they have a critical role in maintaining homeostasis with commensal 
bacteria (136).  
Two predominant NLRs are NOD1 and NOD2. Both bind to fragments of peptidoglycan 
as NOD1 has specificity for meso-diaminopemilic acid (DAP) while NOD2 binds to muramyl 
dipeptide (MDP) (Table 2.2). They have a structure reminiscent of RLRs in which they contain 
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two CARD domains for signaling, a NOD domain, and a sequence of leucine rich repeats. They 
are maintained in a folded inactive state and upon binding to ATP and the PAMP at the NOD 
domain they undergo a conformational change to form a homodimer with other NLRs (Figure 
2.5) (137).  
Understanding the biological pathways and expression patterns of host PRRs has 
important implications for targeting. It allows the use of adjuvants and ligands in vaccine 
formulations to target specific receptors in order to achieve a tailored immune response. It is 
interesting to see repeated patterns within and throughout the families of PRRs. Examples 
include the abundance of leucine rich repeats on PRRs that recognize PAMPs and not nucleic 
acids as well as the prevalence of oligomerization for signal transduction. These observations can 
provide useful insights into the mechanisms that drive the immune response, which will 
ultimately allow us to design more efficacious vaccines. 
2.2.3 Co-stimulation and crosstalk 
Given the diverse repertoire of PAMPs on a pathogen it is likely that an infection will 
stimulate multiple PRRs, making crosstalk and co-signaling essential to combating infection. It 
may be important to replicate this in order to get an adequate immune response for vaccine 
delivery. There are many documented instances of PRR cooperation that center mostly around 
TLRs. For example, TLRs have been shown to act synergistically with CLRs and to cooperate 
with NLRs. For example, Dectin-1 stimulation by β-glucans with simultaneous administration of 
TLR2 or TLR4 agonists increased the pro-inflammatory cytokine secretion from primary 
monocytes and macrophages compared to the ligands being administered individually (138).  
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2.2.4 Targeting mechanisms 
Numerous strategies have evolved for targeting of PRRs with an emphasis on generating 
potent immune responses. Targeting mechanisms are classified as passive or active. In passive 
targeting the drug does not have a target ligand and depends solely on its physicochemical 
properties as well as its interactions in the circulatory system or at tissue sites to be efficacious 
(139). Active targeting employs a ligand that is conjugated to the drug allowing that drug to bind 
to a specific site on a cell or tissue (Figure 2.6). Active strategies are advantageous because they 
increase efficacy by achieving higher accumulation of the drug to the tissue, and are dose 
sparing, which can limit the drug exposure to non-targeted tissue (139). Active strategies that 
commonly target PRRs for drug delivery include functionalizing antibodies, functionalizing 
antigens, cell-mediated targeting, and functionalizing delivery vehicles. 
2.2.4.1 Antibody-mediated targeting 
The strong binding and specificity of antibodies are ideal properties for delivering a 
payload to target cells. In the development of antibody-targeted vaccines, CLRs have been 
attractive targets for delivering antigens because of their endocytic capacity and their high 
expression levels on immature DCs. An antibody-conjugated vaccine that has undergone clinical 
trials is Lipovaxin-MM, produced by Lipotex, which is composed of a single domain antibody 
fragment that targets DC-SIGN for the delivery of a lipid-based vaccine that co-encapsulated 
melanoma antigens and IFN-γ (139). IFN-γ supplied the strong maturation signal that ensured 
that tumor-specific CD8
+
 T cells were activated (139). Separately, antibodies targeted to DC-
SIGN that had been conjugated with OVA generated persistent CD4
+
 and CD8
+
 T cell responses. 
However, they still required a CD40 agonist to protect mice from OVA expressing Listeria 
monocytogenes. 
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In addition to CLRs, antibodies conjugated with antigen have also been targeted to other 
receptors commonly found on APCs. Fc receptors were among the first targets of antibody-
conjugated vaccines. Instead of conjugating a payload to an entire antibody, the payload is 
usually conjugated to the Fc fragment, which is then recognized by the Fc receptor. Fc receptors 
are attractive targets because most of them contain ITAMs, which allow for a pro-inflammatory 
signal to be induced (140). Fc-conjugated drugs have demonstrated activation of CD4
+
 T cells 
and generally led to enhanced antigen-specific humoral and cellular immunity (141; 142). 
Additionally, integrins such as CD11c have been targeted by antibody-conjugated drugs in order 
to ensure that antigens reach APCs (143). It has been reported that targeting through CD11c can 
induce T cell responses as effective as that by targeting some of the CLRs (144). 
Antibody-mediated targeting has proven most successful in directly targeting the 
payloads to tumors. The vast majority of antibody-drug conjugates in clinical trials consist of 
traditional anticancer payloads, such as paclitaxel, docetaxel or doxorubicin encapsulated in 
liposomes or polymer-based nanomedicines, while the conjugated antibody fragments mediate 
targeting to the appropriate tissue (139). Receptors, such as the transferrin receptor or epidermal 
growth factor receptor are often overexpressed in malignant cells, making them excellent targets 
for antibodies (145; 146).  
Given that antibodies are highly specific for their target and can easily be conjugated to 
deliver a payload, they are well suited for niche applications, such as targeting tumors or 
stimulating cell-mediated responses against HIV (147). Free cysteines on the protein provide 
flexibility for different drug conjugation techniques through a reaction with free sulfhydryls 
(Table 2.3). However, their utility as a vaccine component against common respiratory infections 
is limited. For one, therapeutic antibodies currently on the market are expensive and one can 
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reasonably speculate that antibody-targeted vaccines would not be any more economical (148). 
The antibodies themselves are fragile and require further modifications, such as PEGylation, to 
increase their half-life (139). Additionally, immune responses against the targeting antibody are 
possible, which induces rapid clearance and makes repeat immunizations unfeasible (149).   
2.2.4.2 Cell-mediated targeting 
In cell-mediated targeting, immune cells are isolated from the blood of patients and 
exposed in vitro to an antigen or maturation stimuli, upon which they are re-injected into the 
patient. The process is labor intensive and costly, meaning that its use will most likely be 
restricted to highly specialized applications, such as cancer immunotherapy or treatment of HIV. 
Two techniques are commonly used in cell-based targeting: DC immunotherapy or T cell 
adoptive transfers. 
DC immunotherapy has demonstrated great proof of concept for use against a broad 
range of cancers. There are several studies in humans that demonstrate the safety and efficacy of 
this approach. In one study, patients with a form of liver cancer, known as hepatocellular 
carcinoma, had blood samples isolated from the peripheral blood, purified, and incubated with 
GM-CSF and IL-4 to generate immature monocyte-derived DCs (MDDCs) (150). The MDDCs 
were incubated with lysate from a tumor cell line exposing the MDDCs to a number of antigens 
on the tumor. These patients were then vaccinated with the mature MDDCs, whereupon 
researchers witnessed a clinical response with increased IFN-γ secretion and decreasing serum 
levels of α-fetoprotein, a protein known to be expressed at elevated levels with this type of 
cancer (150). A major challenge of DC immunotherapy is ensuring that the DCs are sufficiently 
mature because evidence has shown that immature DCs could induce anergy rather than an 
antitumor immune response (150). A significant recent breakthrough is the use of TLR ligands to 
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induce MDDC maturation. Traditionally, a pro-inflammatory cytokine cocktail containing IL-6, 
TNF-α, IL-1β, and Prostaglandin E2 had been used; however, studies have shown that these DCs 
do not do a very good job at producing IL-12p70 and thus do not induce Th1 responses as 
effectively (151). More antigen-specific T cell proliferation and higher surface expression of 
CD83, CD86, and MHC II were observed upon incubating MDDCs with clinical grade Poly(I:C) 
or monophosphoryl lipid A (151; 152). Although a fairly new and developing field, DC 
immunotherapy has yet to live up to its promise. This is because generating de novo immune 
responses in advanced cancer patients is extremely difficult (153). Tumors progress because they 
promote an environment that induces immune suppression and immune dysfunction. As a result 
it is still unknown if DC immunotherapy primes T cells or if it simply activates pre-existing 
anergic T cells.  
An alternative to DC immunotherapy is T cell adoptive immunotherapy. T cells that can 
penetrate into a tumor belong to a class of lymphocytes called tumor-infiltrating lymphocytes 
(TILs). There is evidence showing that once the tumor-specific T cell meets its cognate antigen 
within the tumor, its migration is inhibited. The idea behind T cell adoptive immunotherapy is to 
excise tumor, extract tumor-specific T cells and encourage proliferation by adding pro-
inflammatory growth factors such as IL-2 before re-injecting them into the patient (154).  
2.2.4.3 Modified antigens as target agents 
A number of creative strategies have been used to modify antigens to actively target 
APCs (Figure 2.6). Specific receptors on APCs are targeted allowing for the modified antigen to 
be internalized and presented more effectively compared to the unmodified antigen (98). Antigen 
modification techniques commonly include chemically conjugating either small molecules such 
as glycans or amino acids or full length antibodies to antigens (155; 156).  
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Perhaps the most common technique to modify antigens is to conjugate them with 
carbohydrates. Given that many antigens on pathogens are heavily glycosylated, researchers 
have attempted to use carbohydrate ligands for PRRs to create a “pathogen mimicking” antigen 
that triggers danger signals and initiates a strong immune response against the antigen (157). 
Carbohydrates, such as mannose, fucose, galactose, β glucans, and Lewis X oligosaccharides 
have all been shown to be ligands for CLRs and are currently being exploited to modulate the 
immune response (158). In one study, researchers cultivated bone-marrow derived DCs 
(BMDCs) and splenic DCs in vitro with OVA that had been modified with a DC-SIGN specific 
ligand, Lewis-X, using a bifunctional crosslinker known as 4-N-maleimidophenyl butyric acid 
(Table 2.3) (158). Compared to unmodified OVA, the Lewis-X OVA enhanced antigen 
presentation, leading to greater T cell proliferation, particularly when OT-I T cells were added to 
the wells of the DCs. This suggests that these modified antigens have the ability to be cross 
presented, which is important for stimulating CD8
+
 T cell responses and inducing cell-mediated 
immunity (156; 158; 159).  
In addition to conjugating carbohydrate ligands to antigens to target CLRs on APCs, TLR 
agonists and NLR ligands have also been studied (160-162). In one example, researchers 
chemically coupled CpG, a TLR9 agonist, to siRNA to target the TLR9
+
 myeloid cells and B 
cells (160). In turn the siRNA was designed to silence the immune suppressor gene Stat3 that 
would presumably hinder tolerogenic cells and stimulate a potent immune response in the 
presence of a tumor. An endosomal TLR, such as, TLR9 was targeted because it was believed 
that this would help the cell uptake the siRNA more efficiently. Incubation with mouse 
splenocytes proved that DCs, macrophages, and B cells efficiently internalized the conjugated 
siRNA more efficiently than the unconjugated siRNA. In vivo, local injection of the CpG-siRNA 
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oligonucleotide inhibited growth of colon carcinoma in mice and resulted in the up-regulation of 
co-stimulatory molecules such as MHC II, CD80, and CD40 on DCs and the production of Th1 
cytokines (160). In this scenario, the CpG served two purposes in that it not only helped target 
the siRNA to immune cells, but also helped stimulate those cells in conjunction with the siRNA. 
Targeting using TLR agonists has also caught the attention of industry and Novartis has used 
their TLR7 agonist to link an antigen from Streptococcus pneumoniae (163). They were able to 
show that mice administered 0.2 μg of the conjugated antigen had comparable survival rates as 
those given 2 μg of unconjugated antigen upon bacterial challenge (163). Mice given 0.2 μg of 
the unconjugated antigen with the soluble TLR7 agonist had significantly lower survival rates 
showing that chemical conjugation was important. 
2.2.4.4 Modified delivery vehicles for active targeting 
Many of the same ligands and techniques to modify soluble antigens can also be used to 
modify delivery vehicles to prepare them for active targeting. Polymeric micro and nanoparticles 
make excellent delivery vehicles because of their ability to stabilize encapsulated protein, tailor 
release rates, become endocytosed by phagocytes, and enable high drug loading efficiency (164).  
Recent research has shown that directly targeting CLRs on BMDCs leads to an enhanced 
immune response characterized by increased particle internalization, up-regulation of activation 
markers, such as MHC II, CD40, and CD86, as well as increased pro-inflammatory cytokine 
secretion (157; 165; 166). In these studies, polyanhydride nanoparticles were surface-
functionalized with di-mannose in order to target the MMR and induce a pathogen-mimicking 
immune response. Functionalization was performed with a two-step reaction using 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide and N-hydroxysulfosuccinimide to link the carboxylic acids 
to a diamine linker (Table 2.3). It is known that pathogens such as Yersinia pestis and 
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Mycobacterium tuberculosis express conserved carbohydrate structures, including a variety of 
mannoses on their cell surface and so it is believed that including these sugars on the surface of 
particles will lead to a more efficacious nanovaccine (165). In addition to the sugars, there is 
evidence that polyanhydrides themselves act as TLR agonists, which lead to a more balanced 
cytokine response and a larger induction of CD8
+
 T cell response (167). The alternative to using 
sugars is to use antibodies specific for CLRs. One research group synthesized an antibody fusion 
protein targeted towards DEC-205 that was linked to chitosan microspheres for the intranasal 
delivery of plasmid DNA to mice (168). This resulted in larger quantities of mucosal IgA and as 
well as protein specific IgG when administered with an anti-CD40 DC maturation stimulus.  
Instead of targeting CLRs, another approach is to surface functionalize biodegradable 
nanoparticles to target TLRs. This was performed by conjugating CpG nucleotides to the surface 
of PLGA nanoparticles in order to target TLR9 (169). Immunized mice had a strong Th1-biased 
immune response that included a high number of circulating effector T cells and ultimately 
resulted in a high degree of protection from West Nile virus infection (169). This makes sense 
because TLR9 is an endosomal receptor known for inducing more of a cell-mediated and Th1 
polarized immune response when triggered (170). In the conjugation technique used, the CpG 
was chemically linked to biotin, while an avidin-linked fatty acid was incorporated on to the 
surface of the particles (Table 2.3) (171). Different variations of the biospecific biotin-avidin 
interactions are often used to link ligands to the surface of nanoparticles (168). Overall, 
conjugating TLR ligands to the surface of nanoparticles has been shown to adjuvant the immune 
response to minimize the need for antigen and to induce cellular immunity when targeting 
endosomal TLRs (172). Ligands for NLRs are more commonly encapsulated into particles as 
opposed to being surface functionalized with them. NOD1 and NOD2 ligands have been 
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encapsulated into PLA nanoparticles and co-delivered with encapsulated HIV Gag p24 antigen to 
increase the antibody response 100-fold compared to the antigen being administered with alum 
(173). Encapsulating NOD ligands into nanoparticles will help APCs endocytose the ligands, but 
the ligands still have to escape the endosome and reach the cytosol to trigger the receptor.  
2.2.5 Targeted vaccines for respiratory viruses 
According to the World Health Organization, respiratory tract infections are the third 
leading cause of death in the world (174). There are many common respiratory viruses including 
influenza viruses, rhinoviruses, enteroviruses, respiratory syncytial viruses (RSV), and 
coronaviruses. An efficacious vaccine against these viral pathogens will result in a balanced 
immune response that activates a strong cell mediated response as well as induce an avid 
antibody humoral response. Innovative strategies are being used to design vaccines for 
respiratory viruses that specifically target PRRs. For example, there has been some interest in 
using flagellins, a TLR5 agonist, as an adjuvant to stimulate the immune response against 
influenza (175; 176). One group genetically fused the TLR5 ligand, flagellin, to the globular 
head of hemagglutinin derived from the influenza virus (177). Healthy human adults were 
immunized with the vaccine that ranged in dose from 0.1-8μg. Those receiving at least a 0.5μg 
dose of the vaccine generated strong hemagglutination-inhibiting antibody titers in excess of the 
1:40 titer that is generally considered protective for influenza (177). The vaccine was deemed to 
be safe and generally was well tolerated. However, these subjects also tended to have strong 
antibody responses against the flagellin. Co-administering other TLR agonists with inactivated 
viruses or using protein subunits is becoming more common, such as the synthetically produced 
TLR4 agonist, glucopyranosyl lipid A, as well TLR 3 agonists, such as Poly(I:C) (178; 179).  
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2.3 Influenza Virus and Influenza Vaccines 
2.3.1 Introduction 
During a given season, 5-15% of the world is infected with influenza resulting in 3-5 
million instances of severe illness and nearly 500,000 deaths (180). Infection with the virus 
results in a highly infectious, acute respiratory disease with fever, headaches, malaise, and 
inflammation of the upper respiratory tract (181). Most influenza illnesses occur in children and 
in the elderly. This is because young children have yet to develop immunity against circulating 
strains, while aging has been associated with a decrease in immune function (182-184). In fact, 
nearly 90% of all influenza-related deaths are thought to occur in individuals older than 65 years 
of age (183). Additional complications can arise when the immune system is weakened by 
influenza allowing secondary infections, such as pneumonia or haemophilus influenzae to 
colonize the lower respiratory tract. 
Accompanying the annual epidemics are pandemics that generally break out every 2-3 
decades. A pandemic occurs when new viral epitopes are introduced into circulating strains, 
which means that the immune system has little to no memory to the newly circulating strain. The 
fact that all human pandemics in the last century have occurred due to avian or swine viral genes 
being introduced into the human population is exemplary of this (183). The most catastrophic 
influenza pandemic on record was the 1918 Spanish Flu that caused 50 million deaths 
worldwide, more fatalities than all of World War I (185). Two other pandemics occurred in the 
20
th
 century, including the Asian Flu of 1956 and the Hong Kong flu of 1967. The most recent 
pandemic was a new strain of the H1N1 virus, termed the swine flu, and it emerged out of 
Mexico in 2009 (186). It spread rapidly to over 213 countries and resulted in at least 16,000 
deaths. Researchers noticed a shift in the age distribution and mortality of the 2009 swine flu 
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pandemic as it afflicted younger populations more readily than the elderly. This is believed to be 
because the elderly may have had prior exposure to similar strains that had circulated decades 
earlier. This shift towards younger age groups is now known to be common in many pandemics 
and is considered to be a signature characteristic used to gauge the onset of a pandemic (187). 
A rapid immune response is essential to limit the pathogenicity of these viruses, which is 
why vaccines that prime the immune system against these pathogens have helped limit the 
morbidity and spread of respiratory virus infections. To this end, in 1952, the World Health 
Organization (WHO) established The Global Influenza Network (180). Since 1973, this 
organization has met before every flu season to determine emerging viral strains and provide 
recommendations so that manufacturers can produce vaccine strains that match circulating 
strains during winter outbreaks. This procedure aids in bringing over 250 million doses of 
inactivated vaccines to market annually (188). When the current vaccine is well matched to 
circulating strains, the vaccine has been shown to be effective in 70-90% of the population. 
However, when the vaccine is poorly matched to the circulating strain, it has been shown to be 
no better than a placebo (180). Even with great leaps in medical technology throughout the last 
century, it is evident that influenza continues to cause widespread suffering and still results in a 
high degree of economic burden to society. As a result considerable improvement needs to be 
made in vaccine manufacturing and efficacy, and this starts with understanding the structure and 
pathogenicity of the influenza virus. 
2.3.2 Structure and pathogenicity 
The influenza virion consists of an enveloped lipid bilayer derived from its host and 
internally it has eight single strands of RNA that encode 11 proteins (Table 2.4) (185). Three of 
these proteins blanket the surface of the virion, which includes hemagglutinin (HA), 
39 
 
 
 
neuraminidase (NA) and the ion channel protein, M2 (Figure 2.7) (189). The remaining eight 
proteins are within the virion and function as a nucleocapsid protein, RNA polymerase complex, 
or an ion channel, or are non-structural proteins.  Researchers have used the differences in the 
internal proteins to classify the virus into three species: A, B, and C. Influenza A infects humans 
and a number of mammals, including pigs, horses, wales, waterfowl, and chickens (189). Even 
though its host reservoir is in aquatic birds, this is the group that induced the aforementioned 
epidemics and pandemics in humans (183).  Influenza B is restricted to humans, while Influenza 
C can infect both humans and pigs. Both are less severe and less common than influenza A.  
The influenza A virus is further classified by the differences in its surface proteins, HA 
and NA. Sixteen different HA (H1-H16) and nine different NA (N1-N9) protein subtypes exist 
(183). Currently, only three HA serotypes, H1, H2, and H3, have become adapted to spread 
within the human population (190). Different serotypes of the influenza A virus have circulated 
throughout the human population in the last hundred years. Since the 1918 Spanish flu pandemic, 
H1N1 was the primary virus in circulation throughout the world (191). In 1958, with the onset of 
the Asian flu pandemic, a new influenza virus with two new surface antigens appeared, known as 
H2N2, and it completely displaced the H1N1 virus. This virus circulated for about 10 years until 
the Hong Kong flu pandemic in 1968, which was brought about by the H3N2 virus (191). This 
strain resulted from the avian H3 replacing the H2, while the NA remained the same. This new 
strain completely replaced the previous H2N2 virus in circulation. In 1978, the H1N1 virus 
reappeared and began circulating with the H3N2. In 2009, a new type of H1N1 virus emerged of 
swine origin and induced a pandemic. This new H1N1 has since replaced the original H1N1 and 
is now responsible for seasonal epidemics (191). 
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Once the virus enters the respiratory tract, the HA protein binds to the terminal sialic acid 
residues on epithelial cells. The cell then attempts to engulf the virus through endocytosis (192). 
With a normal antigen, the cell’s endocytic vesicle would be gradually acidified, breaking the 
antigen down so that it can be displayed on the MHC molecules to activate the adaptive immune 
system. However, the virus hijacks this pathway as the acidic pH of the endosome activates the 
M2 ion channel and allows acidification of the viral capsid (Figure 2.7) (183). This signals the 
HA to fuse the viral membrane to the endosome followed by release of the viral 
ribonucleoproteins and the negatively stranded RNA into the cytoplasm of the host cell (185; 
192). The virus must then rely on the cellular protein, importin, for each of the eight strands of 
RNA to be imported into the nucleus. Once inside the nucleus, the negatively stranded RNA 
segments are transcribed by viral nucleoproteins to make messenger RNAs (mRNA).  The 
mRNA is exported from the nucleus and uses the cell’s ribosomes to make new viral proteins. 
These newly synthesized nucleoproteins are imported back into the nucleus where they meet up 
with viral genomic RNA and they are exported as a complex (185). Simultaneously, HA, NA and 
the M2 ion channel proteins are synthesized by the cell’s ribosomes and are inserted into the 
cell’s endoplasmic reticulum. They are then transported to the cell surface where the cytoplasmic 
tails of these three surface proteins interact with the matrix protein, M1, and the nucleocapsid 
proteins to finalize assembly of the virion. The newly formed virions bud from the cell’s plasma 
membrane ready to infect new cells. Newly budded virions tend to take on more of a filamentous 
shape, while viruses repeatedly passed in cell cultures for use as vaccines are typically spherical 
(185). The NA protein plays a vital role in determining which cell the viral HA binds to as it can 
cleave the sialic acid residues preventing HA from binding to its target. The balance between HA 
binding to its ligand and NA cleaving the ligand interactions helps the virus reach its target cell.  
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Proper function of the HA protein is vital for an infectious virion. HA0 is a 70 kDa 
precursor of HA that is initially translated from cellular ribosomes and is on the surface of newly 
formed virions (190). It assembles as a trimer on the surface of the virus, which increases the 
avidity to host cells through multivalent binding (Figure 2.7). In the bronchiolar epithelium, the 
HA0 trimer encounters cellular serine proteases, such as trypsin, which cleave it into two 
subunits, HA1 and HA2 (190; 193). HA2 is anchored to the viral envelope while HA1 is held to 
HA2 through disulfide interactions (194). The HA1 subunit contains the sialic acid binding 
domain that allows the virus to be taken up into a cell’s endosome. It also contains the globular 
head where most of the epitopes for stimulating an immune response are located (183).  As the 
endosome acidifies the entire protein undergoes an irreversible and thermodynamically favorable 
conformational change exposing a fusion peptide domain on the HA2 subunit (193). This peptide 
domain is hydrophobic allowing for insertion into the cell membrane, thus bringing the cell 
endosome and the viral membrane close together for fusion. For most HAs, the cleavage of 
specific proteases limits infection to only the lungs; however, the avian flu, H5, is more 
worrisome because its HA0 precursor is able to be cleaved by a broader range of proteases, such 
as furin, meaning the virus can spread to other organs, ultimately inducing higher virulence 
(190).   
To optimize its pathogenicity, the influenza virus has mechanisms in place to suppress 
the host immune system. This is mostly done through nonstructural protein 1 (NS1), which has 
been shown to bind and inhibit RLR signaling (Table 2.4) (195; 196). Type I interferon (IFN-I) 
expression is reduced in the host and there is little release of pro-inflammatory cytokines (195; 
197). Viruses lacking the NS1 protein have been shown to induce significant IFN-I and inhibit 
viral replication (195). Furthermore, NS1 outcompetes the host antiviral protein, double-stranded 
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RNA-dependent protein kinase (PKR) for double stranded RNAs to suppress its activity (195). 
Downstream PKR pathways lead to inhibition of cellular translation, meaning viral proteins 
cannot be synthesized from its mRNAs. It also activates the transcription factor, Interferon 
regulatory factor 3 (IRF3), which leads to the expression of IFNs. Mounting evidence suggests 
that the NP protein also has its own unique role in inhibiting PKR activation (198).  Lastly, NS1 
has also been shown to activate phosphatidylinositol 3-kinase (PI3K) in the host, which is a 
pathway that suppresses apoptosis allowing the virus uninterrupted replication and production of 
new virions (197). 
In addition to suppressing the host immune system, the virus is able to directly evade the 
immune system through two robust strategies, antigenic drift and antigenic shift. The former 
occurs because the influenza virus doesn’t have any “proofreading” proteins to correct errors 
made by the RNA polymerase when it synthesizes RNA (180). This is evolutionarily 
advantageous, because it ensures that mutations will be common, resulting in human antibodies 
no longer being able to opsonize the virus. As a result, vaccines need to be updated every year so 
that they can match the strains of circulating viruses. Most antigenic drift sites are located in the 
globular head of the HA1 subunit as the HA2 region has been shown to be strongly conserved 
(183). This makes sense as the globular head of the HA is exposed to antibody opsonization, 
while the HA2 subunit remains mostly hidden and has important functions in fusion, which 
could mutate and result in lower efficacy (Figure 2.7). Even more worrisome is that researchers 
have shown that as few as two amino acid mutations on the H3 or H1 protein can alter its 
specificity for human or avian receptors (190). It is believed that the 1918 Spanish flu pandemic 
occurred because of mutations from the avian H1N1 virus allowing it to infect humans (185).  
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Antigenic shift occurs when two different types of flu viruses infect a cell and exchange 
RNA genes in a process called gene reassortment. This is only able to happen because the 
influenza genome consists of eight individual segments and so if the host is simultaneously 
infected with two viruses, the progeny virions could be composed of RNA segments from both 
of the original virions. Reassortment has significant potential to cause pandemics as a new HA 
subtype can easily be introduced into a population where there has been no prior exposure to that 
HA to gain immunity (185). The 1957 Asian flu pandemic, the 1968 Hong Kong flu, and the 
2009 swine flu pandemic were all caused by reassortment viruses. Pigs are often highlighted due 
to their susceptibility to serve as mixing vessel for reassortment (183). Specifically, the upper 
respiratory tract of humans is composed of sialic acid residues bonded with an α2-6 linkage to 
galactose, while the respiratory tract of avian species is mostly composed of sialic acid residues 
bonded with an α2-3 linkage to galactose (199). HA on influenza viruses specific to avian 
species can only bind to the α2-3 terminated sialic acids, while HA specific to humans can only 
bind to α2-6 terminated sialic acids (199). Pigs on the other hand have α2-3 and α2-6 linked 
sialic acids, which makes them vulnerable to both avian and human viruses. Moreover, this 
provides an enhanced opportunity for avian associated genes to be incorporated into influenza 
viruses specific to humans through reassortment (199). In regards to the avian H5N1 virus, this is 
a serious concern. The H5N1 virus is highly pathogenic and infection results in >70% mortality 
rate and yet the virus is poorly transmitted in humans (200). In a worst case scenario, the virus 
would acquire the ability to be efficiently transmitted, perhaps through reassortment, which 
could induce a potential pandemic due to the lack of adaptive immunological memory in the 
human population. 
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Current circulating strains of the influenza virus are spread through small particle 
aerosols expelled through the air of infected individuals who are coughing (201). This is how the 
virus maintains itself in the human population. Influenza viruses induce symptoms that last 7-10 
days and viral replication generally peaks at 48 hours after infection, but continues to be shed for 
6-7 days (181). The virus initially infects through the upper respiratory tract, but in later stages 
replicates in both the upper and lower respiratory tract. Viral infection in the upper respiratory 
tract causes a loss of the ciliated epithelium, which hinders the host’s ability to trap pathogens in 
mucus and stops mucociliary flow. Replication triggers the release of pro-inflammatory 
cytokines and interferons, which can lead to a systemic immune response that results in the 
classical flu symptoms (185). Serious complications and secondary infections are less common, 
but can occur in high risk groups, such as those who are immunocompromised, those with 
chronic pulmonary diseases, or the elderly. Influenza can be diagnosed by analyzing viral 
antigens or genetic material in clinical samples, or by monitoring the rise and fall in specific 
antibody titers. A very sensitive test is reverse transcriptase-polymerase chain reaction (RT-PCR) 
to look for evidence of the viral genome in respiratory specimens (202). Serologic detection for 
viral antigens is less common. 
The best way for the host to limit the influenza virus is to target the HA protein with 
neutralizing antibodies because this can prevent the virus from binding and fusing to host cells 
(6). Antibodies targeting the NA protein help reduce viral replication by inhibiting the release of 
new viral particles; however they cannot neutralize infectivity. The influenza virus is recognized 
by three PRRs that help stimulate the immune system. Its single-stranded RNA is recognized by 
TLR7 and RIG-I, while the matrix protein M2 activates a member of the NLR family called 
NLRP3 (203). Activation of TLR7 has been found to help antibody isotype switching directly on 
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B cells. RIG-I has a redundant role in that it also recognizes viral RNA, but it is expressed on a 
more diverse repertoire of cells including epithelial cells and mast cells, both of which up-
regulate pro-inflammatory cytokines and Type I interferon (203). Viral clearance from the host 
also depends on an adaptive cell-mediated immune response. Cytotoxic T lymphocytes are 
known to have epitopes to some of internal proteins of the virus including NP, PB2, and PA 
(183; 204). A robust cell-mediated immune response cannot prevent infection against influenza, 
but it can prevent illness and even death. Because the internal proteins of the influenza virus are 
more conserved, a cell-mediated immune response is more apt to handle evolving viral strains. 
2.3.3 H1N1 Virus 
The H1N1 virus is currently one of two circulating influenza A viruses in the human 
population with the other being the H3N2 virus. The H1N1 virus is most notorious for its role in 
both the 1918 Spanish flu pandemic and the 2009 swine flu pandemic. Additional periodic 
outbreaks of H1N1 in the past have also generated widespread fears of an H1N1 pandemic, 
which includes the outbreak at an American military base on Fort Dix in 1976 and the Russian 
Flu epidemic of 1977. More specifically, during the winter of 1975-1976, 200 military personal 
on Fort Dix fell ill with the H1N1 virus. Previously the H1N1 virus of avian origin was 
introduced into the human population through genetic drift in 1918 and circulated until 1958 
when it was replaced by the H2N2 virus during the Asian flu pandemic. The H1N1 virus was not 
in human circulation during the Fort Dix outbreak and so it was concluded that the outbreak was 
caused by zoonotic transmission of swine H1N1 virus into a population that lived in close 
quarters (205). A proactive response was adopted by the military that ensured that the virus never 
made it off the base and into the general population. Zoonotic transmission of avian or swine 
viruses are somewhat common for those who work closely with the animals, but they generally 
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do not result in widespread human-to-human transmission without genetic changes. The H1N1 
virus reappeared once more in 1978 originating from Russia. It was similar to the virus that 
circulated until the 1950’s meaning that those under 25 years of age had no immunological 
memory of the virus and had the highest rate of infection (206). 
Phylogenetic analysis revealed that the 2009 swine influenza virus received its HA, NA, 
and NP proteins from a triple reassortment virus that had been circulating in swine (207). This 
reassortment virus itself had RNA segments that originated from avian, swine, and human 
viruses. In addition, the 2009 swine influenza virus received its RNA that encoded the NA and 
matrix proteins from a Eurasian swine virus (207). This virus had a unique gene composition 
allowing it to quickly circulate in humans around the globe and making it the first pandemic of 
the 21
st
 century (208). Infection from the virus was relatively mild compared to other pandemics. 
This is because the virus didn’t induce a strong cytokine storm like the 1918 H1N1 virus or the 
H5N1 virus that would cause strong damage in the lungs of the host. Researchers found that it 
was the NA protein that induced the hyper cytokine production in H5N1 and the fear was that if 
the H1N1 virus acquired this gene it would result in a virus that could cause many fatalities 
(209). Even though the virus was milder than what was originally feared, the world faced 
significant shortages of the vaccine during 2009 due to manufacturing problems. This left 
millions of people unvaccinated. Adjuvants were not used in the vaccine, but if they had been, 
experts estimate that it would have allowed four times as many people to be immunized leaving 
less people exposed (210). 
2.3.4 Traditional vaccines and new vaccination approaches 
The severity of influenza infections is most effectively prevented by vaccination or 
through the use of antiviral drugs. Vaccination is the best prophylactic technique to prevent 
47 
 
 
 
infection, while antivirals are good therapeutics. Additionally, when a vaccine is given to an 
entire population, it can induce herd immunity, which will prohibit the virus from spreading 
throughout the population (183). 
Current seasonal vaccines depend on generating an antibody response to the HA proteins. 
Vaccines are formulated from the H1N1, H3N2, and an Influenza B strain, and they are either 
inactivated viruses or live, attenuated viruses (183). In both forms, the virus is generally mass 
produced by propagation in chicken eggs. The selected influenza A strain is co-infected into 
chicken eggs with a laboratory adapted strain (PR8) designed for rapid growth in eggs. These 
newly “reassorted” viruses are selected for their ability to grow rapidly and still have the 
epidemic surface proteins (188). It is this strain that is distributed to manufacturers for 
propagation in eggs; however, for influenza B, there are no high growth laboratory adapted 
strains and so the mass produced vaccine is from the wild-type virus. In addition, since 2013, the 
WHO has included a second influenza B strain in their annual list of strain recommendations and 
so some manufacturers have decided to make a quadrivalent vaccine (188). The virus and the 
fluid of the egg, the allantoic fluid, are harvested. Centrifugation at extremely high speeds 
removes the virus from soluble contaminants. After processing, one egg yields enough virus for 
approximately three doses of vaccine for one strain, while the total manufacturing process for a 
season’s worth of vaccines can take up to six months (183; 211). 
Only since 2007 have vaccines become available from viruses cultured in cells (188; 
212). By avoiding eggs, manufacturers don’t have to worry about egg allergies within the general 
public, and can better control scale-up and sterility. The most successful cell lines for growing up 
the influenza virus are Vero cells and Madin-Darby Canine Kidney (MDCK) cells (212). 
However, this process is still very technically challenging and so only a small fraction of 
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vaccines are produced through this technique. For example, the surface proteins HA and NA are 
heavily glycosylated and one challenge with viruses produced in cell culture is replicating these 
glycosylation patterns. In a recent study, researchers found that HA derived from viruses grown 
in MDCK cells had complex glycans that were terminated in α or β galactoses (213). In contrast, 
HA derived from viruses in Vero cells had low molecular weight glycans that terminated only in 
β-galactose or high mannoses. The latter variant stimulated splenocytes to produce more IL-2 
and IFN-γ, while enhancing T cell proliferation (213). It is hypothesized that the HA produced 
from Vero cells is more immunogenic, because the high mannose glycans were able to interact 
with CLRs. 
After culturing the virus in cells or eggs, the grown influenza virus is then chemically 
treated and combined with other strains to make a trivalent inactivated vaccine (TIV). The 
chemical treatment method used will determine the specific type of vaccine. Whole inactivated 
vaccines are made by treating the virus with formaldehyde or β-propiolactone. Split vaccines and 
subunit vaccines are the result of viruses being treated with sodium dodecyl sulfate or other 
detergents.  The detergents breakdown the viral membrane releasing all proteins into solution 
(188). In the subunit vaccine, the HA protein is then purified, whereas all of the contents remain 
in the split vaccine. The subunit vaccine is known to induce the least amount of adverse 
reactions, but is also the least immunogenic (183). To compensate for the lack of 
immunogenicity it is often times given in two administrations to young children. Typically TIV’s 
consist of 15 μg of each HA antigen for a total of 45 μg of HA protein delivered. For the elderly, 
the dosage has been increased to 60 μg of each HA (214).  It is well known that aging is 
associated with a decline in the immune system, which means a decline in vaccine efficacy 
(182). Researchers have found that one reason for this is because TLR expression is decreased 
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and dysregulated on APCs of older individuals. APCs from young adults were able to produce 
statistically higher amounts of TNF-α, IL-6, and IL-12 after TLR engagement compared to older 
adults (182).  
One problem with the TIV vaccines is that they do not elicit a strong mucosal or 
cytotoxic T lymphocyte immune response (215). In contrast live-attenuated influenza vaccines 
(LAIVs), administered intranasally, have been shown to induce strong IgA antibodies in the 
respiratory tract (216). Given that the influenza virus is a respiratory infection this is a very 
important consideration as an efficacious mucosal response could stop the virus from infecting 
the host. The viruses in the LAIVs are reassortment viruses, produced by co-infecting cells or 
chicken eggs with a virus strain that has been passed through low temperatures and only 
replicates efficiently at 25°C along with the epidemic viruses (189). The temperature in the upper 
respiratory tract is slightly higher and so the attenuated virus cannot replicate efficiently and has 
reduced virulence. Yet it is still able to efficiently mimic a natural infection that helps prime the 
immune system.  LAIVs are produced by MedImmune and have been produced as either a 
trivalent or quadrivalent vaccine. Numerous studies have tried to directly compare LAIVs to 
TIVs. In clinical trials with young children, LAIVs have been shown to be more efficacious and 
they resulted in reduced illness than TIVs (217-219). Fewer comparative studies exist for adults; 
however, there was one clinical study involving nearly 2000 healthy young adults that showed 
the TIV vaccine resulted in the best protection (220). This could potentially be because the TIVs 
are known to induce a strong systemic response that leads to a better serum antibody response 
compared to LAIVs. The general consensus in adults is that TIVs induce as good or a better 
immune response than LAIVs (221). Given that LAIVs are live viruses, there is some concern 
that these viruses could revert to their pathogenic form in immunocompromised individuals. One 
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clinical study showed that this generally was not a problem because no adverse reactions 
occurred and there was no detection of increased viral shedding (222).  
A new generation of novel vaccines for influenza is in development, which is working to 
overcome the limitations of TIVs and LAIVs (223). These newer vaccines do not use eggs to 
grow the virus, but often use expression systems to recombinantly produce HA subunits. The 
most successful of these is the baculovirus expression system (BEVS). This protocol was first 
used to make the papilloma virus vaccine and given its record of safety and ability for mass 
production is now being extended to influenza (224; 225). Baculoviruses are DNA viruses that 
have the HA coded into them. The baculovirus is able to infect insect cells, which makes large 
amounts of protein that has been coded into the viral genome. In the case of HA, the system 
makes the HA0 protein that doesn’t get cleaved into HA1 or HA2. Experiments with 
recombinant H5 proteins that were made from both insect cells and mammalian Chinese Hamster 
Ovary (CHO) cells showed that the H5 produced from both cell lines had undergone post-
translation modifications and were glycosylated differently (226). Insect-produced H5 had N-
glycans consisting of mannose that were significantly shorter and less complicated than the 
mammalian cells lines. Upon in vivo injection into mice, the H5 produced from insect cell lines 
had the highest antibody titers. However, the H5 from mammalian cells lines had better 
neutralizing and HA inhibition titers allowing mice immunized with this H5 to have a better 
chance at protective immunity when challenged with a live virus (226). This is another example 
illustrating the importance of how recombinantly produced proteins can be affected by their host 
cell line. Yet other studies have shown that HA produced using the BEVS can induce the same 
immunogenicity as egg based TIVs (227). In terms of mass production, this system also has the 
advantage that no live virus is used, lowering the danger level for those involved in the 
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production process, unlike the egg-based or cell culture methods. One company, Protein 
Sciences Corporation, has an FDA-approved influenza vaccine, named FluBlok, that was 
generated using insect cell fermentations (228). The entire process of cloning, expression, and 
manufacturing took two months, which is significantly shorter than the six months that is 
generally needed for the egg-based method (227; 229). 
There has also been interest in using plants as a source to recombinantly express HA 
antigens. Plant expression systems would have the same beneficial safety features for mass 
production as the BEVS and the potential for scalability (230). In the plant system, a viral vector 
named Agrobacterium tumefaciens is used to introduce recombinant proteins into tobacco plants. 
Plant produced HA is antigenic as confirmed by ELISAs and has been shown to induce an 
immune response in mice with as little as 5 μg (231). Studies with mice and ferrets showed that 
they induce both cellular and humoral immune responses (231; 232). Usually the antigen is 
administered in conjunction with adjuvants, such as, Quil-A or Alum (230). 
Delivery systems are being designed to enhance the versatility of subunit proteins 
produced through these expression systems and adjuvant the immune response. Using 
polyanhydride delivery vehicles, researchers have demonstrated that H5 antigen encapsulation 
into nanoparticles results in sustained protein release and enhanced protein stability during in 
vitro degradation studies (55). Whereas soluble antigen results in weaker immune responses 
requiring larger doses, the polyanhydride nanoparticles slowly release stable and functional 
proteins while also serving as an adjuvant to provide a dose sparing effect for expensive proteins 
(60). Other types of polymers have been used to synthesize nanoparticles and encapsulate or 
adsorb influenza antigens to their surface. This includes the use of calcium phosphate, PCL, or 
PLGA nanoparticles (72; 227; 233; 234). Antigen on calcium phosphate nanoparticles is 
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functionalized to the surface because the calcium phosphate is a hard inorganic material that only 
breaks down in the lysosomes of cells (233). HA loaded PCL particles yielded strong 
hemagglutinin inhibition titers and induced a more balanced Th1 and Th2 immune response with 
a single intranasal or intramuscular immunization in mice (72). Using nanoparticle delivery 
systems opens up new routes for vaccine delivery including intranasal and oral delivery because 
the antigen is stabilized and is no longer exposed to a degradative environment. In one example, 
researchers found that subunit antigen had low mucosal permeability and was often times 
unstable in the intestinal environment (235). Encapsulating the antigen into nanoparticles 
stabilized the antigen and the particles were easily phagocytosed by M cells (235). 
The poor immunogenecitiy of subunit vaccines can be overcome by incorporating 
adjuvants into vaccine formulations, which can be used with or without delivery vehicles. 
Adjuvants are compounds that increases the potency of an immune response to an antigen by 
promoting antigen uptake or targeting specific immune pathways (211). Adjuvants that have 
been FDA-approved for vaccines include the oil-in-water emulsions MF59 and AS03, aluminum 
salts known as alum, and monophosphoryl lipid A (MPLA) (183; 236). MPLA is approved for 
use in the human papilloma virus vaccine and the Hepatitis B virus vaccine, but is not often 
found in influenza vaccines. Alum is sometimes used in influenza TIV vaccines and it functions 
by activating the NLRP3 complex as part of the NLR family of PRRs. Antigen adsorbed to alum 
is presented as a particulate allowing for better internalization and ultimately induction of a 
strong antibody response (236). Alum has a strong safety record since the 1920’s, but the 
disadvantage is that it does not elicit a strong cell-mediated immune response (237). A more 
recent alternative is MF59, which is produced by Novartis. MF59 has been used in many studies 
with influenza and although its mechanism is unknown, the adjuvant has been shown to induce 
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long lasting antibody and T cell responses (238; 239). It works similarly to alum by enhancing 
antigen uptake by APCs and specifically it has been shown to be more effective than alum at 
recruiting neutrophils to the injection site and inducing better antigen transport to the draining 
lymph nodes (240). Even though it induces a strong immune response at the injection site, unlike 
alum, it does not establish an antigen depot (241). AS03 is also an oil-in-water emulsion made by 
GlaxoSmithKline and it has been approved for use against H5N1 and was extensively tested in 
the 2009 H1N1 pandemic influenza vaccine (242; 243).  
Another delivery system being explored as vaccine adjuvants and/or delivery vehicles are 
virus-like particles (VLPs), which are essentially an assembly of influenza structural proteins. 
Morphologically they look like a live virus, but they are packaged without RNA and so they are 
unable to replicate, making them safer than live attenuated vaccines (183). VLPs have been 
produced in baculovirus and plant expression systems (224; 244). The plant-produced VLPs in 
combination with alum have been able to induce an immune response in mice with as little as 0.5 
μg (230). The baculovirus expression system was used to produce H9N2 VLPs, which expressed 
HA, NA, and M1 (245). These recombinant structural proteins were able to self-assemble into 
80-120 nm diameter spheres when expressed and induced protective immune responses in 
BALB/c mice. It has been shown that VLPs induce an immune response with a different profile 
compared to soluble recombinant HA as not only are antibodies against NA produced, but there 
is also more class switching to a Th1 based immune response (246).  
2.4 Conclusions 
Vaccines have a long and proven record of positively contributing to public health. The 
use of nanotechnologies as a delivery platform as well as incorporating ligands that actively 
target immune cells will further improve the efficacy of future vaccines. These next generation 
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systems will have the potential to provide controlled antigen release, dose sparing capabilities, 
single dose vaccination, and modulation of the immune response.  Many of these next generation 
nanovaccines are already in development to combat the influenza virus. The following chapter 
introduces the specific research objectives for this thesis. Later chapters describe research that 
utilizes surface functionalized polyanhydride nanovaccines in order to actively target immune 
cells and future work will investigate applying these systems to design an influenza vaccine.   
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2.6 Figures 
 
Figure 2.1 Hydrolysis and condensation of polyesters (top) and polyanhydrides (bottom). 
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Figure 2.2 Drug release from bulk eroding polymers such as, polyesters (top) and drug released 
from surface eroding polymers such as polyanhydrides (bottom) when incubated in an aqueous 
solution over an extended period of time. 
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Figure 2.3 Methods of particle fabrication. A) Spray drying begins when the solvent and its 
dissolved polymer are atomized in the presence of a stream of warm air. Particles are formed in 
the drying chamber as the solvent evaporates and a cyclone is used to collect the particles. The 
air is filtered as it exits. B) In nanoprecipitation the polymer is dissolved in a solvent while the 
protein to be encapsulated is dispersed in this solvent. Particle formation occurs when exposing 
this solution to an anti-solvent and these particles are collected through vacuum filtration. 
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Figure 2.4 Representative image of a liposome. It consists of a lipid bilayer commonly 
composed of phosphatidylcholine, phosphatidylethanolamine, or phosphatidylserine. The inner 
core is aqueous which is good for encapsulating water soluble proteins or nucleic acids. 
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Figure 2.5 Expression of pattern recognition receptors on an immature antigen presenting cell 
(APC). CLRs are surface receptors that have great diversity in structure and signaling. TLRs 
dimerize upon binding to their ligand in a tail-to-tail type organization and then signal through 
TRAM/TRIF or MAL/MYD88. NF-kB and IRF3 translocate to the nucleus and play a major role 
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in the innate immune systems response to infection. Most TLRs are surface receptors but there 
are several that are expressed in endosomes. RIG-I from the RLR family and NOD1 as well as 
NOD2 from the NLR family are cytosolic PRRs that exist in a folded conformation until their 
PAMP binds. ATP dependent unfolding occurs followed by oligomerization allowing the 
CARDs to signal downstream. 
 
 
Figure 2.6 Representative illustrations of the large diversity of mechanisms that can be utilized 
for active targeting of antigen or drugs. Non-cell based active targeting strategies can fall under 
three categories including functionalized antibodies, functionalized antigen, or functionalized 
materials. There is considerable overlap between all three strategies. 
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Figure 2.7 Structural depiction of an influenza virion. It has 8 strands of RNA that are covered 
in nucleocapsid proteins and are also bound to the RNA polymerase complex. The surface of the 
virion is mostly covered in hemagglutinin (HA) and neuraminidase (NA). HA is a trimer with 
each component having two subunits, HA1 and HA2. HA binds to sialic acid domains through 
its globular head on the HA1 subunit. The fusion domain is expressed on HA2 which remains 
mostly hidden until binding to sialic acid domains inducing a conformational change. 
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2.7 Tables 
Table 2.1 Common classes of biodegradable polymers used in drug delivery. 
 
 
  
8
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Table 2.2 Pattern recognition receptors, their ligands, and their expression on antigen presenting cells. 
PRR Receptor Ligand Cellular Expression Location 
CLRs 
Macrophage Mannose 
Receptor 
Low order Mannoses Immature APCs, tissue macrophages Surface 
DEC-205 Unknown 
Dendritic Cells, Langerhans Cells,  
B Cells, NK cells 
Surface 
DC-SIGN Higher order Mannoses, Mac-1 Immature APCs, tissue macrophages Surface 
Dectin-1 β-glucans 
Dendritic Cells, Macrophages,  
Neutrophils 
Surface 
Macrophage Galactose  
Lectin 
Terminal galactoses, N-acetylgalactosamine Immature APCs Surface 
TLRs 
TLR4 
Lipopolysaccharides, Monophosphoryl  
Lipid A, Glucopyranpsyl Lipid A 
Monocytes, Myeloid Dendritic Cells, 
 M cells 
Surface 
TLR2-TLR1 Complex Pam2CSK4, peptidoglycan, zymosan 
Monocytes, Myeloid Dendritic Cells, 
 T cells 
Surface 
TLR2-TLR6 Complex Pam2CSK4, peptidoglycan, zymosan 
Monocytes, Myeloid Dendritic Cells, 
 T cells 
Surface 
TLR5 Flagellin Epithelial Cells Surface 
TLR3 Poly(IC), Poly(ICLC), dsRNA Dendritic Cells Endosome 
TLR9 CpG DNA Plasmacytoid Dendritic Cells, B cells Endosome 
TLR7 ssRNA, Imiquimod Plasmacytoid Dendritic Cells Endosome 
TLR8 ssRNA Circulating Monocytes Endosome 
TLR11 Flagellin, Profilin 
Macrophages, Dendritic cells,  
Liver and Kidney Epithelial Cells 
Endosome 
RLRs 
RIG-I short ssRNA, dsRNA, poly(da:dT) Epithelial Cells, Mast Cells Cytosolic 
MDA5 long dsRNA, Poly(IC) Epithelial Cells Cytosolic 
NLRs 
NOD1 meso-diaminopemilic acid (DAP) Epithelial Cells, Paneth Cells Cytosolic 
NOD2 muramyl dipeptide (MDP) Monocytes Cytosolic 
APAF-1 cytochrome c Epithelial Cells, Paneth Cells Cytosolic 
Ipaf Flagellin Epithelial Cells, Paneth Cells Cytosolic 
NLRP3 ssRNA, extracellular ATP Epithelial Cells, Paneth Cells Cytosolic 
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Table 2.3 Chemical techniques used to functionalize drug delivery vehicles with ligands. 
1)
 Intermediates are 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-
hydroxysulfosuccinimide (Sulfo-NHS).  
2)
 Heterobifunctional linker that is 4-(4-N-maleimidophenyl)butyric acid hydrazide (MBPH).  
4)
 Heterobifunctional linker that is succinimidyle-4-(N-maleimidomethyl)cyclohexane-1-carboxylate 
(SMCC)  
5)
 Homobifunctional linker that is glutaraldehyde  
6)
 Intermediate that is 4-Toluenesulfonyl chloride (TsCl) 
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Table 2.4 The function of proteins expressed on an influenza virion. 
Protein/Complex Abbreviation Location Function 
Hemagglutinin HA 
Surface of Lipid 
Envelope 
Responsible for membrane viral  
and cellular membrane fusion 
Neuraminidase NA 
Surface of Lipid 
Envelope 
Cleaves virion from host cell receptor 
to allow viral propagation 
Ion Channel 
Protein 
M2 
Transmembrane 
Protein 
Helps regulate virus uncoating by 
allowing ions in  
or out of the lipid envelope 
Matrix Protein M1 
Inner Membrane 
Protein 
Interacts with nucleocapsids to help 
assembly 
Nonstructural  
Protein 1 
NS1 
Within Lipid 
Envelope 
Suppresses host immune system 
Nonstructural  
Protein 2 
NS2 
Within Lipid 
Envelope 
Helps with viral RNA replication that  
occurs in the nucleus 
Nucleocapsid 
Protein 
NP Bound to RNA 
Bound to viral RNA and influences 
 viral RNA synthesis 
RNA Polymerase  
Complex 
PA, PB1, PB2 Bound to RNA 
Directly synthesizes messenger RNAs 
andinvolved in genome replication 
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CHAPTER 3: RESEARCH OBJECTIVE AND THESIS ORGANIZATION 
3.1 Research Objectives 
The overall goal of this research is to synthesize targeted nanoparticle-based vaccines 
against influenza virus. Even though there are a large number and a wide variety of influenza 
vaccines manufactured for human use every year, the virus continues to pose a significant public 
health problem.  First, it has the ability to rapidly change its antigenic structure thereby avoiding 
the immune system, and secondly it has a large presence in animal reservoirs making zoonosis a 
constant threat. Current vaccines are limited, because they have different levels of efficacy 
across age groups and are notably weaker in the elderly. The intramuscular vaccines induce poor 
mucosal immune responses, and generally, they need to be stored cold. Additionally, the 
manufacturing process requires several months of lead time, putting significant strain on the 
ability to match the vaccine to circulating strains. A new generation of rationally designed 
influenza vaccines is necessary to combat these threats. In this regard, the use of nanovaccine 
technologies in influenza vaccine development shows great promise. Nanovaccine technologies 
can adjuvant the immune response and provide dose-sparing. This could help alleviate the 
burden on manufacturers because lower amounts of antigen will be required, while 
simultaneously increasing the efficacy, especially in at-risk populations. Nanovaccines have also 
been successfully administered by different routes, including intranasally, which is important for 
the induction of mucosal immune responses. This could improve patient compliance for 
influenza vaccines. The rational design of a safe influenza A vaccine utilizing the polyanhydride 
nanovaccine platform that induces long lasting protective immunity is described in this thesis. 
The study has been organized into several specific goals (SGs) as shown below: 
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SG1: Study the interactions between carbohydrate-functionalized nanoparticles and serum 
proteins and their effects on dendritic cell activation; 
SG2:  Investigate the safety and biocompatibility of carbohydrate-functionalized nanoparticles in 
vivo; 
SG3: Evaluate the ability of carbohydrate-functionalized nanoparticle-based formulations to 
induce humoral and cell-mediated immunity; and 
SG4: Test the efficacy of lead candidate targeted nanovaccine formulations using the 
hemagglutinin antigen. 
SG1 describes in vitro studies that focused on determining the role of the interactions 
between polymer chemistry, carbohydrate functionalization, and serum protein adsorption on 
dendritic cell activation. These studies identified nanoparticle formulations that are efficiently 
internalized by dendritic cells and that induced dendritic cell maturation. In SG2, the safety and 
biocompatibility of these carbohydrate-functionalized nanoparticles were evaluated by analyzing 
the histopathology of the liver, kidneys, and lungs of mice administered with these nanoparticle 
treatments. The cytokine and chemokine secretion in the bronchoalveolar lavage fluid as well as 
biomarkers in the blood and urine were analyzed for histopathological changes. In SG3, the 
ability of the carbohydrate-functionalized to induce potent cellular and humoral immune 
responses was evaluated using a model antigen, ovalbumin. In SG4, the results from the studies 
described in SG1, SG2, and SG3 were utilized to design efficacious nanoparticle-based 
formulations containing the influenza hemagglutinin antigen based on immune response 
evaluations as well as live viral challenge.  
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3.2 Thesis Organization 
The rationale, methods, results, and conclusions of the four specific goals are discussed in 
the following three chapters. Chapter 4 focuses on SG1, which covers the in vitro cell culture and 
cellular stimulation with the carbohydrate-modified nanoparticles. Chapter 5 outlines the 
completion of SG2 and discusses the safety and biocompatibility of the carbohydrate-modified 
nanoparticles. The ability of carbohydrate-modified nanoparticles to adjuvant the in vivo immune 
response shown by SG3 was evaluated in Chapter 6. Chapter 7 describes the use of a novel robot 
to synthesize combinatorial libraries of nanoparticles. This robot can surface functionalize 
nanoparticles which will aid in the screening and selection of functional groups that can target 
receptors on cells. Chapter 8 summarizes SG4 and evaluating where mice immunized with 
hemagglutinin loaded nanoparticles can withstand a live viral challenge. Chapter 9 highlights 
ongoing and future work and summarizes the results of this thesis.  
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4.1 Abstract 
Biodegradable polyanhydride nanoparticles have been used as vaccine adjuvants and 
delivery vehicles. Upon parenteral administration, the surface characteristics of these 
nanoparticles may be modified by serum protein adsorption, likely affecting how the particles 
interact with antigen presenting cells. These studies investigated the role of the differential 
adsorption of serum proteins onto carbohydrate-functionalized and non-functionalized 
polyanhydride nanoparticles of different chemistries on interactions with dendritic cells (DCs). 
Di-mannose (a carboxymethyl-modified disaccharide of 1,2-α-linked-D-mannopyranoside) or 
glycolic acid was covalently linked to nanoparticles synthesized using copolymers of 1,6-bis(p-
carboxyphenoxy)hexane (CPH) and sebacic acid (SA) and 1,8-bis(p-carboxyphenoxy)-3,6-
dioxaoctane (CPTEG) and CPH. Serum protein adsorption to CPH:SA nanoparticles enhanced 
particle internalization, but did not enhance uptake of CPTEG:CPH nanoparticles. When DCs 
were cultured with nanoparticles, the surface expression of MHC II, CD86, and CD206 was 
enhanced and mediated by both polymer chemistry and functionalization. Cytokine secretion by 
DCs was differentially modulated by both polymer chemistry and functionalization. The amount 
and profile of serum proteins adsorbed indicated that polymer hydrophobicity and 
functionalization enhanced protein adsorption. Overall polymer chemistry, functionalization, and 
serum protein adsorption influenced nanoparticle interactions with DCs and elucidating the 
complex relationships between these parameters and dendritic cell maturation will enable 
rational design of targeted vaccines and immunotherapies. 
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4.2 Introduction 
Vaccine delivery vehicles based on biodegradable polymeric nanoparticles present 
several advantages over traditional vaccines, including stabilization of encapsulated antigens, 
tailored erosion profiles leading to sustained antigen release, and enhanced adjuvant activity (1; 
2). In particular, biodegradable polyanhydride nanoparticles have demonstrated the ability to 
induce immunomodulatory activity, be internalized effectively by antigen presenting cells, and 
provide dose-sparing capabilities (3-5). 
Dendritic cells (DCs) have the ability to internalize, process, and present antigen to naïve 
T cells, establishing them as a powerful link between the innate and adaptive immune responses 
(6; 7). Dendritic cells use pattern recognition receptors (PRRs) to bind microbial associated 
molecular patterns (MAMPs) that in turn result in cellular activation. Examples of PRRs include 
Toll-like receptors (TLRs), NOD-like receptors (NLRs), and C-type lectin receptors (CLRs) (6). 
Specifically, CLRs comprise a diverse group of over 60 receptors that bind to carbohydrate 
moieties using highly conserved carbohydrate recognition domains (8). Many of them function 
by internalizing antigen for loading onto major histocompatibility complex (MHC) class I and II 
molecules while others function in tandem with other PRRs to influence intracellular signaling 
(9).  
An oft-used strategy in vaccine development is to use specific ligands to target PRRs, 
such as, CLRs, in order to impart potent adjuvant properties (10; 11). This “pathogen-
mimicking” strategy allows for more efficient processing and presentation of antigen in the 
context of MHC I and II and interaction with T cells. This immune enhancing activity has been 
achieved previously by using delivery vehicles whose surfaces have been modified by attaching 
anti-CLR antibodies or carbohydrate moieties. While antibody-mediated targeting of CLRs 
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offers a high degree of specificity, a major limitation of this approach is that antibodies elicit 
immune responses that neutralize their effectiveness because of their inherent immunogenicity 
(12). In contrast, carbohydrate ligands are generally non-immunogenic and can be more readily 
synthesized in pure form (12). Previous studies have demonstrated the effectiveness of 
functionalizing drug and/or vaccine delivery vehicles with carbohydrates (13-16). For example, 
di-mannose is present on the surface of Mycobacterium tuberculosis (and other pathogens) and is 
known to target a CLR, the macrophage mannose receptor (17). The macrophage mannose 
receptor, also known as CD206, is commonly expressed on immature DCs and macrophages and 
is known to bind to lower order mannose moieties and mediate internalization of microorganisms 
expressing mannosylated glycoproteins (18; 19).
 
 This receptor-mediated internalization 
mechanism can be exploited to enhance the ensuing immune response. 
Recent work from our laboratory has shown that differential protein adsorption onto 
polyanhydride particles is mediated by polymer chemistry, which in turn influences the in vitro 
activation (e.g., phagocytosis, cell surface marker expression, cytokine secretion) of DCs (20; 
21). It has also been shown that copolymers based on sebacic acid (SA) and 1,6-bis(p-
carboxyphenoxy)hexane (CPH) and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and 
CPH (Figure 4.1A) have different characteristics that could potentially affect the immune 
response (3; 13; 21; 22). Contact angle and degradation kinetics data have demonstrated that the 
20:80 CPTEG:CPH chemistry is significantly more hydrophobic than the 20:80 CPH:SA 
chemistry (23; 24). These two formulations have been shown to be potent adjuvants, based on 
their ability to enhance both humoral and cell-mediated immunity (3; 4; 25).
 
However, the role of nanoparticle surface modification following serum protein 
adsorption on DC activation is yet unclear. It is known that serum proteins will adsorb onto the 
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surfaces of parenterally administered nanoparticles and affect how nanoparticles interact with 
antigen presenting cells and the nature of the resulting immune response. For example, the 
binding of complement proteins or immunoglobulins could provide important ligands to enhance 
antigen presenting cell-mediated phagocytosis of the nanoparticles and the subsequent 
processing of the encapsulated antigen. The purpose of this study was to investigate the role of 
polymer chemistry and carbohydrate functionalization on interactions with DCs. We 
hypothesized that nanoparticle surface functionalization would enhance the interactions between 
polyanhydride nanoparticles and DCs resulting in differential modulation of DC maturation and 
polyfunctionality as compared to non-functionalized particles. The current studies demonstrate 
that polymer chemistry-dependent functionalization affect DC biology by differentially 
regulating DC surface marker expression and cytokine production. This work provides insights 
into the in vivo performance of functionalized nanoparticles and demonstrates that these particles 
serve as more than vaccine-delivery vehicles as they directly interact with and modulate DC 
responses.   
4.3. Materials and Methods 
4.3.1 Materials 
The chemicals needed for monomer synthesis included 1,6-dibromohexane, triethylene 
glycol, 4-p-hydroxybenzoic acid, and 1-methyl-2-pyrrolidinone which were purchased from 
Sigma-Aldrich (St. Louis, MO). 4-p-fluorobenzonitrile was obtained from Apollo Scientific 
(Cheshire, UK), while toluene, sulfuric acid, acetonitrile, dimethyl formamide, acetic anhydride, 
methylene chloride, pentane, and potassium carbonate were obtained from Fisher Scientific 
(Fairlawn, NJ). Chemicals used for polymerization and nanoparticle synthesis included 
petroleum ether, pentane, acetic anhydride, chloroform, and methylene chloride, and they were 
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also purchased from Fisher Scientific. 
1
H NMR analysis was conducted using deuterated 
chloroform from Cambridge Isotope Laboratories (Andover, MA). Cadmium selenide quantum 
dots (QDs) emitting at 630 nm were kindly synthesized by Dr. Yanjie Zhang of Iowa State 
University. Materials for nanoparticle functionalization included N-hydroxysuccinimide (NHS) 
from Fisher Scientific, ethylenediamine from Sigma Aldrich, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) and glycolic acid from Acros Organics (Geel, 
Belgium). 
Materials for 2-D gel electrophoresis included 4-20% Tris-HCl linear gradient 
polyacrylamide gels, 7 cm non-linear pH 3-10 immobilized pH gradient (IPG) strips, Flamingo 
gel stain, and Precision Plus protein standards, all of which were obtained from BioRad 
Laboratories (Richmond, CA). Rehydration buffer and sodium dodecyl sulfate equilibration 
buffer was formulated from urea, Bromophenol Blue, tris-Cl, glycerol, and sodium dodecyl 
sulfate was received from Fisher Scientific and CHAPS detergent was purchased from BioRad 
Laboratories. 
The DC culture medium was composed of β-mercaptoethanol (Sigma-Aldrich), 
granulocyte-macrophage colony-stimulating factor (GM-CSF) (PeproTech, Rocky Hill, NJ), heat 
inactivated fetal bovine serum (Atlanta Biologicals, Atlanta, GA), and RPMI 1640, 
penicillin/streptomycin, and L-glutamine (MediaTech, Herndon, VA). Escherichia coli 
lipopolysaccharide (LPS) 026:B6 was purchased from Sigma Aldrich.  
Materials used in flow cytometry included BD stabilizing fixative solution from BD 
Bioscience (San Jose, CA), while FITC anti-mouse CD11c (clone N418), antigen presenting cell 
anti-mouse CD206 (clone C068C2), PE-Cy7 anti-mouse CD86 (clone GL-1), FITC Armenian 
hamster IgG isotype control (clone HTK888), antigen presenting cell rat IgG2aκ isotype control 
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(clone RTK2758), PE-Cy7 rat IgG2aκ isotype control (clone RTK2758) were purchased from 
Biolegend (San Diego, CA). V500 rat anti-mouse I-A/I-E (clone m5/114.15.2) and V500 IG2bκ 
isotype control (clone A95-1) were obtained from BD Bioscience. 
4.3.2 Monomer and Polymer Synthesis 
Sebacic acid (SA) was purchased from Sigma Aldrich, while CPH and CPTEG diacids 
were synthesized as described previously (23; 26; 27). Techniques described by Shen et al.
  
and 
Conix were used to synthesize SA and CPH prepolymers and a melt polycondensation reaction 
was carried out to synthesize 20:80 CPH:SA and 20:80 CPTEG:CPH copolymers (23; 28; 29).
 
Purity, chemical structure, and molecular weight of the polymers were determined using 
1
H 
NMR spectroscopy on a Varian VXR 300 MHz spectrometer. The 20:80 CPH:SA copolymer 
had a molecular weight of 13.5 kDa, while the 20:80 CPTEG:CPH copolymer had a molecular 
weight of 7.5 kDa, which is consistent with previous work (5; 22). The actual molar ratios were 
determined to be 22:78 CPH:SA and 21:79 CPTEG:CPH using 
1
H NMR analysis. 
4.3.3 Nanoparticle Synthesis: 
Polyanhydride nanoparticles were synthesized using an anti-solvent nanoencapsulation 
technique (5). A 20 mg/mL polymer solution in methylene chloride was poured into a pentane 
bath so that the ratio of solvent to anti-solvent was 1:250. 20:80 CPH:SA nanoparticles were 
synthesized at room temperature, whereas 20:80 CPTEG:CPH nanoparticles were synthesized in 
a 4 °C cold room with the pentane bath held at -40 °C. For the QD-loaded particles, the synthesis 
procedures were identical to that of the blank nanoparticles except for the addition of 1% (w/w) 
of QDs into the methylene chloride to form QD-loaded nanoparticles. The particles were 
collected by vacuum filtration. Particle morphology was examined by a FEI Quanta 250 
scanning electron microscope (SEM) (Kyoto, Japan) after being coated with 2 nm of iridium 
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using a Quorum Q150TS sputter coater (Lewes, UK). Nanoparticle size distribution was 
characterized using ImageJ image analysis software (National Institutes of Health, Bethesda, 
MD) with an average of 200 nanoparticles per image. 
4.3.4 Nanoparticle Functionalization 
The particles were functionalized with either di-mannose or a glycolic acid linker, which 
links the di-mannose to the ethylenediamine (Figure 4.1C). Fluorous solid-phase extraction-
based iterative synthesis was performed to obtain α-1,2-linked-di-mannopyranoside with a 
fluorous allyl group (30). The fluorous tag was cleaved by ozonolysis, while oxidation with 
Jones Reagent produced a carboxylic acid group for coupling to nanoparticles. Birch reduction 
was used to yield a deprotected carboxymethyl-modified disaccharide of 1,2-α-linked-D-
mannopyranoside (17; 30). A previously optimized two-step amide coupling reaction covalently 
linked the di-mannose to the nanoparticles (14; 15). The first reaction involved incubating the 
nanoparticles with 10 mole equivalents of EDC, 12 mole equivalents of NHS, and 10 mole 
equivalents of ethylenediamine for one hour on a tube rotor at 4 °C. The nanoparticles were then 
washed with nanopure water and were collected by centrifugation at 10,000 rcf and 10 min. 
After being sonicated briefly at 40 Hz, the nanoparticles were incubated with 10 mole 
equivalents of EDC, 12 mole equivalents of NHS, and 10 mole equivalents of di-mannose for 
one hour at 4 °C allowing the di-mannose to be attached to the free amine of the ethylenediamine 
on the surface of the nanoparticles.  
4.3.5 Characterization of Functionalized Nanoparticles 
Quasi-elastic light scattering (QELS) using a Zetasizer Nano (Worchester, UK) was 
employed to determine the zeta potential (ζ) of the nanoparticles. A sonicated solution of 100 
μg/mL of nanoparticles was suspended in cold water before measurement. The sugar density on 
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the surface of the nanoparticles was quantified using a phenol-sulfuric acid assay performed in 
flat bottom 96-well plates (31). A reaction time of 30 min at 95 °C was used for the sugars on the 
nanoparticle surface to be reduced inducing a color change in the solution. The absorbance of 
each well was measured at a wavelength of 490 nm using a SpectraMax M3 spectrophotometer 
(Molecular Devices, Sunnyvale, CA). This was compared against soluble di-mannose standards, 
while non-functionalized nanoparticles were used as a negative control. Energy dispersive X-ray 
spectroscopy (EDS) was performed to assay for nitrogen content from the ethylenediamine. 
4.3.6 Dendritic Cell Culture and Stimulation 
Bone marrow was harvested from C57BL/6 mice purchased from Harlan Laboratories 
(Indianapolis, IN). Specific pathogen-free conditions were used to house the mice where all 
bedding, caging, and feed were sterilized before being used. Approval by the Iowa State 
University Institutional Animal Care and Use Committee was received before conducting animal 
procedures. Bone marrow derived dendritic cells were cultured and differentiated as previously 
described (22; 32; 33). Bone marrow cells were cultured in RPMI medium containing 1% v/v L-
glutamine, 1% v/v penicillin/streptomycin, 0.1% v/v β-mercaptoethanol, 10% v/v heat-
inactivated fetal bovine serum and 10 ng/mL granulocyte-monocyte colony stimulating factor 
until day 10 of culture. After 10 days of culture a small sample of the population was analyzed 
via flow cytometry and confirmed to be at least 80% CD11c positive. A final cell count was 
carried out and one million cells were placed into flat bottom 24-well plates. On the 11
th
 day of 
culture, the DCs were stimulated with 125 μg/mL of QD-loaded or blank (i.e., no QDs) 
nanoparticles. Each nanoparticle suspension was briefly sonicated at 40 Hz to evenly disperse the 
aggregated particles. DCs treated with 200 ng/mL LPS were used as a positive control, while 
non-stimulated DCs served as a negative control. After 48 h of stimulation, cells were harvested 
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for flow cytometric analysis and cytokine secretion. During the internalization experiments, 
“false positives” were accounted for by incubating QD-loaded nanoparticles in culture medium 
for 48 h, followed by centrifugation to pellet the nanoparticles and then exposing the 
supernatants to cells, as described previously (34). 
4.3.7 Flow Cytometric Analysis and Cytokine Secretion Assays 
Expression of cell surface markers MHC II, CD206, and CD86 was analyzed using a 
Becton-Dickinson FACSAria III flow cytometer (San Jose, CA) and the raw fcs files were 
analyzed with FlowJo software (TreeStar Inc., Ashland, OR). Cell-free supernatants were 
collected and analyzed using a BioRad Bio-Plex 200 system (Hercules, CA) for the cytokines IL-
6, IL-1β, TNF-α, and IL-12p40. 
4.3.8 Serum Protein Adsorption onto Nanoparticles 
Nanoparticles were suspended in a 0.1 M phosphate buffered saline (PBS) solution at pH 
7.4 at a concentration of 13.3% w/v. C57BL/6 mouse serum was purchased from Innovative 
Research (Novi, MI) and was stored in aliquots at -80 °C until use. A 1:4 volume ratio of 
nanoparticle suspension to serum was incubated for 30 min at 37 °C in a shaker to achieve 
adsorption. Non-serum coated particles were incubated in PBS for the same duration under the 
same conditions to serve as a control. Following incubation, the particles were pelleted from the 
suspension by centrifugation at 12,000 rcf for 10 min. The supernatant was removed and 
replaced by an equal volume of PBS. Non-adsorbed proteins were removed from the 
nanoparticles by pelleting the nanoparticle suspension once more by centrifuging at 12,000 rcf 
for 10 min. The process of pelleting nanoparticles and resuspending them in PBS was repeated 
thrice. After the last wash, nanoparticles were dried in a vacuum oven for one hour and stored at 
-20 °C until further use. 
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4.3.9 Characterization of Protein Adsorption 
Proteins adsorbed to the nanoparticles were quantified and characterized using a 
bicinchoninic acid (BCA) assay and 2-D gel electrophoresis following elution. 10 mg of dried 
nanoparticles were suspended in 250 μL of elution buffer for 10 min at 95 °C to elute the 
adsorbed serum proteins. The elution buffer consisted of a solution of 10% w/v sodium dodecyl 
sulfate and 2.3% w/v dithiothreitol. The nanoparticles were separated from the eluted proteins in 
the elution buffer by centrifugation at 12000 rcf for 10 min. This protocol has been shown in 
previous studies to remove nearly all of the adsorbed proteins from particles (20; 21). The eluted 
protein solution was passed through a detergent removal column (Thermo Scientific, Rockford, 
IL) to remove the sodium dodecyl sulfate that would impede isoelectric focusing during 2-D gel 
electrophoresis. Portions of the eluted protein solution used in the BCA assay were dialyzed 
against PBS using a 3 kDa MWCO spin column (Corning, NY) to remove the dithiothreitol that 
would otherwise interfere with the reagents of the BCA assay. Equal volumes of the eluted 
protein solution were then used in a BCA protein assay kit to determine the amount of proteins 
adsorbed to the nanoparticles.  
Additionally equal volumes of the eluted protein solution from the 20:80 CPTEG:CPH 
nanoparticles were loaded onto 7 cm IPG strips, pH 3-10, and underwent active rehydration 
where the proteins were allowed to diffuse into the IPG strip during a voltage ramping protocol 
that included 50V for 12 h, 500V for 1 h, 1000V for 1 h, and 8000V for 8 h. This was carried out 
using an Ettan IPGPhor III system (GE Healthcare, Piscataway, NJ). The set point for current 
was 50 μA. The eluted protein solution from the 20:80 CPH:SA nanoparticles required passive 
rehydration for the proteins to separate by isoelectric points. Equal volumes of eluted protein 
solution from 20:80 CPH:SA nanoparticles were loaded onto 7 cm IPG strips, pH 3-10, and were 
then coated in mineral oil for 12 h to prevent drying during the passive rehydration process. 
102 
 
 
 
Subsequently, the rehydrated IPG strips underwent the same voltage ramping protocol as 
described before. 
The second dimension of separation was carried out by loading the IPG strips onto 7 cm 
4-20% Tris-HCl polyacrylamide gels for 2.5 h at 110V. Also loaded into the gel were Precision 
Plus protein standards from BioRad which included molecular weight standards ranging from 
250 kDa to 10 kDa. The gels were then placed in a fixative solution, which contained 40% v/v 
ethanol and 10% v/v acetic acid, for 3 h at 4 °C. Subsequently the gels were stained with a 
BioRad fluorescent flamingo gel stain for 8 h at 4 °C. Nanopure water was used to wash the gels 
to reduce background fluorescence and placed on a Typhoon 8600 (GE Healthcare) to scan for 
fluorescence. Progenesis SameSpots software (Nonlinear Dynamics, Durham, NC) was used to 
identify the molecular weight and isoelectric point of each fluorescent protein spot. The 
fluorescent intensity of each protein spot was quantified using ImageQuant
TL
. After accounting 
for the fluorescent intensity of the entire gel, the individual protein spots were presented as a 
percentage of the total fluorescent intensity. 
4.3.10 Statistical Analysis 
Least squared means analysis using a Tukey-Kramer correction to adjust for multiple 
comparisons was performed to determine statistical significance among the treatments. A p-value 
less than 0.05 was considered significant. 
4.4 Results 
4.4.1 Nanoparticle characterization  
Particle morphology and size of non-functionalized and functionalized nanoparticles 
were analyzed using scanning electron microscopy (Table 4.1 and Figure 4.1B). Consistent with 
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previous work, the 20:80 CPH:SA nanoparticles were slightly larger than the 20:80 CPTEG:CPH 
nanoparticles (35). There were no significant differences in the size of the functionalized 
particles compared to the corresponding non-functionalized particles (data not shown), which is 
also consistent with previous work (15). 
Nanoparticles were analyzed to determine their ζ potential, carbohydrate content, and 
elemental composition (Table 4.1). The QELS data showed that the non-functionalized 
nanoparticles had strongly negative ζ potentials (-23 to -31 mV) due to the deprotonated 
carboxylic acid end groups of the polyanhydrides. In contrast, the functionalized nanoparticles 
exhibited a positive charge (8 to 16 mV) due to the protonated amines on the linker. The phenol-
sulfuric acid assay was used to confirm the presence of sugar on the nanoparticles, which showed 
that the functionalized 20:80 CPH:SA nanoparticles had slightly higher sugar densities than their 
20:80 CPTEG:CPH counterparts. EDS was used to determine the nanoparticle surface elemental 
composition. The linker-functionalized particles exhibited greater nitrogen content than the di-
mannose particles even though the ζ potentials for both types of particles were relatively similar. 
As expected, the EDS data also showed that the oxygen content on the 20:80 CPTEG:CPH 
nanoparticles was higher than that on the 20:80 CPH:SA nanoparticles.  
4.4.2 Serum protein adsorption influenced 20:80 CPH:SA nanoparticle internalization 
To determine how nanoparticle chemistry, functionalization, and serum protein 
adsorption affect interactions with DCs, we first measured the ability of DCs to internalize QD-
loaded nanoparticles. At 48 hours post-incubation with nanoparticles, DCs incubated with 20:80 
CPH:SA nanoparticles demonstrated a significantly higher percentage of nanoparticle 
internalization as compared to 20:80 CPTEG:CPH nanoparticles (Figure 4.2). Pre-treating the 
non-functionalized 20:80 CPH:SA nanoparticles with mouse serum significantly increased the 
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percentage of nanoparticle-positive DCs, however, serum protein adsorption had no effect on the 
internalization of the 20:80 CPTEG:CPH nanoparticles (closed vs. open bars). Nanoparticle 
functionalization, either with linker alone or linker plus di-mannose, regardless of nanoparticle 
chemistry, had no effect on DC internalization. Altogether, these data suggest that both 
chemistry and serum protein adsorption can affect particle internalization by DCs. Based on 
these findings, for the remainder of the experiments presented in this manuscript, we utilized 
nanoparticles pre-incubated with mouse serum in order to better mimic the conditions under 
which DCs and nanoparticles would interact in vivo. 
4.4.3 DC surface marker expression is differentially regulated by chemistry and functionalization 
Following encounter with antigen, DCs not only internalize antigen, but undergo a 
process of maturation in order to acquire the ability to initiate adaptive immune responses. Part 
of this maturation process is the ability to increase the cell surface expression of proteins that 
facilitate the interaction with and activation of T cells (6). In order to further characterize how 
nanoparticle chemistry and functionalization affect the maturation of DCs, we measured the 
surface expression levels of major histocompatibility complex (MHC) II and CD86 on DCs. 
Using flow cytometry, we assessed the expression of these surface markers following a 48 hour 
incubation with the different nanoparticle formulations. The non-functionalized 20:80 
CPTEG:CPH nanoparticles induced significantly higher levels of MHC II and CD86 expression 
on DCs as compared to DCs incubated with the non-functionalized 20:80 CPH:SA nanoparticles 
(Figure 4.3A and 4.3B, non-functionalized nanoparticles). Functionalization of the 20:80 
CPTEG:CPH nanoparticles did not affect the level of MHC II surface expression on DCs (Figure 
4.3A, black bars) but did significantly increase the surface expression of CD86 on DCs as 
compared to non-functionalized 20:80 CPTEG:CPH nanoparticles (Figure 4.3B, black bars). 
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DCs incubated with functionalized 20:80 CPH:SA nanoparticles demonstrated significantly 
increased surface expression of both MHC II and CD86 as compared to incubation with non-
functionalized 20:80 CPH:SA nanoparticles (Figure 4.3A and 4.3B, open bars). Altogether, these 
data demonstrate that polymer hydrophobicity (i.e., the CPH-rich formulation) and the surface 
modification of less hydrophobic nanoparticles by linker or di-mannose will up-regulate the 
expression of cell surface markers on DCs.  
Stimulation of DCs and macrophages with di-mannose has been previously shown to 
increase the surface expression of CD206, the mannose receptor (14; 15). To determine if the 
expression of this receptor was modulated by the functionalization of our nanoparticles, we 
measured surface CD206 expression on DCs in our experiments. Chemistry did not differentially 
affect CD206 surface expression (Figure 4.3C, non-functionalized). Regardless of chemistry, 
linker and di-mannose modified particles induced significantly higher levels of CD206 surface 
expression with the di-mannose modification resulting in the highest level of CD206 expression 
(Figure 4.3C). These findings are consistent with previous studies that demonstrated increased 
expression of this receptor in the presence of mannosylated ligands (14; 15).  
4.4.4 DC cytokine production is differentially regulated by nanoparticle chemistry and 
functionalization 
The development and skewing of adaptive immune responses are also dependent on the 
production of cytokines by DC and other antigen presenting cells (36). In order to determine how 
the nanoparticle formulations impact cytokine production, cytokine secretion from culture 
supernatants of DCs incubated with serum-coated nanoparticles was analyzed. DCs incubated 
with non-functionalized 20:80 CPH:SA nanoparticles secreted significantly higher amounts of 
IL-6, IL-1, and TNF- as compared to DCs incubated with non-functionalized 20:80 
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CPTEG:CPH nanoparticles (Figure 4.4). However, functionalization had differing effects on 
cytokine production depending on chemistry. Linker- and di-mannose-functionalized 20:80 
CPTEG:CPH nanoparticles resulted in significantly increased secretion of IL-6, IL-1, and TNF-
 by DCs as compared to non-functionalized 20:80 CPTEG:CPH nanoparticles (Figure 4.4A, 
4.4B and 4.4C, black bars). In contrast, functionalization of 20:80 CPH:SA nanoparticles 
resulted in a decrease in cytokine production by DCs as compared to 20:80 CPH:SA non-
functionalized nanoparticles (Figure 4.4A, 4.4B and 4.4C, open bars). Altogether, these data 
demonstrate that while chemistry does play a role in the induction of cytokine production by 
DCs, carbohydrate surface modification can modulate such responses in a chemistry-dependent 
manner.  
4.4.5 Adsorption of immune activating serum proteins onto polyanhydride nanoparticles 
The data presented so far suggest that nanoparticle chemistry and surface modification 
differentially regulate particle internalization, surface expression of cell surface markers, and 
cytokine production by DCs. As we have previously demonstrated, nanoparticle hydrophobicity 
affects adsorption of serum proteins and results in differential interactions with DCs (20; 37; 38). 
Together with hydrophobicity, surface functionalization can also affect the interaction between 
the particles and serum proteins. To better understand the differential effects of hydrophobicity 
and surface functionalization on interactions with serum proteins, we assessed the amount and 
type of proteins that are adsorbed by the different nanoparticle formulations following incubation 
with serum. The 20:80 CPTEG:CPH nanoparticles adsorbed a significantly greater amount of 
serum protein, which was at least five times higher compared to that adsorbed by the 20:80 
CPH:SA nanoparticles (Figure 4.5). Linker and di-mannose modification of the 20:80 
CPTEG:CPH nanoparticles resulted in significantly higher amounts of adsorbed serum proteins, 
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as compared to non-functionalized 20:80 CPTEG:CPH nanoparticles (Figure 4.5, last 3 bars). In 
contrast, functionalizing the 20:80 CPH:SA nanoparticles with linker or di-mannose had only a 
modest impact on protein adsorption compared to the 20:80 CPTEG:CPH formulation (Figure 
4.5, first 3 bars).  
The eluted serum proteins were further characterized using 2-D gel electrophoresis 
(Figure 4.6). Based on this analysis, albumin and IgG were the most abundant proteins adsorbed 
onto both nanoparticle formulations (Table 4.2). In addition, there were a large number of 
immune activating proteins adsorbed onto the nanoparticles. The predominant candidates 
included IgG and complement component C3, which was represented by the two proteins C3a 
and C3b (39; 40). 
Overall, the 20:80 CPTEG:CPH nanoparticle formulation demonstrated a greater amount 
of serum protein adsorption. On the 2-D gels, eluted serum proteins from 20:80 CPTEG:CPH 
nanoparticles (Figure 4.6) showed a greater diversity of proteins adsorbed as compared to the 
20:80 CPH:SA nanoparticles (Figure 4.6 and Table 4.2A and 4.2B). Independent of nanoparticle 
chemistry, functionalizing with di-mannose resulted in adsorption of mannose binding protein C, 
which was not detected in the serum eluted from the non-functionalized nanoparticles.  
4.5 Discussion 
Initiation of adaptive immune responses requires antigen capture and processing by DCs 
and the subsequent maturation of these cells as they traffic from the site of antigen encounter to 
the draining lymph node (41). During this process, DCs up-regulate surface expression of MHC 
II, necessary for antigen presentation to T cells (i.e., signal 1), and surface expression of co-
stimulatory molecules such as CD86 (i.e., signal 2). In addition, DCs secrete cytokines (i.e., 
signal 3), which are necessary to enhance and skew the adaptive immune response (36). In this 
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work, we demonstrate that nanoparticle chemistry and surface functionalization differentially 
regulated DC maturation and polyfunctionality (i.e., cell surface marker expression and cytokine 
secretion). Understanding how these factors affect DC maturation can lead to rational 
nanoparticle-based vaccine design, which targets specific aspects of DC maturation as well as the 
nature and magnitude of the subsequent immune response. Moreover, this work demonstrates 
how polyanhydride nanoparticles function as more than just vaccine-delivery vehicles. 
Nanoparticle chemistry and surface functionalization, prior to antigen delivery, can serve as 
modulators of antigen presenting cell responses, thus tailoring the ensuing adaptive immune 
response.  
As indicated in Table 4.1, the functionalized 20:80 CPH:SA nanoparticles had slightly 
higher sugar densities than the functionalized 20:80 CPTEG:CPH nanoparticles. This could be 
attributed to the higher glass transition temperature of the 20:80 CPH:SA nanoparticles, which 
makes these particles less likely to aggregate and block functionalization (23). The EDS data in 
Table 4.1 indicates that the glycolic acid-functionalized particles have higher nitrogen content 
than the di-mannose particles even though the ζ potentials for both types of particles were 
relatively similar. This could be attributed to the larger di-mannose being richer in carbon and 
oxygen, which reduces the nitrogen content. Likewise, the higher oxygen content on the surface 
of the 20:80 CPTEG:CPH nanoparticles compared to that on the 20:80 CPH:SA nanoparticles 
can be attributed to the presence of ethylene glycol moieties in the CPTEG backbone. 
Our initial studies demonstrated that nanoparticle chemistry alone plays a major role in 
determining the level of nanoparticle internalization by DCs in vitro. The less hydrophobic 20:80 
CPH:SA formulation was internalized at significantly higher levels as compared to the more 
hydrophobic 20:80 CPTEG:CPH nanoparticles (Figure 4.2). Prior incubation with mouse serum 
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enhanced the internalization of 20:80 CPH:SA nanoparticles, but had no effect on the 
internalization of 20:80 CPTEG:CPH nanoparticles. This result demonstrates that nanoparticle 
chemistry is an important aspect of vaccine design, as serum protein adsorption alone may or 
may not change the biological effect(s) in vivo. Functionalization did not significantly affect 
nanoparticle internalization by DCs regardless of chemistry or the presence of serum. These data 
suggest that surface modification is not sufficient to alter the initial interactions between DCs 
and nanoparticles, and thus, does not have a major effect on nanoparticle internalization.  
To further characterize how nanoparticle chemistry and functionalization can modulate 
DC maturation and function, we assessed DC surface marker expression and cytokine production 
profiles. Despite the lower DC internalization levels, the non-functionalized 20:80 CPTEG:CPH 
nanoparticles induced significantly higher surface expression of MHC II and CD86 than did the 
non-functionalized 20:80 CPH:SA nanoparticles (Figure 4.3). This bystander effect has been 
observed previously, specifically for MHC II and CD86, where DC internalization of 
polyanhydride nanoparticles alone did not directly correlate with enhanced activation (34). These 
findings are also consistent with previous reports that suggest the importance of hydrophobicity 
as a danger signal that triggers immune activation (34; 42). The cell surface marker expression 
data presented in this work reinforces this concept as MHC II and CD86 expression on DCs were 
up-regulated most strongly when stimulated by the more hydrophobic non-functionalized 20:80 
CPTEG:CPH nanoparticles.  
While the hydrophobic 20:80 CPTEG:CPH nanoparticles induced higher expression of 
MHC II and CD86, nanoparticle functionalization had no effect on MHC II surface expression 
levels regardless of chemistry (Figure 4.3A). This data would suggest that carbohydrate 
modification of nanoparticles and engagement of CLRs does not affect MCH II expression. 
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However, functionalization did increase surface expression of CD86 (Figure 4.3B), as we 
observed a step-wise increase in CD86 expression by stimulated DCs: non-functionalized < 
linker- < di-mannose-functionalized nanoparticles. As surface modification increases the 
complexity (i.e., more receptor-ligand binding) of the particle-DC interaction, it may enhance or 
sustain intracellular signals necessary to induce more robust MHC II and CD86 expression. 
These findings suggest that the increased expression of MHC II (i.e., signal 1, antigen 
presentation) was more dependent on nanoparticle chemistry than surface functionalization of 
the nanoparticles. In contrast, expression of co-stimulatory molecules such as CD86 (i.e., signal 
2), while also dependent on chemistry, was further modulated by surface functionalization. 
Cytokine secretion by DCs is a key factor in promoting and skewing subsequent adaptive 
immune responses, also known as signal 3. When assessing cytokine expression profiles of DCs 
stimulated with the different nanoparticle formulations, we observed a differential pattern of 
cytokine secretion. In the presence of serum proteins, the less hydrophobic non-functionalized 
20:80 CPH:SA nanoparticles induced the secretion of significantly higher amounts of IL-6, IL-
1, and TNF- as compared to the non-functionalized 20:80 CPTEG:CPH nanoparticles (Figure 
4.4). This is unlike the pattern we observed for surface marker expression (Figure 4.3), where the 
more hydrophobic 20:80 CPTEG:CPH nanoparticles resulted in higher surface expression of 
these molecules. This would suggest that in terms of cytokine production by DCs the bystander 
effect (i.e., particle negative DCs) induced by the non-functionalized 20:80 CPTEG:CPH 
nanoparticles plays a lesser role as compared to surface receptor expression.  
Interestingly, nanoparticle functionalization resulted in opposite effects on cytokine 
expression depending on nanoparticle chemistry (Figure 4.4). For the 20:80 CPH:SA 
nanoparticles, functionalization resulted in a negative regulation of cytokine production for IL-6, 
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IL-1, and TNF-. In contrast, functionalization of the 20:80 CPTEG:CPH nanoparticles led to 
the up-regulation of cytokine release by DCs, resulting in significantly higher amounts of IL-6, 
IL-1, and TNF- as compared to non-functionalized 20:80 CPTEG:CPH nanoparticles. This 
suggests that the functionalized 20:80 CPTEG:CPH nanoparticles would induce a more robust 
signal 3, likely through a bystander effect, which is consistent with previous studies that showed 
that the 20:80 CPTEG:CPH formulation induced more robust T cell responses (43).
 
Altogether, 
these data demonstrate that nanoparticle chemistry itself can differentially regulate DC cytokine 
production. More importantly, our data also shows that surface modification of polyanhydride 
nanoparticles can affect cytokine production in a chemistry-dependent manner.  For 
completeness, the cell surface marker expression and cytokine secretion data for the non-serum-
adsorbed particles are shown in the Supporting Information section. 
Dendritic cell maturation is triggered by signals received during its interactions with the 
antigen or pathogen and the environmental milieu in which encounter occurs. Some of these 
interactions are mediated by plasma membrane receptors including PRRs, CLRs, Fc gamma 
receptors, and complement (C) receptors (44). Some of these receptors recognize foreign 
molecules while others recognize host proteins, namely serum proteins. Serum proteins adsorbed 
onto our nanoparticles will likely modulate the way the nanoparticles interact with DCs. 
Moreover, we hypothesize that chemistry and surface modification of the nanoparticles would 
lead to differential interactions with serum proteins and may contribute to the differences in 
internalization, DC surface receptor expression, and cytokine production.  Following analysis of 
adsorbed serum protein onto our different nanoparticle formulations, we determined (as 
expected) that the more hydrophobic 20:80 CPTEG:CPH nanoparticles adsorbed two-to-four 
fold greater amounts of protein regardless of functionalization as compared to the 20:80 CPH:SA 
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nanoparticles (Figure 4.5). In addition, linker- and di-mannose functionalization of the 
nanoparticles increased the levels of adsorbed protein as compared to the non-functionalized 
nanoparticles. This increase in the amount of serum protein adsorption upon functionalization 
suggests that in addition to hydrophobicity, electrostatic interactions may also affect protein 
adsorption.  
The 2-D gel electrophoresis data (Figure 4.6) further confirmed the polymer chemistry-
dependent effects on serum adsorption. Not only did the more hydrophobic 20:80 CPTEG:CPH 
particles adsorb more total serum proteins, they also adsorbed a more diversified profile of 
proteins. The characterization of the eluted proteins shown in Table 4.2 indicated that serum-
abundant protein such as albumin and IgG were adsorbed onto the nanoparticles, regardless of 
chemistry.  
Based on the 2D gel electrophoresis analysis, neither linker nor sugar functionalization 
appeared to have a major effect on the profile of adsorbed serum proteins. However, sugar 
functionalization enhanced the adsorption of mannose-binding protein, especially on the 20:80 
CPTEG:CPH nanoparticles (Table 4.2). This is an interesting observation, suggesting that the 
presence of the ligand alone is not enough to bind mannose-binding protein, and that other 
aspects including hydrophobicity, presence of oxygen moieties, and electrostatic interactions 
may also lead to enhanced binding profiles. The presence of the mannose binding protein C in 
the serum eluted from the functionalized nanoparticles is significant because the mannose 
binding protein C is a complement-activating protein that may aid in the enhanced activation of 
DCs (45).  
The complement protein, C3a, adsorbed onto the 20:80 CPTEG:CPH but not the 20:80 
CPH:SA nanoparticle formulation. C3a is produced from the enzymatic cleavage of C3 and is 
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characterized as an anaphylatoxin, a potent inducer of inflammation, which acts via binding onto 
C3a receptors (40; 46). Binding of C3a onto 20:80 CPTEG:CPH nanoparticles may lead to 
enhanced inflammatory signals by cells interacting with the particles. Surface modification either 
by linker or di-mannose did not markedly alter the level of C3a adsorption, suggesting 
functionalization does not greatly affect the way C3a interacts with the CPTEG:CPH 
nanoparticles. The absence of C3a on 20:80 CPH:SA nanoparticles suggests this formulation 
may not provide efficient binding conditions for adsorption and points to the use of this 
formulation in situations where C3a-mediated responses are not desired. We also observed 
binding of C3b, generated from the enzymatic cleavage of C3 (40). C3b is a potent opsonin, 
whose action is mediated by C3b receptors found on DC plasma membranes (47). We did not 
observe any marked differences in C3b adsorption between chemistries or following 
functionalization. In addition to hydrophobicity, C3b, given its function, could partly mediate the 
level of particle internalization. However, by itself, C3b does not appear to be the major driving 
force behind the previously observed dichotomy between CPTEG:CPH (low) and CPH:SA 
(high) internalization by DCs.  
While both nanoparticle formulations adsorbed serum proteins, the differences in total 
protein amount cannot be directly correlated to DC maturation. This is not surprising given the 
multi-factorial nature of DC-nanoparticle interactions. Moreover, while we did observe 
differences in the bound proteins, namely mannose-binding lectin and C3a, again, these 
differences do not provide a direct mechanism by which the differential effects on DC 
maturation occur with our nanoparticle formulations. However, these data demonstrate that 
nanoparticle-serum protein interactions must be taken into account during the rational design of 
nanoparticle-based vaccines.  
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4.6 Conclusions 
Our results show that polyanhydride nanoparticle chemistry, surface functionalization of 
the nanoparticles by carbohydrates, and serum protein adsorption influenced nanoparticle 
interactions with DCs. In this study, we characterized the DC response to nanoparticle 
stimulation in terms of internalization ability, MHC II expression (signal 1), up-regulation of co-
stimulatory molecule (CD86; signal 2) and cytokine production (signal 3). The events described 
here are critical for antigen recognition and for the subsequent induction of an adaptive immune 
response. In this work, we demonstrated that the more hydrophobic CPTEG:CPH nanoparticle 
formulation was not internalized with high efficiency and did not induce production of IL-6, IL-
1, or TNF- by DCs. However, this formulation enhanced the surface expression of MHC II 
and CD86. In contrast, the less hydrophobic CPH:SA nanoparticle formulation was efficiently 
internalized by DCs, induced higher amounts of IL-6, IL-1, and TNF-secretion, but did not 
trigger surface expression of MCH II or CD86. While functionalization of either chemistry by 
linker or di-mannose did not change internalization efficiency or surface maker expression levels 
in the presence of serum, it resulted in differing effects on cytokine production, in a chemistry-
dependent manner. Functionalization of the CPTEG:CPH nanoparticles enhanced cytokine 
secretion, while functionalization of the CPH:SA nanoparticles led to a decrease in cytokine 
production. These observations enhance our understanding of how non-functionalized and 
carbohydrate-functionalized particles could interact with immune cells in vivo and of the need to 
consider the impact of nanoparticles on host cells in the context of adsorbed serum proteins. 
Such an understanding will aid in the rational design of nanoparticle-based vaccines. 
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4.9 Figures 
 
Figure 4.1 Polyanhydride chemistry, nanoparticle preparation, and surface functionalization. A) Structure 
of monomer diacids: sebacic acid (top left), 1,6-bis(p-carboxyphenoxy)hexane (top right) and 1,8-bis(p-
carboxyphenoxy)-3,6-dioxaoctane (bottom). B) Copolymers are used to synthesize nanoparticles using 
anti-solvent nanoprecipitation. Scanning electron photomicrographs of 20:80 CPTEG:CPH (left) and 
20:80 CPH:SA (right) nanoparticles are shown. C) The nanoparticle surface was functionalized with di-
mannose (left) or a glycolic acid cap (right) using an ethylenediamine linker.  
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Figure 4.2 Serum coated nanoparticle internalization by DCs is a strong function of polymer 
chemistry. Serum coated or non-serum coated QD-loaded nanoparticles were incubated with 
DCs for 48 hours before harvesting the DCs and analyzing them by flow cytometry. Data are 
expressed as the mean ± SEM of two independent experiments performed in triplicate. * 
indicates statistical significance (p < 0.05) between 20:80 CPH:SA and 20:80 CPTEG:CPH 
nanoparticles for the same functionalization and serum treatment; # indicates statistical 
significance (p < 0.05) between serum coated and non-serum coated particles of the same 
chemistry and functionalization. NF = non-functionalized in Figure. 
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Figure 4.3 Surface functionalization and nanoparticle chemistry influence the expression of (A) 
MHC II, (B) CD86, and (C) CD206 when DCs were incubated for 48 hours with serum coated 
nanoparticles. Data is expressed as the means ± SEM of two independent experiments performed 
in triplicate. ^ indicates statistical significance (p < 0.05) from non-stimulated cells; 
+
 indicates 
statistical significance (p < 0.05) between functionalized and non-functionalized particles of the 
same chemistry; * indicates statistical significance (p < 0.05) between 20:80 CPH:SA and 20:80 
CPTEG:CPH nanoparticles for the same functionalization and serum treatment. NF = non-
functionalized in Figure. 
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Figure 4.4 Pro-inflammatory cytokine secretion from DCs incubated with serum-coated 
nanoparticles for 48 hours is dependent upon nanoparticle chemistry, and surface 
functionalization. The cellular supernatants of DCs were assayed for (A) IL-6, (B) IL-1β, and (C) 
TNF-α. Data are expressed as the mean ± SEM of two independent experiments performed in 
triplicate. Stimulation of DCs with LPS served as a positive control and the recovered 
supernatants had mean cytokine concentrations of 58,362 pg/mL for IL-6, 36 pg/mL for IL-1β, 
and 23,419 pg/mL for TNF-α. ^ indicates statistical significance (p < 0.05) from non-stimulated 
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cells; + indicates statistical significance (p < 0.05) between functionalized and non-
functionalized particles of the same chemistry; * indicates statistical significance (p < 0.05) 
between 20:80 CPH:SA and 20:80 CPTEG:CPH nanoparticles for the same functionalization and 
serum treatment. NF = non-functionalized in Figure. 
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Figure 4.5 Adsorption of serum proteins is dependent on nanoparticle chemistry and surface 
functionalization. Data are presented as the mean ± SEM of three independent experiments 
performed in triplicate. + indicates statistical significance (p < 0.05) between the functionalized 
and non-functionalized particles of the same chemistry; * indicates statistical significance (p < 
0.05) between 20:80 CPH:SA and 20:80 CPTEG:CPH nanoparticles for the same 
functionalization and serum treatment. The p-value for the comparison between the serum 
protein adsorption on di-mannose-functionalized 20:80 CPH:SA nanoparticles and the 
corresponding non-functionalized particles was 0.0843. NF = non-functionalized in Figure. 
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Figure 4.6 Serum protein adsorption patterns are affected by nanoparticle chemistry and surface 
functionalization. Shown are representative 2-D gels of adsorbed serum proteins eluted from (A) 
non-functionalized 20:80 CPTEG:CPH, (B) linker-functionalized 20:80 CPTEG:CPH, (C) di-
mannose-functionalized 20:80 CPTEG:CPH, (D) non-functionalized 20:80 CPH:SA, (D) linker-
functionalized 20:80 CPH:SA, and (E) di-mannose-functionalized 20:80 CPH:SA nanoparticles. 
NF = non-functionalized in Figure. 
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4.10 Tables 
Table 4.1 Nanoparticle size and characterization. 
Nanoparticle Type 
Average 
Diametera 
 (nm) 
Polydispersity 
Index 
Zeta 
Potentialb 
 (mV) 
Sugar Densityc 
 (µg/mg) 
EDS Percentagesd 
Average % C Average % N Average % O 
20:80 CPTEG:CPH        
NF 149 ± 33 0.108 -23.7 ± 0.9   83.85 ± 1.41 0.16 ± 0 .11 16.1 ± 1.52 
Linker  159 ± 31 0.104 11.9 ± 2.1   79.27 ± 1.35 2.07 ± 0.84 18.09 ± 0.95 
Di-mannose  176  ± 31 0.105 8.4 ± 1.7 6.6 ± 1.71 80.14 ± 1.18 0.85 ± 0.51 19.01 ± 1.19 
20:80 CPH:SA       
NF 227 ± 60 0.157 -31 ± 0.5   91.82 ± 1.74 0.24  ± 0.18 8.18 ± 1.75 
Linker  242 ± 72 0.163 15.8 ± 1.6   85.13 ± 2.38 4.15  ± 1.24 10.09 ± 1.55 
Di-mannose  251 ± 49  0.149 14.1 ± 1.9 12.3 ± 2.01 88.98 ± 1.20 2.2 ± 0.91 8.72 ± 0.85 
a
Nanoparticle sizes were determined using ImageJ v1.36b analysis of scanning electron 
photomicrographs using at least 200 particles from each image.  
b
Zeta potential measurements are the mean ± standard deviation from three independent 
experiments.  
c
Mean ± standard deviation of the sugar density was determined using a phenol-sulfuric acid 
assay measured in triplicate.  
d
EDS was used to identify an increase in nitrogen content to confirm surface attachment of the 
sugar and ethylenediamine. This is shown as mean ± standard deviation from five independent 
experiments. 
 
Table 4.2A Percent fluorescent intensity of each protein spot for 20:80 CPTEG:CPH 
nanoparticles
a 
Fluorescent Intensities 
Protein Non-functionalized Linker Di-mannose 
Albumin 29.91% 26.89% 19.06% 
IgG Heavy Chain 17.26% 14.45% 10.36% 
IgG Light Chain 9.73% 8.65% 17.39% 
C3a 5.74% 10.14% 5.97% 
C3b 6.53% 7.57% 4.07% 
IgM 9.85% 10.72% 1.78% 
Apolipoprotein A-I 1.34% 2.97% 5.96% 
Apolipoprotein E 3.54% 6.25% 5.32% 
Apolipoprotein H 0.00% 4.45% 4.32% 
Transferrin 3.87% 0.00% 0.00% 
Mannose Binding Protein C 0.00% 0.78% 20.22% 
Apolipoprotein C-III 0.00% 0.00% 0.00% 
Unidentified Protein Spots 12.23% 7.14% 5.54% 
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Table 4.2B Percent fluorescent intensity of each protein spot for 20:80 CPH:SA nanoparticles
a 
Fluorescent Intensities 
Protein Non-functionalized Linker  Di-mannose  
Albumin 20.04% 31.40% 21.74% 
IgG Heavy Chain 27.57% 27.89% 13.46% 
IgG Light Chain 20.28% 13.75% 29.41% 
C3a 0.00% 0.00% 0.00% 
C3b 7.98% 10.94% 7.73% 
IgM 9.49% 2.59% 0.00% 
Apolipoprotein A-I 0.00% 0.00% 0.00% 
Apolipoprotein E 0.00% 0.00% 6.05% 
Apolipoprotein H 4.12% 0.00% 0.00% 
Transferrin 0.00% 2.00% 0.00% 
Mannose Binding Protein C 0.00% 4.71% 7.26% 
Apolipoportein C-III 0.00% 1.09% 3.84% 
Unidentified Protein Spots 10.53% 5.64% 10.51% 
a
Each protein spot was quantified using ImageQuant
TL
 and normalized to the total fluorescence 
intensity of the gel. Data is the average of two independent experiments. 
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4.11 Supporting Information 
 
Supporting Figure 4.1 Surface functionalization and nanoparticle chemistry influenced the 
expression of (A) MHC II, (B) CD86, and (C) CD206 when dendritic cells (DCs) were incubated 
for 48 hours with non-serum coated nanoparticles. The addition of 20:80 CPH:SA nanoparticles 
to the culture wells did not statistically affect the surface expression of MHC II on DCs, while 
linker and di-mannose modification enhanced the expression of CD86 and CD206 on DCs. 
Regardless of functionalization, the presence of the 20:80 CPTEG:CPH nanoparticles 
significantly increased the cell surface expression of MHC II, CD86, and CD206 on DCs. Data is 
expressed as the mean ± SEM of two independent experiments. ^ indicates statistical significance 
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(p < 0.05) from non-stimulated (NS) cells; + indicates statistical significance (p < 0.05) between 
functionalized and NF particles of the same chemistry; * indicates statistical significance (p < 
0.05) between 20:80 CPH:SA and 20:80 CPTEG:CPH nanoparticles for the same 
functionalization. NF = non-functionalized in Figure. 
 
 
Supporting Figure 4.2 For 20:80 CHP:SA and 20:80 CPTEG:CPH nanoparticles, surface 
functionalization with di-mannose enhanced dendritic cell (DC) secretion of A) IL-6, B) IL-1β, 
and C) TNF-α. Polymer chemistry had little influence on the cytokine secretion of DCs cultured 
with non-serum coated linker functionalized particles. Functionalization with di-mannose 
generally increased cytokine secretion from DCs incubated with non-serum coated particles of 
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both polymer chemistries. Data is expressed as the mean ± SEM of two independent experiments 
performed in triplicate. ^ indicates statistical significance (p < 0.05) from non-stimulated cells; + 
indicates statistical significance (p < 0.05) between functionalized and NF particles of the same 
chemistry; * indicates statistical significance (p < 0.05) between 20:80 CPH:SA and 20:80 
CPTEG:CPH nanoparticles for the same functionalization and serum treatment. NF = non-
functionalized in Figure. 
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5.1 Abstract 
Carbohydrate functionalization of nanoparticles allows for targeting of C-type lectin 
receptors. This family of pattern recognition receptors expressed on innate immune cells, such as 
macrophages and dendritic cells, can be used to modulate immune responses. In this work, the in 
vivo safety profile of carbohydrate-functionalized polyanhydride nanoparticles was analyzed 
following parenteral and intranasal administration in mice. Polyanhydride nanoparticles based on 
1,6-bis-(p-carboxyphenoxy)hexane and 1,8-bis-(p-carboxyphenoxy)-3,6-dioxaoctane were used. 
Nanoparticle functionalization with di-mannose (specifically carboxymethyl-α-D-
mannopyranosyl-(1,2)-D-mannopyranoside), galactose (specifically carboxymethyl- -
galactoside), or glycolic acid induced no adverse effects after administration based on 
histopathological evaluation of liver, kidneys, and lungs. Regardless of the polymer formulation, 
there was no evidence of hepatic or renal damage or dysfunction observed in serum or urine 
samples. The histological profile of cellular infiltration and the cellular distribution and kinetics 
in the lungs of mice administered nanoparticle treatments followed similar behavior as that 
observed in the lungs of animals administered saline. Cytokine and chemokine profiles in 
bronchoalveolar lavage fluid indicated surface-chemistry dependence on modest secretion of IL-
6, IP-10, and MCP-1; however, there was no evidence of any deleterious histopathological 
changes. Based on these analyses, carbohydrate-functionalized nanoparticles are safe for in vivo 
applications. These results provide foundational information towards the evaluation of the 
capabilities of these surface-modified nanoparticles as vaccine delivery formulations. 
5.2 Introduction 
The development of novel strategies to improve adjuvant formulations by directly 
targeting innate immune cells is an important area of interest in the design of novel vaccines (1-
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4). Biodegradable nanoparticles possess promising characteristics in this regard by playing dual 
roles, both as adjuvants and delivery vehicles (5). In particular, polyanhydride particles have 
been demonstrated to induce enhanced expression of MHC I and II on and stimulation of antigen 
presenting cells (APCs), which are fundamental to initiating adaptive immune responses (6-8). 
After in vivo administration, the nanoparticles interact with a variety of cells, including APCs (9; 
10). Before analyzing the effects of surface modification upon vaccine efficacy, an assessment of 
their safety and biocompatibility is necessary (11).  
The use of polymeric nanoparticle systems for drug and vaccine delivery offers several 
advantages, including controlled delivery of encapsulated payload(s), and depending on their 
chemical properties, improved biocompatibility, receptor targeting capabilities, sustained 
antigen/drug release kinetics, adjuvanticity, and opportunities for both local and systemic 
delivery (12; 13). Polyanhydride nanoparticles have displayed these characteristics in both in 
vitro and/or in vivo settings (6; 9; 14-20). In particular, the use of biodegradable nanoparticles for 
lung delivery is an attractive proposition because of the following advantages: 1) uniform 
particle distribution in the lung; 2) local administration of vaccine antigens or therapeutic drugs; 
3) sustained delivery of macromolecules; 4) improved patient compliance associated with non-
invasive immunization and administration of fewer doses; and 5) avoidance of first pass 
metabolism, among others (2; 12; 21-23).  
In previous in vitro studies, it was demonstrated that di-mannose functionalization of 
polyanhydride nanoparticles, which would induce signaling via C-type lectin receptors (CLRs) 
on APCs, enhanced the activation of macrophages and dendritic cells (DCs) (6; 17; 18; 24). 
Because of the role of CLR signaling in stimulating innate immunity, identifying safe and 
effective means to selectively target APC receptors such as the macrophage mannose receptor 
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(MMR) and the macrophage galactose binding lectin (MGL) will provide novel approaches to 
enhance and shape adaptive immunity (3; 25; 26). Both the charge and surface properties of 
these polyanhydride nanoparticles are altered upon functionalization and could engage additional 
signaling cascade(s), which may affect the magnitude of immune response to the presence of 
these functionalized adjuvants/delivery vehicles. In this regard, even though these functionalized 
particles have displayed desirable properties (i.e., activation of APCs) in vitro, the focus of this 
study was to perform a systematic evaluation of their safety and biocompatibility profile in vivo 
to assess any toxicological effects that might be associated with functionalization.  
5.3 Materials and Methods 
5.3.1 Materials 
Chemicals needed for monomer synthesis, polymerization, and nanoparticle synthesis 
included anhydrous (99+%) 1-methyl-2-pyrrolidinone (Aldrich, Milwaukee, WI); 1,6-
dibromohexane, 4-p-hydroxybenzoic acid, N,N-dimethylacetamide and triethylene glycol (Sigma 
Aldrich, St. Louis, MO); 4-p-fluorobenzonitrile (Apollo Scientific, Cheshire, UK); acetic acid, 
acetic anhydride, acetone, acetonitrile, dimethyl formamide (DMF), hexanes, methylene 
chloride, pentane, potassium carbonate, sodium hydroxide, sulfuric acid, and toluene (Fisher 
Scientific, Fairlawn, NJ). For NMR characterization, deuterated dimethyl sulfoxide was 
purchased from Cambridge Isotope Laboratories (Andover, MA). For nanoparticle tracking 
AlexaFluor
® 
647 hydrazide was purchased from Life Technologies (Grand Island, NY). For 
nanoparticle functionalization, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, 
N-hydroxysuccinimide, and ethylenediamine were purchased from Thermo Scientific (Waltham, 
MA). Glycolic acid was purchased from Acros Organics (Pittsburgh, PA). Materials required for 
the lung tissue processing included: Dulbecco’s Modified Eagle Medium and Hank’s balanced 
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salt solution (Life Technologies, Grand Island, NY); HEPES buffer, penicillin-streptomycin, and 
L-glutamine, (Mediatech, Herndon, VA); and heat inactivated fetal bovine serum (Atlanta 
Biologicals, Atlanta, GA); and ammonium chloride, potassium bicarbonate, 0.5 M EDTA and 
sodium azide (Fisher Scientific). β-mercaptoethanol and rat immunoglobulin (rat IgG) were 
purchased from Sigma Aldrich (St. Louis, MO). Materials used for flow cytometry included: 
stabilizing cellular fixative solution (BD Bioscience, San Jose, CA); unlabeled anti-CD16/32 
(i.e., anti-FcγR) (Southern Biotech, Birmingham, AL); FITC conjugated anti-mouse CD11c 
(clone N418), PE conjugated anti-mouse CD11b (clone M1/70), Alexa Fluor
®
 700 conjugated 
anti-mouse F4/80 (clone BM8), PerCP/Cy5.5 conjugated anti-mouse Ly-6G/Ly-6C (Gr-1) (clone 
RB6-8C5), PE/Cy7 anti-mouse CD326 (clone G8.8) and their corresponding isotype controls: 
FITC conjugated Armenian Hamster IgG (clone HTK888), PE-conjugated rat IgG2bκ (clone 
RTK4530), Alexa Fluor
® 700 conjugated rat IgG2aκ (clone RTK2758), and PerCP/Cy5.5 
conjugated rat IgG2bκ (clone RTK4530) and PE/Cy7 conjugated rat IgG2aκ (clone RTK2758) 
(BioLegend, San Diego, CA). Endotoxin-free saline was obtained from the Iowa State University 
College of Veterinary Medicine Pharmacy. 
5.3.2 Monomer and polymer synthesis 
Monomers of 1,6-bis(p-carboxyphenoxy) hexane (CPH) and 1,8-bis(p-carboxyphenoxy)-
3,6-dioxaoctane (CPTEG) were synthesized as described previously (15; 27). The 50:50 
CPTEG:CPH copolymer was synthesized by melt polycondensation as previously described 
(15). The chemical structure was characterized with 
1
H NMR using a Varian VXR 300 MHz 
spectrometer (Varian Inc., Palo Alto, CA). The synthesized 50:50 CPTEG:CPH copolymer had a 
Mw of 10,500 Da, and the polydispersity index (PDI) of this copolymer was 1.5, which is 
consistent with previous work (15; 20).  
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5.3.3 Nanoparticle synthesis 
Polyanhydride nanoparticles were synthesized using anti-solvent nanoencapsulation as 
described previously (28).
 
Briefly, for flow cytometry, AlexaFluor
® 
647 hydrazide (1% w/w) and 
20 mg/mL 50:50 CPTEG:CPH polymer were dissolved in methylene chloride (at 4°C). For 
histological and cytokine analyses, blank nanoparticles were synthesized. The polymer solution 
was sonicated at 40 Hz for 30 s using a probe sonicator (Ultra Sonic Processor VC 130PB, 
Sonics Vibra Cell, Newtown, CT) and rapidly poured into a pentane bath (at -40°C) at a solvent 
to non-solvent ratio of 1:250. Particles were collected by filtration and dried under vacuum for 
30 min.  
5.3.4 Sugar synthesis 
5.4.4.1 Synthesis of carboxymethyl α-1,2-linked dimannoside 
Synthesis of carboxymethyl α-1,2-linked dimannose was carried out using fluorous-solid 
phase extraction (FSPE) as per literature procedure (29-31).
 
Each glycosylation was performed 
with 2.0 equivalents of the donor in anhydrous dichloromethane at 0 ºC for 15 min. Facile 
purification of crude product by FSPE enabled easy preparation of the protected linear α-1,2-
linked dimannose in high yield. FSPE was very helpful in the context of this particular synthesis 
as isolation of the target compound using regular silica gel chromatography turned out to be 
difficult owing to the formation of unwanted side products (hydrolyzed and rearranged donor). 
The reducing terminal of the disaccharide was further functionalized by ozonolysis followed by 
Jones oxidation to yield a carboxylic acid. Global deprotection was carried out using Birch 
reduction condition to produce the desired deprotected dimannoside (6). 
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5.4.4.2 Synthesis of carboxymethyl-β-galactoside 
Allylated β-galactose acetate was subjected to Ruthenium catalyzed Sharpless oxidation, 
which resulted in carboxylic acid terminated β-galactose acetate in high yield. Base catalyzed 
deacetylation yielded the desired galactoside in high yield. 
5.3.5 Surface functionalization 
carboxymethyl-α-D-mannopyranosyl-(1,2)-D-mannopyranoside and carboxymethyl- -
galactoside were conjugated onto the surface of polyanhydride nanoparticles using an amine-
carboxylic acid coupling reaction (6; 17; 18; 24). Particles with glycolic acid groups on the 
surface (linker) and non-functionalized (NF) particles were used as controls. The conjugation 
reaction was performed in two reaction steps, as described previously (6; 18). Briefly, a 
nanoparticle suspension (10 mg/mL) was made using nanopure water, and 10 equivalents of 1-
ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and 12 equivalents of N-
hydroxysuccinimide (NHS), and 10 equivalents of ethylenediamine were added. This reaction 
was carried out at 4°C temperature for 1 h at a constant agitation of 17 rcf. Following the 
reaction, the particles were centrifuged at 10,000 rcf for 10 min and the supernatant was 
removed. The particles were washed with the same volume of nanopure water, centrifuged at 
10,000 rcf for 10 min and the supernatant was removed. A second reaction was performed with 
10 eq. of EDC, 12 eq. of NHS and 10 eq. of the corresponding functionalizing agent (i.e., di-
mannose or galactose) in nanopure water, using constant agitation at 17 rcf for 1 h at 4°C. 
Particles were sonicated before and after each reaction to break aggregates. After the reactions 
were completed, nanoparticles were collected by centrifugation (10,000 rcf, 10 min) and dried 
under vacuum for 1 h.  
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5.3.6 Nanoparticle characterization 
Morphological and size characterization of both the functionalized and the NF 
nanoparticles was performed using scanning electron microscopy (SEM, FEI Quanta 250, Kyoto, 
Japan) and quasi-elastic light scattering (QELS, Zetasizer Nano, Malvern Instruments Ltd., 
Worchester, UK). The QELS experiments were used to measure the ζ-potential of the 
nanoparticles. To quantify the amounts of the carbohydrates conjugated to the nanoparticles, a 
high throughput version of a phenol-sulfuric acid assay was used (6; 32). A microplate reader 
(SpectraMax M3, Molecular Devices, Sunnyvale, CA) was used to obtain the absorbance of 
standards and samples using a wavelength of 490 nm. The total amount of sugar per unit weight 
of nanoparticles (μg/mg) was calculated. 
5.3.7 Mice 
Female Swiss Webster outbred mice were purchased from Harlan Laboratories 
(Indianapolis, IN). Mice were housed in specific pathogen-free conditions where all bedding, 
caging, and feed were sterilized prior to use. All animal procedures were conducted with the 
approval of the Iowa State University Institutional Animal Care and Use Committee.  
5.3.8 Liver and kidney histological and biomarker examination 
Separate groups of five Swiss Webster outbred mice were subcutaneously injected with 5 
mg of polyanhydride nanoparticles (non- or surface-functionalized) in 1.5 mL of phosphate 
buffer saline (PBS) at the nape of the neck (33). Control animals received treatment that included 
Alum (100 μL) or saline (1.5 mL). Urine samples were collected at 7 and 30 days post-
administration, prior to necropsy. Whole blood was collected via cardiac puncture in heparinated 
tubes, and liver and kidney tissues were harvested during necropsy and placed in phosphate-
buffered formalin. Formalin-fixed tissues after 7 and 30 days post-administration were 
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embedded, sectioned, and stained with hematoxylin and eosin (H&E), and blindly evaluated by a 
board-certified veterinary pathologist. Histopathological damage caused by inflammation, the 
distribution of inflammatory cells, and tissue necrosis were evaluated using a 0-5 scoring system 
for each independent parameter.  
5.3.9 Serum biomarker analysis 
Serum biomarkers of kidney and liver function were analyzed using an Ortho Vitros 5.1 
Chemistry Analyzer by the Iowa State University Clinical Pathology Laboratory. Toxicological 
biomarkers analyzed included blood urea nitrogen (BUN), albumin, alkaline phosphatase (Alk 
Phos), alanine aminotransferase (ALT), serum creatinine, glucose, total bilirubin, cholesterol and 
total triglycerides. Normal range values for these biomarkers were obtained from the Laboratory 
and compared with literature (34; 35).  
5.3.10 Urine creatinine and total protein quantification analysis 
Creatinine levels were measured in urine samples collected at 7 and 30 days post-
administraton using a creatinine assay kit (Sigma Aldrich). The ELISA-based colorimetric assay 
was performed following the manufacturer’s specifications. Quantification of creatinine was 
performed using standards provided by the manufacturer. Total protein amount in urine was 
quantified using a micro-bicinchoninic acid (BCA) assay at an absorbance of 562 nm using a 
plate reader (SpectraMax M3).  
5.3.11 Intranasal administration of particle formulations 
Five separate groups of Swiss Webster mice were intranasally administered nanoparticle 
formulations. To sedate the mice prior to intranasal adminsitration of the nanoparticles, the mice 
were intraperitoneally injected with 90 μL of anesthetic solution (20 mg/mL ketamine + 1 
mg/mL xylazine). Particle treatment groups included mice that were administered: 1) 500 μg of 
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non-functionalized, 2) linker-functionalized, 3) galactose-functionalized or 4) di-mannose 
functionalized 50:50 CPTEG:CPH nanoparticles. Mice intranasally administered saline were 
used as a control. Nanoparticles were suspended in PBS and sonicated before administration. For 
all formulations, a volume of 50 μL was intranasally administered. After mice were deeply 
anesthetized, they were held upright by the nape of the neck and nanoparticle suspension was 
slowly applied through the nostrils of each mouse with a micropipette. They were held in this 
position until the breathing rate of the animals was back to normal. Mice were monitored after 
anaesthesia and mobile function was restored.  
5.3.12 Lung histological evaluation  
Lungs from Swiss Webster mice were excised at 6 h, 24 h and 48 h post-immunization 
and formalin-fixed. Tissues were embedded, sectioned, and stained with H&E, and blindly 
evaluated by a board-certified veterinary pathologist. Adverse reactions in the lung tissue caused 
by inflammatory infiltration, necrosis, edema, bronchial associated lymphoid tissue (BALT) 
hyperplasia, and hemorrhage were evaluated using a 0-5 scoring system for each independent 
parameter.  
5.3.13 Flow cytometric analysis of lung tissue 
Mice were euthanized at 2 h, 24 h, and 48 h time points post-immunization. Lungs were 
processed as previously described (9). Briefly, lungs were excised and perfused with PBS. Lungs 
were incubated in Hank’s Balanced Salt Solution with 1 mg/mL collagenase D and 60 U/mL 
DNAse II for 20 min at 37°C. Lung tissue was homogenized using a gentleMACS
®
 tissue 
dissociator (Miltenyi Biotec, Cambridge, MA). To remove debris, samples were centrifuged for 
250 rcf for 20 s, and filtered with a 40 μm cell filter. Red blood cells were lysed using ACK lysis 
buffer (150 mM ammonium chloride, 10 mM potassium bicarbonate, and 0.1 mM EDTA). Cell 
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samples (1 x 10
6 
cells/mL) were blocked to prevent non-specific binding with 1% Rat IgG, 0.1% 
anti-mouse CD16/32 and 0.1% unconjugated Armenian Hamster IgG. Cells were surface stained 
with CD11c, CD11b, Ly6G/C Gr-1, and F4/80 markers. Samples were fixed with stabilizing 
fixative solution (BD Biosciences) and analyzed on a FACSCanto
TM 
flow cytometer (Becton-
Dickinson, San Jose, CA) and the data was processed using FlowJo vX software (TreeStar Inc., 
Ashland, OR). 
5.3.14 Bronchoalveolar lavage (BAL) fluid collection 
BAL fluid was collected after 6 h, 24 h, and 48 h post immunization (36; 37). Briefly, 
after mice were euthanized, a sterile catheter was inserted into the exteriorized trachea of each 
mouse. Using a 1 mL syringe attached to the catheter, 1 mL of PBS was infused into the lungs, 
and aspirated back to the syringe. The process was repeated 2-3 times, per mouse, while 
massaging the chest externally. Samples were placed on ice, and centrifuged at 300 rcf for 30 s at 
RT to remove cellular debris, and stored at -20°C until further analysis. 
5.3.15 Cytokine and chemokine analysis  
BAL fluid samples obtained at 6 h, 24 h and 48 h post-immunization were analyzed using 
a 13-plex cytokine and chemokine quantification kit (MILLIPLEX
®
 MAP mouse 
cytokine/chemokine magnetic bead panel, EMD Millipore, Billerica, MA). Analytes quantified 
included: IL-6, KC, MCP-1, MIP-1α, MIP-2, IP-10, TNF-α, IFN-γ, IL-1β, IL-10, IL-12p40, 
MIG, and RANTES. The assay was performed following manufacturer’s instructions, and data 
was acquired and analyzed using a Bio-Plex 200
 TM
 system (Bio-Rad, Hercules, CA) as 
described in previous protocols (8; 17). 
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5.3.16 Statistical analysis 
Statistical analysis was used to analyze the cell surface marker expression and cytokine 
secretion data. Two-way ANOVA and Dunnett’s test were used to determine statistical 
significance among treatments and p-values < 0.05 were considered significant. 
5.4 Results 
5.4.1 Functionalization and characterization of carbohydrate-modified nanoparticles 
Our previous work has shown that amphiphilic nanoparticle chemistries were suitable for 
protein stabilization (16; 24; 28; 38; 39), demonstrated potent adjuvant responses (20), and were 
effectively taken up by and activated APCs (6; 17; 24; 40). Therefore, the 50:50 CPTEG:CPH 
nanoparticle formulation was chosen to perform the carbohydrate functionalization and to 
evaluate safety upon in vivo administration.  
Particle morphology was characterized using scanning electron microscopy, as shown by 
the photomicrographs in Figure 5.1. The size of these particles was measured using ImageJ 
software (version 1.47v, NIH, Bethesda, MD). The diameter of the non-functionalized 50:50 
CPTEG:CPH nanoparticles was 182 ± 59 nm. After functionalization, the diameter increased to 
223 ± 61 nm, 228 ± 43 nm, and 236 ± 55 nm, for linker-, galactose-, and di-mannose-modified 
particles, respectively. In addition, the ζ-potentials and the surface concentration of the sugars for 
each formulation were measured and are shown in Figure 5.1. The NF particles are negatively 
charged, consistent with the presence of carboxylic acid moieties with a ζ-potential of -21 ± 3.2 
mV, while the addition of the amine linker to which the neutral sugar moieties (i.e., galactose 
and di-mannose) were attached resulted in a positively charged surface with ζ-potentials of 18 ± 
2.5 mV, 16 ± 2.1 mV and 19 ± 1.9 mV, respectively. After the carbohydrate modification was 
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completed, quantification of the amount of sugar linked to the particle surface was measured 
using a phenol sulfuric acid assay and indicated that 15 ± 5.5 μg of galactose or 19 ± 2.4 μg of 
di-mannose were present per milligram of particles.  
5.4.2 Kidney histological evaluation and renal function 
Following subcutaneous administration of 5 mg of particles to mice, serum, urine, and 
kidney samples were collected at 7 and 30 days. Histological evaluation of the tissue sections 
was performed and renal function biomarker levels were analyzed. Blood urea nitrogen (BUN) 
was measured in serum samples, while creatinine and total protein were quantified in urine 
samples. As shown in the representative histological images in Figure 5.2A, the inflammatory 
changes in the kidney during the period of the study were unremarkable as no significant 
differences were observed between the histological scores of mice treated with saline and the 
animals treated with the various nanoparticle formulations. Using a five point scale, the 
inflammatory infiltration scores ranged from 0-2, in all groups, with an average of 0.67, and 
these levels did not worsen between 7 to 30 days post-administration indicating that no acute or 
chronic inflammation was induced (Figure 5.2B). The distribution of the cellular infiltration had 
an average score of ~1.67, with only one mouse that was administered the galactose 
nanoparticles receiving a score of 3 at 7 days post-administration. In summary, these studies 
show that there was no histological evidence of tissue damage in the kidneys. Figure 5.2C shows 
renal function biomarker levels, BUN, and creatinine, both indicative of normal glomerular 
filtration rate. For the two biomarkers assessed and the total protein/creatinine ratio in the urine, 
there were no significant differences in urine samples collected at 7 or 30 days post-
administration from mice that were treated with saline and samples from mice that received any 
of the nanoparticle treatments. Both BUN and creatinine levels were within previously reported 
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normal range levels (41; 42). Even though BUN levels were slightly lower than the reference 
values, there were no significant differences between the saline and particle groups. Variations in 
normal BUN levels have been previously reported to be mouse strain-dependent (34; 35; 43).  
5.4.3 Liver histological evaluation and hepatic function 
Seven and 30 days after subcutaneous administration of 5 mg of nanoparticle 
formulations, histological evaluation of the tissue sections was performed. Cholestasis and 
hepatocellular damage were evaluated in serum samples by measuring the levels of alkaline 
phosphatase (Alk Phos) and alanine aminotransferase (ALT), respectively. As shown in Figure 
5.3A, the inflammatory changes in the liver were mild, and these were interpreted as non-
specific background changes common to this mouse strain. Representative histological images of 
liver tissue are shown. The inflammatory infiltration scores ranged from 0-2 (on a scale of 0-5) 
in all the animals studied, with an average of ~1, regardless of the treatment as shown in Figure 
5.3B. These scores did not significantly change between the two time points analyzed. The 
frequency of cellular infiltration within the liver (distribution score) was also low; the 
distribution score ranged from 0-3, with an average of ~1.8. In Figure 5.3C, the levels of Alk 
Phos, ALT, and albumin are shown. There were no significant differences in the serum levels of 
any of the biomarkers analyzed between saline and nanoparticle treatment groups in the levels of 
these serum biomarkers at either time point. The ALT levels in mice administered the particle 
formulations were slightly higher than the upper limit of the reference values at day 30 post-
administration; however, these were no different than the levels observed in mice treated with 
saline at the same time point.  
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5.4.4 Lung histological evaluation 
Based upon the results obtained so far, which suggested that the subcutaneous 
administration of carbohydrate-functionalized polyanhydride nanoparticles did not have a 
detrimental effect upon liver or kidney function of the treated animals, we next evaluated the 
safety profile upon intranasal administration of surface-modified polyanhydride nanoparticles. 
Previous work from our laboratories has shown that nanovaccines delivered intranasally resulted 
in protective long-term immunity (20). After intranasal administration of 0.5 mg of nanoparticle 
formulations, tissue samples were collected at 6, 24, and 48 h post-administration to evaluate 
acute histological changes. Figure 5.4A shows representative histological images from the lung 
for each treatment group at the 24 h time point (when the highest histological scores were 
registered). The parameter that contributed mostly to the final histological score was 
inflammation as shown in Figure 5.4B. Inflammatory infiltrates tended to be focused on 
bronchioles and adjacent alveolar spaces with neutrophils predominating. In general, the 
inflammatory scores peaked at 24 h, with scores up to 4 in some animals. The animals that 
received the linker and galactose-functionalized nanoparticles displayed a higher level of 
inflammation. In addition, the average necrosis values increased with time, with the highest 
value at 48 h, regardless of treatment groups (data not shown). There were only two mice with 
minor hemorrhage, with a score of 1, 24 h after administration of the NF particles. Hemorrhage 
was likely a tissue collection artifact. There were no mice with signs of edema or BALT 
hyperplasia at any time point analyzed (data not shown). Total histological scores are shown in 
Figure 5.4C. 
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5.4.5 Distribution of lung cellular populations 
Given the inflammatory cell infiltration scores described above, the cell types recruited 
into the lungs following particle administration were assessed by flow cytometry. Cellular 
populations were analyzed in whole lung homogenate at 2 h, 24 h, and 48 h post-intranasal 
administration. Flow cytometric analysis was performed and populations were identified with the 
following surface marker combinations: dendritic cells (CD11c
+
 CD11b
-
), interstitial 
macrophages (CD11c
-
 CD11b
+ 
F4/80
+
), neutrophils (CD11b
+ 
Ly6G/C Gr-1
+
), and activated 
monocytes (CD11b
+ 
Ly6G/C Gr-1
-
) (44-47). Figure 5.5 shows the cellular population 
distribution in the lungs. The percentage of DCs (Figure 5.5A) increased with time for all the 
treatment groups including the saline control and ranged from 1-4% of total lung cells. The 
percentage of interstitial macrophages (Figure 5.5B) peaked at 24 h, with all the treatment groups 
following similar dynamics. The neutrophil percentage (Figure 5.5C) at 2 h was the highest (2.5-
5%) and with time, these populations decreased to 1.5-2.5% of all the cells; this behavior was 
observed in the tissue from the animals that received all the treatment groups except the NF 
nanoparticles, in which the neutrophil population peaked at 24 h. As another measure of cellular 
recruitment into the lungs, the presence of activated monocytes was assessed (Figure 5.5D) and 
the presence of this cell type followed similar dynamics as neutrophils, starting at 4-6%, and 
decaying to 1.5-3% of total lung cells by 48 h. These data support the histological evaluation, as 
no major changes were observed in the inflammatory cell populations in the lungs of mice 
treated with saline or mice administered any of the nanoparticle formulations. 
5.4.6 Cytokine/chemokine secretion 
To assess the inflammatory environment in the lungs following intranasal administration 
of 0.5 mg of nanoparticle formulations, the BAL fluid was collected and used to measure the 
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amounts of the following chemokines and cytokines: IL-6, KC, MCP-1, MIP-1α, MIP-2, IP-10, 
TNF-α, IFN-γ, IL-1β, IL-10, IL-12p40, MIG, and RANTES. Negligible amounts (i.e., below the 
levels of detection) of IFN-γ, IL-1β, IL-10, IL-12p40, MIG, and RANTES were observed (data 
not shown). Figure 5.6 shows the kinetics of the secretion of IL-6, KC, MIP-2, TNF-α, IP-10, 
MCP-1, and MIP-1α. Two distinct trends were observed. The secretion of IL-6, KC, MIP-2, and 
TNF-α peaked at 6 h post-administration, while the highest amounts of IP-10, MCP-1, and MIP-
1α secreted were observed 48 h post-administration. The BAL fluid from animals that received 
the linker and galactose-modified nanoparticle groups showed consistently higher amounts of 
these cytokines compared with saline. The absence of a major cytokine/chemokine response after 
intranasal administration of the nanoparticle formulations is consistent with the histological data 
and provides further evidence of the safety and biocompatibility of these materials following 
pulmonary delivery. 
5.5 Discussion 
In this work we report on the safety profile of surface-functionalized polyanhydride 
nanoparticles following parenteral or intranasal administration to mice. The safety and 
biocompatibility of non-functionalized polyanhydride nanoparticles has been demonstrated 
previously (33); however, the ability of di-mannose functionalized nanoparticles to initiate 
signaling via CLRs warrants a systematic evaluation of the potential toxicity associated with the 
induction of innate and/or inflammatory responses by these novel biomaterials.  
As shown in Figure 5.1, the particle morphology and size of the functionalized particles 
were similar to previously reported data (6; 19; 28; 48; 49). The characterization of 
polyanhydride nanoparticles before and after surface modification was consistent with previous 
studies (6; 17; 18). The change in zeta potential from negative to positive charge after linker 
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attachment can be beneficial for enhanced cellular uptake, as reported previously (50; 51). In 
addition, carbohydrate functionalization is known to enhance both APC activation in vitro (6; 17; 
18) as well as the therapeutic efficacy of drug delivery (4). 
Based on the histological analysis scores reported in this work, subcutaneous 
administration of 5 mg of carbohydrate-functionalized nanoparticles did not result in tissue 
damage of the liver or kidney when assessed at 7 or 30 days post-administration and is consistent 
with previously reported safety profiles of parenterally administered polyanhydride nanoparticles 
(33). The histological changes noted in hepatic tissue samples after nanoparticle administration 
were mild, which is comparable to other biodegradable polymer formulations, but much less than 
that exhibited by extremely cytotoxic metal particles of similar size (11). No other histological 
changes such as distortion and swelling of hepatocytes, cellular binucleation, or hydropic 
degeneration of the tissue were detected in the liver samples, as reported with other nanoparticle 
formulations (52). The histological scores of the kidney samples of mice administered saline 
alone were not significantly different when compared to the scores from the kidneys of mice 
administered the various particle formulations. No interstitial edema, inflammatory cell 
infiltration, tubular epithelial flattening, urinary casts, or signs of renal histopathological lesions 
were detected, which have been reported previously for other nanoparticles (53; 54). Based on 
the data presented here, the systemic effects of functionalized nanoparticle administration, in 
terms of hepatic and renal health, are consistent with effects of other biodegradable nanoparticle 
systems (33; 55; 56).  
In addition to histological evaluation, serum and urine biomarkers, which are indicators 
of renal and hepatic injury and inflammation, were used to evaluate the safety of the 
functionalized nanoparticles. The levels of BUN, urine creatinine, and total protein/creatinine 
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ratio in mice receiving the particle treatments were not significantly different from the levels in 
animals receiving the saline. Even though BUN content level was lower than the reference 
values provided, the values were consistent with previously reported data in Swiss Webster mice 
(43). Creatinine and total protein to creatinine ratio levels in mice administered the particles were 
no different than in animals receiving the saline control, and consistent with amounts reported in 
urine from mice of this lineage (35; 41). Creatinine, a byproduct of muscle metabolism, is an 
important indicator of kidney function. When glomerular filtration rate is impaired, creatinine 
levels rise in the blood and in the urine (57). Creatinine measurement is commonly used because 
urinary excretion of any biomarker that is filtered through the glomerulus is affected by the 
glomerular filtration rate and therefore used to normalize other markers, such as total protein or 
albumin (58). Together with urine specific gravity, these markers are part of the standard clinical 
diagnosis for renal function during impairments such as chronic kidney disease (59), acute 
kidney injury (60), or renal injury (41). Together, the inability to detect elevated levels of key 
biomarkers in serum and urine combined with the histopathology assessment of liver and kidney 
samples, demonstrates that there were no detrimental effects on renal or hepatic systems in mice 
treated with 5 mg of di-mannose functionalized nanoparticles.  
The use of the pulmonary route offers several advantages for drug and vaccine delivery 
since the lungs allow targeted (2), non-invasive administration (22), and the capability to ensure 
systemic or local delivery of agents (12; 21). However, the respiratory system is also a more 
delicate environment, and parameters such as particle size (61-63), charge (2; 50; 51), chemistry 
(9; 33), and material (12; 64) affect deposition, distribution, and biocompatibility. In previous 
work, a single intranasal administration of non-functionalized polyanhydride nanovaccines 
demonstrated the ability to induce protective immunity upon lethal challenge (9; 20; 65). The 
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current work builds upon these studies by evaluating the safety profile of carbohydrate-
functionalized nanoparticles in the lung. The acute histopathology results from lung tissues after 
administration of particle formulations (Figure 5.4) displayed a bell-shaped curve with a peak at 
the 24 h time point. The lesions in the lung samples were mild to moderate, likely attributable to 
the administration procedure itself, because the lungs of the mice administered the saline control 
group received similar scores. As shown in Figure 5.4B, the major contributor to the histological 
scores was inflammatory cell infiltration.  
The inflammatory infiltrates found in the lung samples after intranasal administration 
were consistent with the recruitment kinetics described for other pulmonary innate immune 
responses (36; 50; 61; 66), in which initial cellular recruitment was primarily composed of 
mononuclear cells and neutrophils. Next, neutrophils and macrophage infiltrates appeared in the 
lung tissue by 24 h, and were still present 48 h post-administration. Since the differences in the 
inflammatory cell infiltrates in the lung samples may be attributed to pulmonary recruitment of 
cells from circulation (50), we analyzed the kinetics of various cell populations in the lungs of 
treated animals. As shown in Figure 5.5, there were no significant changes in lung cellular 
populations between the various particle treatment groups, but all of them followed similar 
kinetics. Consistent with the histological data and previous studies (66; 67), neutrophils were the 
first cells to be recruited to the administration site, followed by macrophages and/or DCs. 
Overall, the lung cellular populations observed were not statistically distinguishable from the 
populations in the lungs of mice receiving saline. This observation suggests that the 
administration of the nanoparticles likely caused a mild inflammatory response similar to that 
induced by the administration of saline, and supports the conclusion that the particle 
formulations themselves were not detrimental to the health of the treated animals.  
151 
 
 
 
Another component of lung response to foreign material is the secretion of cytokines and 
chemokines to recruit a cellular response and mediate clearance. The presence of these molecules 
can mediate leukocyte trafficking, inflammation, and link the innate and adaptive immune 
responses (68). However, overproduction of chemokines and cytokines can cause severe tissue 
damage (68; 69). As shown in Figure 5.6, different kinetics were observed for the analyzed 
cytokines and chemokines. The amounts of IL-6, KC, MIP-2 and TNF-α levels were elevated at 
early time points but decreased by 48 h, while the amounts of IP-10, MCP-1 and MIP-1α 
secreted were the highest at 48 h. The observed differential production of these 
cytokines/chemokines is likely related to the dynamic nature of the innate immune response and 
the different cell types that produce, utilize, and respond to these molecules. Nevertheless, our 
data indicate that intranasal administration of any of the nanoparticle formulations did not cause 
a major increase in cytokine or chemokine production that would result in severe tissue damage. 
Altogether, the histological evaluation of lung tissue, the unremarkable changes in the 
recruitment of inflammatory cells to the lung, and the absence of a major cytokine/chemokine 
response after intranasal administration of carbohydrate-functionalized polyanhydride 
nanoparticles provide confirmatory evidence of the safety and biocompatibility of these novel 
materials for pulmonary delivery.  
5.6 Conclusions 
The studies reported herein demonstrate the safety and biocompatibility of carbohydrate-
functionalized polyanhydride nanoparticles upon parenteral and intranasal administration. The 
results showed that a 5 mg dose of either linker- or di-mannose-functionalized nanoparticles did 
not induce hepatic or renal tissue damage or cause elevation of damage-related or functional 
biomarkers in serum or urine following subcutaneous administration. In addition, a 0.5 mg dose 
152 
 
 
 
of either linker- or di-mannose-functionalized nanoparticles administered intranasally did not 
result in demonstrable tissue changes in the lungs of treated animals. The favorable histological 
profile, distribution and kinetics of cellular populations, and the lack of a remarkable pro-
inflammatory cytokine and chemokine profile in the lungs of mice administered functionalized 
nanoparticles supported the biocompatibility of the linker- and di-mannose-functionalized 
nanoparticles. Together, these studies demonstrate the safety of administering carbohydrate-
functionalized nanoparticles in vivo and provide foundational information to evaluate the 
capabilities of these surface-modified nanoparticles for drug and vaccine delivery.  
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5.9 Figures  
 
Figure 5.1 Polyanhydride nanoparticle characterization. Chemical structures of the surface 
moieties on non-functionalized, linker-, galactose-, and di-mannose-functionalized nanoparticles 
are presented. Particle size data represent the mean ± standard deviation (SD) of data collected 
from scanning electron microscopy photomicrographs using ImageJ software from four 
independent experiments. Zeta potential data were measuring using QELS and represent the 
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mean ± SD of four independent experiments. Sugar density data were measured using a phenol 
sulphuric acid assay and are presented as the mean ± SD of four independent experiments. 
 
Figure 5.2 Administration of a 5 mg dose of surface-functionalized 50:50 CPTEG:CPH 
nanoparticles did not affect renal function. Panel A shows representative histological sections of 
kidney samples from Swiss Webster mice (n= 6) seven days post-administration of the 
nanoparticle formulations. Panel B shows the inflammatory scores of kidney samples after 
histopathological evaluation. Panel C displays the levels of blood urea nitrogen (BUN) in serum 
and creatinine and total protein/creatinine ratio in urine samples from Swiss Webster mice seven 
and 30 days post-administration. Reference levels provided by the Iowa State University Clinical 
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Pathology Laboratory are indicated as dashed lines. No significant differences were observed 
when compared to mice administered saline (n = 5 at each time point).  
 
Figure 5.3 Administration of a 5 mg dose of surface-functionalized 50:50 CPTEG:CPH 
nanoparticles did not affect induce hepatic inflammation or alter hepatic function. Panel A shows 
representative histological sections of liver samples from Swiss Webster mice (n= 6) seven days 
post-administration of the nanoparticle formulations. Panel B shows the inflammatory scores of 
liver samples after histopathological evaluation. Panel C displays the levels of alkaline 
phosphatase, alanine aminotransferase, and albumin in serum samples from Swiss Webster mice 
seven and 30 days post-administration. Reference levels provided by the Iowa State University 
Clinical Pathology Laboratory are indicated as dashed lines. No significant differences were 
observed when compared to mice administered saline (n = 5 at each time point). 
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Figure 5.4 Mild to moderate inflammation was observed in lung samples upon histological 
evaluation post-administration of surface-functionalized polyanhydride nanoparticles. Lung 
tissue samples from Swiss Webster mice were collected at 6, 24 and 48 hours post-
administration. A) Representative images of each treatment group at 24 h post-administration. B) 
Inflammatory infiltration scores on a scale of 0-5 after histopathological evaluation. C) 
Composite histopathological scores representing the sum of five individual parameters 
(inflammatory infiltration, necrosis, edema, bronchial associated lymphoid tissue hyperplasia, 
and hemorrhage), with a total possible score of 25. No significant differences were observed 
when compared to mice administered saline (n = 6 at each time point). 
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Figure 5.5 Cellular distribution of lung homogenates of Swiss Webster following administration 
of surface-functionalized polyanhydride nanoparticles. Cellular populations were analyzed by 
flow cytometry at 6, 24 and 48 hours post-administration and various cell populations were 
analyzed. A) dendritic cells; B) interstitial macrophages; C) neutrophils; and D) activated 
monocytes. No significant differences were observed in these distributions when compared to 
mice administered saline (n = 6 at each time point). 
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Figure 5.6 Low amounts of cytokine/chemokine secretion were observed in bronchoalveolar 
lavage fluid 6, 24 and 48 hours after intranasal administration of surface-functionalized 
polyanhydride nanoparticles. The amounts of IL-6, KC, MIP-2, TNF-α, IP-10, MCP-1 and MIP-
1α in the bronchoalveolar lavage fluid were quantified using a Multiplex magnetic bead assay. * 
represents groups that are statistically significant (p ≤ 0.05) compared to the saline control (n = 5 
at each time point).  
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6.1 Abstract 
Enhancing the activation of antigen presenting cells (APCs) by receptor-mediated 
endocytosis of nanoparticles is a promising approach to tailoring the adaptive immune response. 
C-type lectin receptors (CLRs) are a class of pattern recognition receptors (PRRs) that bind to 
carbohydrates and that are expressed on APCs. In this work, the carbohydrate di-mannose was 
covalently functionalized to the surface of polyanhydride nanoparticles in order to interact with 
the macrophage mannose receptor (MMR). These nanoparticles contained ovalbumin (Ova) and 
were administered subcutaneously to C57BL/6 mice. Using an adoptive transfer model, the 
antigen-specific T cell response induced by these formulations was evaluated. The non-
functionalized nanoparticles and soluble Ova alone induced the greatest CD8
+
 T cell and induced 
strong activation of the transgenic CD8
+
 T cells as evidenced by the population of OTI cells 
containing intracellular IFN-γ and TNF-α. In contrast, the carbohydrate-functionalized 
nanoparticles induced less antigen-specific CD8
+
 T cell expansion. A memory recall response 
was observed in the animals that received non-functionalized or soluble protein formulations 
when the mice were challenged with Ova-expressing tumor cells. In the weeks following primary 
immunization, animals receiving the functionalized or non-functionalized nanoparticles showed 
significantly higher antibody titers compared to that induced in animals receiving soluble 
protein. It was shown that the surface functionalization of the nanoparticles is labile and is lost 
within a few hours of incubation in aqueous solutions. These results provide important insights 
into the complex interactions between nanoparticle chemistry and innate and adaptive immunity.  
6.2 Introduction 
The induction of long lasting and protective immune responses is an important 
deliverable of many vaccine regimens. In this context, the inability to induce cellular responses 
has led to a lack of efficacious vaccines for diseases requiring avid T cell responses, such as HIV 
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or tuberculosis (1; 2). One strategy to overcome this hurdle is to enhance the activation of 
antigen presenting cells (APCs), such as dendritic cells (DCs), by exploiting receptor-mediated 
uptake of vaccine formulations. With a wide array of pattern recognition receptors (PRRs) to 
internalize antigen and activate downstream signaling, DCs lie at the crossroads of the innate and 
adaptive immunity (3). They efficiently present antigen to cognate T cells and provide important 
co-stimulatory signals that direct the outcome of the immune response 
An important class of PRRs expressed on DCs are C-type lectin receptors (CLRs) (4). 
There are over 60 types of CLRs expressed on the surface of APCs and they recognize a diverse 
range of carbohydrate structures (4). Some well characterized CLRs include cluster of 
differentiation (CD) 205 (also referred to as DEC-205), dendritic cell-specific intercellular 
adhesion molecule-3-grabbing non-integrin (DC-SIGN), and the macrophage mannose receptor 
(MMR). Engaging the MMR on DC and macrophage (MØ) cultures in vitro has been the focus 
of recent efforts from our laboratories (5-8). In these studies, polyanhydride microparticles and 
nanoparticles functionalized with di-mannose were internalized more efficiently by phagocytic 
cells. Additionally, incubating these carbohydrate-functionalized particles to DC or MØ cultures 
resulted in the secretion of higher amounts of pro-inflammatory cytokines (e.g., TNF, IL-6) and 
upregulated cell surface marker expression (e.g., CD80/86, CD40, MHC II) on these cells 
relative to that induced by non-functionalized particles.  
In our previous work, we showed that polyanhydride nanovaccines induced long-lived 
antibody responses for at least 40 weeks post-immunization (PI) (9). The immunomodulatory 
capabilities of these nanovaccines helped enhance isotype switching and promoted higher 
antibody titers compared to a regimen consisting of soluble antigen (10; 11). Additionally, these 
vaccine formulations induced cell-mediated immunity more effectively than alum and also 
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elicited robust recall responses (10). The nanoparticles also provide prolonged release of a 
variety of encapsulated antigens that maintain both conformational and biological activity upon 
release (12-14). Formulations consisting of a soluble bolus with encapsulated antigen were 
shown to induce the most robust adaptive immune responses compared to an regimen on which 
all of the antigen was encapsulated within particles, priming the immune response against the 
antigen, and providing a prolonged presence of antigen to enhance the development of B cells 
(11; 15; 16).   
Towards rational design of vaccines, this work focused on monitoring the adaptive 
immune response induced by di-mannose functionalized polyanhydride nanovaccines, using 
ovalbumin (Ova) as a model antigen. Here, CD8
+
 and CD4
+
 OVA-specific, transgenic T cells 
were adoptively transferred to C57BL/6 mice to evaluate the antigen-specific T cell response 
induced by a single dose of carbohydrate functionalized nanoparticles. In addition, serum was 
collected from the animals and analyzed for anti-Ova IgG titers. Our results indicate that 
carbohydrate-functionalized nanoparticles did not outperform non-functionalized nanoparticles 
in inducing robust expansion of the Ova-specific T cells or avid antibody responses.  
6.3 Materials and Methods 
6.3.1 Materials 
For CPH and CPTEG monomer synthesis 1,6-dibromohexane, triethylene glycol, 4-p-
hydroxybenzoic acid, and 1-methyl-2-pyrrolidinone were purchased from Sigma-Aldrich (St. 
Louis, MO). 4-p-fluorobenzonitrile was obtained from Apollo Scientific (Cheshire, UK), while 
toluene, sulfuric acid, acetonitrile, dimethyl formamide, acetic anhydride, methylene chloride, 
pentane, and potassium carbonate were obtained from Fisher Scientific (Fairlawn, NJ). 
Polymerization of the monomers required acetic anhydride, methylene chloride, and hexane 
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which were also purchased from Fisher Scientific.
 1
H NMR analysis was conducted using 
deuterated chloroform from Cambridge Isotope Laboratories (Andover, MA). Chemicals from 
Fisher Scientific were used in the synthesis of nanoparticles including methylene chloride, and 
pentane. Ovalbumin was purchased from Sigma-Aldrich and passed through a Detoxi-Gel 
Endotoxin removing column from Thermo Scientific. Materials for nanoparticle 
functionalization included N-hydroxysuccinimide (NHS) from Fisher Scientific, ethylenediamine 
from Sigma Aldrich, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and glycolic acid 
from Acros Organics (Geel, Belgium). 
Adoptive transfer experiments required sterile PBS from Mediatech (Manassas, VA) and 
heparin from Fresenius Kabi USA (Waltham, MA). Complete tissue culture medium (CTCM) 
was composed of β-mercaptoethanol (Sigma-Aldrich), heat inactivated fetal bovine serum 
(Atlanta Biologicals, Atlanta, GA), and RPMI 1640, penicillin/streptomycin, and L-glutamine, 
all purchased from Mediatech. Ammonium-Chloride-Potassium (ACK) lysing buffer consisted 
of ammonium chloride, potassium bicarbonate, and ethylenediaminetetraacetic acid (EDTA), all 
of which were purchased from Fisher Scientific. Cells were stimulated in phorbol 12-myristate 
13-acetate (PMA), ionomycin, and brefeldin A, all of which were acquired from Sigma-Aldrich. 
Flow cytometry was performed using the Fix/Perm Buffer kit from eBioscience. FITC-labeled 
anti-mouse Thy1.2 (clone 53-2.1), PE-labeled anti-mouse TNF-α (clone MP6-XT22), APC-
labeled anti-mouse CD8b (clone eBioH35-17.2), APC-labeled anti-mouse CD4 (clone GK1.5), 
PerCp-Cy5.5-labeled anti-mouse IL-2 (clone JES-5H4) and PE-Cy7-labeled anti-mouse IFN-γ 
(clone XMG1.2) were obtained from Biolegend or eBioscience. Compensation beads were 
obtained from eBioscience. Cells were washed in FACS buffer which consisted of PBS 
(pH=7.4), sodium azide from Fisher Scientific, and 2% heat inactivated fetal bovine serum. 
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Enzyme-linked immunosorbent assays (ELISAs) were completed with AP-conjugated 
anti-mouse IgG (H&L), AP-conjugated anti-mouse IgG2c, or AP-conjugated anti-mouse IgG1, 
all of which were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA), 
PBS-Tween (0.2% Tween), and p-nitrophenyl phosphate (Fisher Scientific). Wells were blocked 
with 2 wt. % gelatin from Becton Dickinson (Sparks, MD). 
6.3.2 Monomer, polymer, and nanoparticle synthesis 
1,6-bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-carboxyphenoxy)-3,6-
dioxaoctane (CPTEG) diacids were synthesized as described previously (17; 18). These diacids 
were used in a melt polycondensation reaction to synthesize 20:80 CPTEG:CPH copolymer 
(Figure 6.1A) (19).
 
Purity, chemical structure, and molecular weight of the polymers were 
determined using 
1
H NMR spectroscopy on a Varian VXR 300 MHz spectrometer. Differential 
scanning calorimetry (DSC, TA Instruments) and gel permeation chromatography (GPC, Waters) 
were used to determine polymer glass transition temperature and polydispersity, respectively. 
The 20:80 CPTEG:CPH copolymer had a molecular weight of 9.2 kDa from 
1
H NMR 
measurements, which is consistent with previous work (13; 20). The actual molar ratio was 
determined to be 22:78 CPTEG:CPH using 
1
H NMR analysis. 
Polyanhydride nanoparticles were synthesized using an anti-solvent nanoencapsulation 
technique (21). A 20 mg/mL polymer solution with 2% (w/w) Ova was dispersed in methylene 
chloride and poured into a pentane bath so that the ratio of solvent to anti-solvent was 1:250. 
This procedure was carried out at 4 °C with the pentane bath held at -40 °C and the particles 
were collected by vacuum filtration. Particle morphology was examined by a FEI Quanta 250 
scanning electron microscope (SEM, Kyoto, Japan) after being coated with 2 nm of iridium 
using a Quorum Q150TS sputter coater (Lewes, UK). Nanoparticle size distribution was 
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characterized using ImageJ image analysis software (National Institutes of Health, Bethesda, 
MD) with an average of 200 nanoparticles per image. 
6.3.3 Nanoparticle functionalization 
The particles were functionalized with either di-mannose or a glycolic acid linker, which 
links the di-mannose to the ethylenediamine. Fluorous solid-phase extraction-based iterative 
synthesis was performed to obtain α-1,2-linked-di-mannopyranoside with a fluorous allyl group 
(22). The fluorous tag was cleaved by ozonolysis, while oxidation with Jones Reagent produced 
a carboxylic acid group for coupling to nanoparticles. Birch reduction was used to yield a 
deprotected carboxymethyl-modified disaccharide of 1,2-α-linked-D-mannopyranoside (23). A 
previously optimized two-step amide coupling reaction covalently linked the di-mannose to the 
nanoparticles (6; 7). The first reaction involved incubating the nanoparticles with 10 molar 
equivalents of EDC, 12 molar equivalents of NHS, and 10 molar equivalents of ethylenediamine 
for one hour on a tube rotor at 4 °C. The nanoparticles were then washed with nanopure water 
and were collected by centrifugation at 10,000 rcf and 10 min. After being sonicated briefly at 40 
Hz, the nanoparticles were incubated with 10 molar equivalents of EDC, 12 molar equivalents of 
NHS, and 10 molar equivalents of di-mannose for one hour at 4 °C allowing the di-mannose to 
attach to the free amine of the ethylenediamine on the surface of the nanoparticles (Figure 6.1B).  
6.3.4 Characterization of functionalized nanoparticles 
The sugar density on the surface of the nanoparticles was quantified using a phenol-
sulfuric acid assay performed in flat bottom 96-well plates (24). A reaction time of 30 min at 95 
°C was used for the sugars on the nanoparticle surface to be reduced inducing a color change in 
the solution. The absorbance of each well was measured at a wavelength of 490 nm using 
spectrophotometry (SpectraMax M3, Molecular Devices, Sunnyvale, CA). This was compared 
against soluble di-mannose standards, while non-functionalized nanoparticles were used as a 
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negative control. Energy dispersive X-ray spectroscopy (EDS) was also performed to assay for 
nitrogen content from the ethylenediamine on the particles. 
To track the zeta potential of the non-functionalized and functionalized nanoparticles as a 
function of time, 5 mg of nanoparticles and 1 mL PBS were placed in 1.5 mL microcentrifuge 
tube, sonicated, and incubated at 37°C in a 100 rpm rotator. 40 μL of particle suspension was 
removed at each time point and diluted in 960 μL of cold nanopure water for a final 
concentration of 200 μg/mL. The surface potential was measured in mV using a ZetaSizer Nano 
(Worchester, UK).  
6.3.5 Animals 
Recipient female C57BL/6 Thy1.1, donor OT-I Thy1.2 C57BL/6 mice, and donor OT-II 
Thy1.2 C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME). All mice 
were housed under specific pathogen-free condition with all the bedding, caging, water, and feed 
sterilized prior to use. The Iowa State University Institutional Animal Care and Use Committee 
approved all animal procedures. 
6.3.6 Adoptive transfer and mouse immunizations 
7.5 x 10
5
 OT-I Thy1.2
+
 CD8
+
 T cells were transferred into Thy1.1
+
 recipient C57BL/6 
mice on Day -1. Lymph nodes of the OT-I donors were harvested, processed, and the number of 
cells were counted using a Beckman Coulter Z1 particle counter. Flow cytometry was performed 
on an aliquot of the cells to assess the frequency of Thy1.2
+
 CD8
+
 T cells in order to calculate 
the total number of OT-I cells to be administered. Adoptive transfers were performed via a tail 
vein injection of 100 μL of OT-I cells in PBS. One day later the recipient mice were immunized 
subcutaneously at the nape of the neck with 200 μL of PBS containing one of the vaccine 
treatments. There were five immunization groups each consisting of eight mice with one group 
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serving as a naïve (i.e., saline-administered) control and another group receiving 100 μg of 
soluble Ova, as previously described (25). Separate groups of mice also received either non-
functionalized Ova-containing 20:80 CPTEG:CPH nanoparticles, Ova-containing linker-
functionalized 20:80 CPTEG:CPH nanoparticles, or di-mannose functionalized 20:80 
CPTEG:CPH nanoparticles. In the particle formulations, 90 μg of the Ova was administered as 
soluble antigen and 10 μg were encapsulated into 500 μg of nanoparticles (i.e, 2 % loaded). The 
same experimental design was utilized to evaluate the Thy1.2
+
 CD4
+
 T cell responses. 
6.3.7 T cell expansion and intracellular cytokine staining 
At days 2, 6, and 10 PI, approximately 100 μL of blood was collected from the saphenous 
vein of each mouse and dispensed into PBS containing 500 unit/mL heparin solution to prevent 
clotting. ACK lysis buffer was added to the suspension to lyse red blood cells. CTCM medium 
was added following 3 min of lysing to neutralize the lysis buffer. The cells were centrifuged at 
250 xg at 4 °C for 10 min and the lysing step was repeated once more. Cells were enumerated 
and 5 x 10
5
 total cells were added to each well of a 96 well microtiter plate. These cells were 
stimulated at 37 °C in a 5% CO2 environment for 5 h with CTCM medium that consisted of 50 
ng/mL PMA, 500 ng/mL ionomycin, and 10 μg/mL brefeldin A. Cells were also stimulated with 
brefeldin A only to serve as a baseline control. Fixative/permeation buffer was added for 
overnight incubation at 4°C and the following day the cells were labeled with monoclonal 
antibodies directed at surface markers and for detection of intracellular cytokines. The cells were 
incubated in FACS buffer and were analyzed using a BD FACS Canto flow cytometer. 
6.3.8 Antigenic challenge 
5 x 10
6
 EG7 ovalbumin expressing tumor cells were administered to the right rear flank 
four weeks PI to OT-I and OT-II recipient mice. Four days post challenge, 100 μL of peripheral 
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blood was collected from each mouse and the intracellular cytokine staining procedure was 
repeated to determine the efficacy of a memory response.  
6.3.9 Antibody titer 
Flat-bottomed, high-binding 96 well plates were coated with 100 μL of 5 μg/mL Ova in 
each well and allowed to incubate at 4°C overnight. On the following day, the wells were 
emptied and 2% (w/v) gelatin blocking buffer was allowed to incubate for 2 h at room 
temperature. The blocking buffer was removed and the plates were washed in PBS-Tween 
(PBST) buffer. Serum was added to the wells and 1:2 dilutions were performed across the plate 
in antibody dilution buffer consisting of PBS and 1% (v/v) normal goat serum. The plates were 
allowed to incubate at 4°C overnight. On the third day, the plates were washed in PBST and 
alkaline phosphatase-conjugated goat anti-mouse IgG (or a subclass of IgG) was added at 1:1000 
dilution. After 2 h of incubation at room temperature, the plates were washed in PBST and 100 
µL (1 mg/mL) of alkaline phosphatase substrate was added. One hour later, the plates were 
analyzed at a wavelength of 405 nm using a spectrophotometer.  
6.3.10 Statistical analysis 
An unpaired t test was performed to determine statistical significance among the 
treatments. A p-value less than 0.05 was considered significant. 
6.4 Results 
6.4.1 Nanoparticle characterization 
Nanoparticles based on 20:80 CPTEG:CPH were synthesized for use in this work 
because this chemistry has previously been demonstrated to induce robust antibody titers and 
induce a cell-mediated response (Figure 6.1) (9; 25). When added to DC cultures in vitro, 
carbohydrate modification of 20:80 CPTEG:CPH nanoparticles resulted in enhanced cell surface 
marker expression and induced secretion of pro-inflammatory cytokines by the DCs compared to 
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the addition of nanoparticles of other chemistries (7). Using SEM, the nanoparticle size was 
determined to be approximately 180 nm and the morphology was comparable to that observed in 
previous studies (Table 6.1) (7; 9). Carbohydrate functionalization did not significantly affect 
nanoparticle size. Carbohydrate modification was characterized by EDS and the colorimetric 
phenol-sulfuric acid assay. A strong nitrogen peak was detected on both the linker and di-
mannose functionalized nanoparticles confirming the presence of the ethylenediamine (Table 
6.1). The phenol-sulfuric acid assay indicated the presence of di-mannose on the nanoparticles 
relative to the non-functionalized nanoparticles. The results of the EDS and phenol-sulfuric acid 
assay were also consistent with previous work (5-7; 26).  
The zeta potential was recorded for all the nanoparticle formulations as a function of time 
during incubation in PBS (Figure 6.2). Upon suspension in PBS, the zeta potential of the 
negatively charged non-functionalized particles was -19 mV and is consistent with previous 
observations (7; 12; 26). In contrast, the initial zeta potential of the linker-functionalized 
particles was +13 mV, as expected, because of the presence of the positively charged amine 
groups. When these measurements were carried out as a function of time, it was observed that 
the surface charge of the linker-functionalized particles decreased. After 2-3 h of incubation, the 
surface charge became negative and plateaued after 24 hours at approximately -10 mV. In 
contrast, the zeta potential of the non-functionalized nanoparticles remained unchanged for the 
entire duration of the experiment. These results indicate that the engagement of the MMR 
provided by the functionalization would not last for beyond a few hours. 
6.4.2 Carbohydrate-functionalized nanoparticles induced reduced antigen-specific CD8
+
 T cell 
expansion 
Thy1.1
+
 mice were subcutaneously immunized with a total of 100 μg of Ova, which for 
the particle groups consisted of 90 μg of soluble protein and 10 μg of protein encapsulated into 
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500 μg of the 20:80 CPTEG:CPH nanoparticles. One day prior to immunization all the mice 
were given 7.5 x 10
5
 OT-I Thy1.2
+
 CD8
+
 T cells intravenously. This number of T cells was 
chosen based on preliminary studies, which showed that peripheral blood samples could be used 
to track OT-I cell proliferation using flow cytometry (data not shown). This adoptive transfer 
model enabled better evaluation of the antigen-specific CD8
+
 T cell response induced by the 
different nanoparticle formulations.   
Peripheral blood was collected from each mouse at days 2, 6, and 10 PI to measure the 
expansion kinetics of the Ova-specific T cells in the circulation. Peripheral blood mononuclear 
cells (PBMCs) were labeled with anti-CD8ß and Thy1.2 (Figure 6.3A). The percentage of 
circulating endogenous CD8
+
 T cells within the lymphocyte gate varied from 10-15%. There 
were significantly fewer Ova-specific T cells, but they could easily be discerned using flow 
cytometry. The data indicated that the peak expansion of Ova-specific CD8
+
 T cells occurred at 
day 6 PI and by day 10 the contraction phase of the OT-I T cells had been completed (Figure 
6.3B). In these studies, the non-functionalized nanoparticles and soluble Ova treatment groups 
induced the greatest expansion of CD8
+
 T cells in the peripheral blood.  
The PBMCs were labeled with antibodies specific for the intracellular cytokines TNF-α 
and IFN-γ to characterize T cell activation (Figure 6.4A). Cells from immunized animals showed 
significantly greater amounts of pro-inflammatory cytokines relative to cells from animals that 
were administered saline (Figure 6.4B). As a percentage, the functionalized particles induced  a 
similarly sized population of OT-I T cells that were double positive for TNF-α and IFN-γ as did 
treatment of the mice with the non-functionalized particles. However, there were fewer CD8
+
 T 
cells in the peripheral blood of the mice that received the functionalized particle treatments, and 
so the numbers of the TNF-α and IFN-γ producing cells are lower in these groups.  
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6.4.3 Carbohydrate-functionalized nanoparticles induced weak memory recall responses 
Four weeks PI, mice receiving OT-I Thy1.2
+
 T cells were challenged with EG7 
ovalbumin expressing tumor cells. Four days following the challenge, peripheral blood was 
collected to analyze the ability of each vaccination group to mount a recall response. No 
significant differences were observed in the number of antigen-specific CD8
+
 T cells present in 
100 μL of peripheral blood between any of the immunized animals. Both non-functionalized 
nanoparticles and soluble protein induced significantly more cells expressing TNF-α and IFN-γ 
(Figure 6.5). In contrast, the carbohydrate-functionalized particles induced virtually no recall 
response as indicated by the percentage of OT-I T cells that were positive for the presence of 
IFN-γ and TNF-α. 
6.4.4 Nanovaccines induced robust antibody titers 
Thy1.1
+
 mice were immunized in the same manner and with the same treatment groups 
as previously described. However, one day prior to immunization all the mice were given 7.5 x 
10
5
 OT-II Thy1.2
+
 CD4
+
 T cells intravenously to assess the ability of the Ova-specific CD4
+
 T 
cells to enhance the antigen-specific IgG response. Peripheral blood was collected every two 
weeks and antibody titers were quantified using an ELISA (Figure 6.6A). The data indicated a 
dramatic increase in titer between 4 and 6 weeks. At each time point, the animals vaccinated with 
nanoparticles had higher titers than those in animals vaccinated with soluble Ova or animals 
treated with saline. In particular, it was observed that the animals vaccinated with the 
carbohydrate-functionalized nanoparticles showed titers that were similar to that induced in the 
animals that were vaccinated with the non-functionalized particles.  
At day 42, the serum was analyzed for isotype switching. The vast majority of IgG 
secreted was IgG1 (Figure 6.6B & 6.6C), as expected. However, animals vaccinated with the 
non-functionalized nanoparticles, soluble protein, and di-mannose-functionalized nanoparticles 
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showed a small but significant production of IgG2c compared to mice receiving the saline 
treatment or linker-functionalized nanoparticles. Mice immunized with non-functionalized 
nanoparticles produced the most IgG2c.  
6.5 Discussion 
Recent investigations have revealed that engaging CLRs on DCs can be a novel strategy 
to rationally design vaccines (27-30). Nanoparticles were designed to enhance APC activation by 
covalently linking carbohydrate ligands specific for the MMR onto their surface. The work 
described herein assessed the adaptive immune response in animals subcutaneously immunized 
with di-mannose-functionalized polyanhydride nanoparticles.  
Both the non-functionalized nanoparticles and soluble Ova induced 10-fold greater 
expansion of CD8
+
 T cells, which was significantly higher than that induced by the 
carbohydrate-functionalized nanoparticles (Figure 6.3B). It is interesting to note that at day 2, 
more CD8
+
 T cells were recovered from the peripheral blood of animals treated with saline 
compared to that of any of the other vaccination groups. This suggests that at day 2, the T cells in 
the vaccinated groups receiving antigen are not in the peripheral blood, but more likely in the 
lymph node. By day 10, the OT-I T cells in the peripheral blood from all the animals studied 
(independent of immunization) contracted to near baseline levels (Figure 6.3B). It is well known 
that the majority of effector T cells succumb to apoptosis when antigen levels fall (31). This 
observation is interesting in that even though the nanoparticles prolonged the release of antigen, 
the kinetics of the T cell response were not changed relative to that induced by administering 
soluble protein.  
At peak expansion of an acute response, CD8
+
 T cells have a functional profile that 
includes production of large amounts of IFN-γ and TNF-α and low amounts of IL-2 (32). The 
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efficacy of the T cell responses was evaluated by analyzing the production of IFN-γ and TNF-α 
six days PI (Figure 6.4). Compared to animals that received saline, the T cells from immunized 
animals (soluble or particle-based) produced significantly higher amounts of IFN-γ and TNF-α. 
In addition, the percentage of cytokines produced by the T cells of animals receiving the 
different immunization regimens was similar suggesting that the T cells were similarly activated 
in all the animals. However, given that the carbohydrate-functionalized particles induced less 
expansion of T cells than that induced by the non-functionalized particles or soluble protein, the 
total number of T cells expressing these cytokines was reduced. This ultimately suggests that the 
CTL response generated in animals receiving these particles would be less efficacious than that 
induced in animals receiving the non-functionalized nanoparticles.  
Most studies that have targeted CLRs use monoclonal antibodies directly conjugated to 
antigen, while others use carbohydrate-functionalized antigen (2; 33-36). In this work, 
carbohydrate-functionalized polyanhydride nanoparticles were administered to animals to 
analyze the adaptive immune response. Many trends observed in vivo by other investigators also 
translate to the carbohydrate-functionalized polyanhydride nanoparticles. For example, it has 
been observed that targeting antigen to DC receptors without maturation stimuli can result in 
tolerogenic or weaker CTL responses (36; 37). Successful targeting strategies for inducing CTLs 
combine targeting CLRs with other adjuvants, such as Poly(I:C) or anti-CD40 (38; 39). It is 
possible that using one of these adjuvants together with DC targeting would result in a 
synergistic T cell response. 
In this regard, there are many examples in the literature of CLRs working synergistically 
with other adjuvants and TLR ligands to modulate the immune response. In one approach, 
dectin-1 stimulation by β-glucans with simultaneous administration of TLR2 or TLR4 agonists 
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increased the secretion of pro-inflammatory cytokines from primary monocytes and 
macrophages compared to the cytokine secretion when the ligands were administered 
individually (40). The importance of this synergy is further revealed by stimulating human DCs 
using nanoparticles co-encapsulating both TLR ligands and antigen and then coating those 
nanoparticles with DC-SIGN-specific antibodies. It was observed that co-encapsulation led to 
increased DC maturation and 100-fold enhancement of CTL responses compared to that induced 
by administering soluble TLR ligands alone (41). Given the diverse repertoire of PAMPs on 
pathogens, it is likely that an infection will stimulate multiple PRRs, making crosstalk and co-
signaling essential to combating infection. It may be important to replicate this effect by using 
combination adjuvants in order to induce appropriate immune responses. 
The ability of the nanovaccines to induce memory recall responses was tested by 
challenging the mice with Ova-expressing tumor cells 4 weeks PI (Figure 6.5). CD8
+
 T cell 
activation was investigated 4 days post challenge. The CD8
+
 T cells of animals treated with both 
the non-functionalized nanoparticles and soluble protein secreted significant amounts of IFN-γ 
and TNF-α, indicating the importance of a strong primary CD8+ T response to induce an 
efficacious memory recall response. In contrast, the weak primary CD8
+
 T cell responses in the 
animals immunized with the functionalized nanoparticles translated into no recall response.  
The strength and type of the adaptive immune response generated uses cues from the 
innate immune response (42). APCs provide three essential signals to stimulate T cells, the first 
of which is presentation of the antigenic epitope on major histocompatibility complex (MHC) 
proteins (43). Signal 2 is the co-stimulatory molecules such CD80/86 or CD40 recognized by 
CD28 or CD40L on the T cells, respectively. Signal 3 is provided by secreted cytokines 
generated by the APC. The T cell requires all three of these signals to become fully activated or 
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it may undergo apoptosis or become altered so that it cannot become activated (43). This is why 
live pathogens, such as viruses, are the most efficient primers of CTL responses. They have 
complex patterns that trigger several PRRs which induces cellular activation while 
simultaneously presenting antigen by stimulating all three of these signals (2).  
Some studies have shown that the addition of IL-12 or Type I interferons enhance the 
proliferation and survival of activated T cells (44; 45). This has furthered the concept that signal 
3, which is related to cytokine secretion, is very important for generating potent CD8
+
 T cell 
responses (46). Past in vitro investigations have shown that the carbohydrate-functionalized 
particles induced increased cytokine secretion that drove acute-phase responses, such as TNF-α, 
IL-1β, and IL-6, but they did not induce significantly different IL-12 production compared with 
non-functionalized nanoparticles (7). This could potentially explain why the carbohydrate-
functionalized particles generated a limited CD8
+
 T cell response.  
Targeting antigen to CLRs on the surface of DCs is also intended to enhance CD4
+
 T cell 
responses and antibody-mediated responses. There is some discrepancy in the literature on 
whether targeting techniques require adjuvants to boost antibody titers (36). In targeting DEC-
205, Dectin-1, the MMR, or CLEC9A, very weak antibody responses were observed without the 
use of an adjuvant (47; 48). Upon use of Ova targeted to CLEC9A
+
 APCs, CD4
+
 T cells 
differentiated into FOXP3
+
 regulatory T cells without an adjuvant (47). Co-administration of an 
adjuvant altered the CD4
+
 response to a Th1 profile with Poly(I:C) or to a Th17 profile with 
curdlan. Other studies observed avid antibody titers by targeting CLRs without an adjuvant and 
the general consensus remains that strong antibody titers can be generated without an adjuvant 
(49). In this study, the animals receiving nanovaccines showed robust antibody titers relative to 
animals receiving soluble protein (Figure 6.6A). At each time point, the animals immunized with 
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the carbohydrate-functionalized nanoparticles induced similar levels of antibody titers compared 
to that induced in animals immunized with non-functionalized nanoparticles. The surface-
eroding polyanhydride nanoparticles provide a sustained release of antigen, ultimately enabling 
antigen persistence, which has been shown to be important for inducing long-lived plasma cells 
and B cells (10; 50). By creating an antigenic depot, all three types of nanoparticles induced the 
formation of particulate antigen, which is more easily recognized by B cells (9). Additionally, 
the antibody titer data reinforce the CD8
+
 T cell data. The predominant IgG subtype within the 
antibody production in animals receiving any type of vaccination in this study was observed to 
be IgG1 (Figure 6.6B and 6.6C). However, animals vaccinated with non-functionalized particles, 
soluble protein, and di-mannose-functionalized particles induced measurable amounts of IgG2c 
as well. The animals vaccinated with the linker-functionalized particles had the least IgG2c 
production, and correspondingly the least CD8
+
 T cell expansion. Both the T cell data and the 
antibody class switching observations suggest that carbohydrate functionalization did not 
polarize the T cell response to generate Th1 effector cells. 
Figure 6.2 shows that the surface charge of the functionalized particles changes with time 
upon exposure to buffer. These results suggest that when the particles erode, they shed both 
ethylenediamine as well as the attached carbohydrate. As a result, labile surface modification 
may not provide a persistent “danger signal” that is needed to trigger PRRs, induce DC 
maturation, and activate T cells. The data in Figure 6.2 indicate that the particles are losing the 
targeting ligand within one day. It is known that DC maturation occurs in the first 24 hours, but 
in contrast, T cell activation requires multiple days (51). These data may also explain why the 
antibody responses were similar in the animals receiving the non-functionalized and 
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functionalized particles. B cell activation occurs in germinal centers, which begin to develop 
about 7-10 days after exposure to antigen (52).  
Unexpectedly, the carbohydrate-functionalized nanoparticles did not upregulate the 
adaptive immune response. In vitro data from previous studies showed that the functionalized 
nanoparticles were internalized effectively by MØ and DCs (6-8). Additionally these cells 
showed signatures of enhanced activation upon incubation with carbohydrate functionalized 
nanoparticles (5). The discrepancy between the in vitro results from previous studies and the in 
vivo results from the current study can be attributed to several factors. As alluded to earlier, the 
sugar could erode from the surface of the nanoparticles before the DCs interact with the 
functionalized surface. Alternatively, the type of response from a cell can depend on the avidity 
with which the ligand binds to a receptor (53; 54). The in vivo environment behaves more like an 
infinite sink compared to wells in tissue culture plates (55). As a result, DCs in vivo may have 
reduced opportunities to interact with nanoparticles and their carbohydrate surfaces as they 
otherwise would in vitro. Many other cells express CLRs and scavenger receptors including 
those of the mononuclear phagocytic system (56; 57). This system is comprised of highly 
phagocytic macrophages whose job is to maintain homeostasis in tissues (57). As a result 
functionalized nanoparticles could be getting taken up by this system which means the antigen 
encapsulated within the nanoparticles may be degraded and not be presented to T cells. Say 
something about the MMR receptor and the need to present multiple signals here, as discussed at 
the vaccine meeting. Nonetheless, these studies generated important insights with respect to the 
in vivo immune response to carbohydrate functionalized nanoparticles. It is possible that 
inducing a more persistent danger signal, perhaps by conjugating polyanhydrides with 
carbohydrates prior to nanoparticle synthesis, will help enhance T cell activation in vivo.  
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6.6 Conclusions 
This study investigated the capabilities of carbohydrate-functionalized polyanhydride 
nanoparticles to induce adaptive immune responses in mice using adoptive transfer of antigen-
specific T cells. Animals receiving non-functionalized nanoparticles and soluble protein 
formulations had more OT-I CD8
+
 T cell expansion compared to animals that received 
carbohydrate-functionalized nanoparticles. Additionally, mice receiving these particles showed a 
reduced ability to produce pro-inflammatory cytokines and had a weak memory recall response 
upon challenge with antigen-specific tumor cells. Nonetheless animals immunized with all the 
particle formulations, regardless of functionalization, showed robust antibody responses 
compared to animals that received soluble protein. It is hypothesized that the carbohydrate 
modification may not provide a persistent danger signal that is needed to trigger PRRs, induce 
DC maturation, and activate T cells. It is possible that co-stimulation with another adjuvant or 
TLR ligand could provide the maturation signals to synergize with the targeting of CLRs to 
induce robust T cell immunity.   
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6.9 Figures 
 
Figure 6.1 Schematic of polyanhydride chemistry, surface functionalization, and in vivo 
procedure. A) Structure of monomer diacids 1,6-bis(p-carboxyphenoxy)hexane (left) and 1,8-
bis(p-carboxyphenoxy)-3,6-dioxaoctane (right). B) The nanoparticle surface was functionalized 
with a glycolic acid cap (middle) or with di-mannose (right) using an ethylenediamine linker.  
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Figure 6.2 Zeta potential kinetics of non-functionalized and linker-functionalized nanoparticles. 
The ethylenediamine linker results in positively charged nanoparticles. After 4 h of incubation in 
PBS at 37°C, the zeta potential of the particles becomes negative and by 24 h the zeta potential 
of the particles reach a plateau. In contrast, the zeta potential of the non-functionalized 
nanoparticles does not change with time. 
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Figure 6.3 Expansion and contraction of CD8
+
 OT-I T cells. A) Representative flow cytometry 
gating strategy. Lymphocytes were gated first and then the transferred T cell population was 
identified by gating for Thy1.2 and CD8b. * indicates significance from the saline population (p 
< 0.05). B) Peripheral bleeds revealed that OT-I T cells for each treatment group expanded from 
day 2 to day 6 and contracted from day 6 to day 10 with soluble and non-functionalized particle 
treatment groups inducing the most T cell proliferation. 
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Figure 6.4 Intracellular cytokine production by CD8
+ 
OT-I T cells at day 6. Intracellular 
cytokine staining was performed on OT-I T cells at their peak populations, which was day 6. A) 
OT-I T cells from immunized groups strongly expressed IFN-γ. All treatment groups were 
significant from the saline populations with the most cytokine production being induced in the 
animal receiving the soluble antigen and the non-functionalized particle formulations. B) OT-I T 
cells from immunized groups readily produced TNF-α in addition to IFN-γ. C) Representative 
flow cytometry contour plots for each treatment group. * indicates significance from the saline 
population (p < 0.05). 
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Figure 6.5 Memory recall response of CD8
+ 
OT-I T cells 4 days after tumor challenge. Four 
weeks post immunization, mice were challenged with Ova-expressing tumor cells. Peripheral 
bleeds four days after challenge were performed to see which formulations induced T cell 
memory. A) The number of OT-I cells in each peripheral bleed for each treatment group was 
similar. B) & C) Mice from both soluble and non-functionalized groups produced significantly 
more IFN-γ and TNF-α compared to that produced by the saline-treated mice. * indicates 
significance from the saline population (p < 0.05). 
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Figure 6.6 Antibody response at select time points following immunization and adoptive transfer 
of OT-II T cells. Mice that received OT-II T cells that were then immunized with one of the 
treatment groups were bled at days 14, 28, and 42 to analyze antibody titers. At each time point, 
immunized mice produced significantly more total IgG than saline mice. The particle 
formulations also outperformed the soluble protein. B) and C) Little class switching was induced 
with the day 42 titers as most of the antibody produced was IgG1. Animals receiving the soluble, 
non-functionalized, and di-mannose-functionalized nanoparticle immunization produced 
significantly more IgG2c compared to that of animals receiving saline. * indicates significance 
from the saline population (p < 0.05). # indicates significance from the soluble population (p < 
0.05). 
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6.10 Tables 
Table 6.1 Nanoparticle size and characterization.   
Group 
Average 
Diameter  
(nm) 
Surface composition by EDS Sugar 
Density 
 (μg/mg) 
Average % 
C 
Average % 
N 
Average % 
O 
Non-functionalized 177 ± 39 79.5 ± 2.9 0.04 ± 0.1 20.5 ± 2.8   
Linker 186 ± 33 73.7 ± 2.7 5.54 ± 1.5 20.8 ± 1.5   
Di-mannose 179 ± 44 71.6 ± 2.5 7.00 ± 1.7 21.4 ± 1.1 13.4 ± 2.59 
 
Nanoparticles were sized with ImageJ of SEM files using 200 particles to record the average 
diameter. Nanoparticle functionalization was characterized by EDS and a phenol-sulfuric acid 
assay. EDS was used to identify an increase in nitrogen content to confirm surface attachment of 
the sugar and ethylenediamine. This is presented as the mean ± SD through seven independent 
readings. Mean ± SD of the sugar density was determined by a phenol-sulfuric acid assay 
measured in triplicate. 
197 
 
 
 
CHAPTER 7: HIGH THROUGHPUT AUTOMATED SYNTHESIS OF 
PROTEIN-LOADED POLYANHYDRIDE NANOPARTICLE LIBRARIES 
 
Jonathan T. Goodman
1
, Lucas Dunshee
1
, Akash Mitra
1
, and Balaji Narasimhan
1 
To be Submitted to ACS Combinatorial Sciences December, 2015 
  
                                                     
1
 Department of Chemical & Biological Engineering, Iowa State University, Ames, Iowa 50011 
198 
 
 
 
7.1 Abstract 
A valuable resource in rapidly synthesizing and screening nanoscale biomaterial-based 
carriers for drug and vaccine delivery involves the development of high throughput techniques to 
make combinatorial libraries. This study describes the development of an automated high 
throughput robot for synthesizing polyanhydride nanoparticles encapsulating protein antigens. 
Polyanhydrides are a class of safe and biodegradable polymers that have been widely used as 
drug and vaccine delivery vehicles. The robot contains a multiplexed homogenizer and has the 
capacity to handle parallel streams of monomer or polymer solutions to synthesize both polymers 
and/or nanoparticles. Copolymer libraries were synthesized using the momomers, sebacic acid 
(SA), 1,6-bis(p-carboxyphenoxy)hexane (CPH), and 1,8-bis(p-carboxyphenoxy)-3,6-dioxactane 
(CPTEG). Nanoparticle libraries of varying copolymer compositions encapsulating the model 
antigen, ovalbumin, were synthesized using flash nanoprecipitation. Concentrations of the 
surfactant, Span 80, were varied to test its effect on protein encapsulation efficiency as well as 
protein release kinetics. It was observed that the surfactant did not significantly affect protein 
release rate, but its presence enhanced protein encapsulation efficiency. Particles synthesized 
with the high throughput method were compared to particles made with conventional anti-
solvent nanoprecipitation in order to validate the high throughput approach. Protein burst and 
release kinetics between the two methods were similar, even though particles synthesized using 
the high throughput technique were observed to be smaller. Finally, it was demonstrated that the 
high throughput method could be adapted to functionalize the surface of the particles to aid in the 
design of targeted drug and vaccine delivery systems. These results suggest that the newly 
developed automated high throughput system is a viable alternative to conventional methods for 
studying and screening vaccine and drug delivery vehicles. 
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7.2 Introduction 
The concept of combinatorial libraries and high throughput screening gained widespread 
support in the 1980s when the pharmaceutical industry successfully pioneered these techniques 
to synthesize and screen small molecules that would fill their drug pipelines (1). High throughput 
technologies are needed because of limitations in our ability to make accurate predictions about 
the activity and efficacy of drugs or drug delivery vehicles. They allow for a greater number of 
compounds to be screened enabling the empirical selection of a drug or drug delivery vehicle 
with the most favorable properties. Combinatorial libraries are advantageous relative to 
conventional methods because they have the potential to integrate multiple components 
including the synthesis and the screening process together reducing the overall workload (2; 3). 
The key challenge remains in the actual design step to ensure that high throughput mechanisms 
and automation equipment most efficiently screen and select drugs or drug delivery vehicles for 
their optimal properties. 
Combinatorial methods have been used to optimize biomaterials design and drug delivery 
vehicles for many complex biomedical end-use applications, including targeting cancer, 
optimizing gene delivery, penetrating the blood brain barrier (BBB), and modulating the immune 
response (2-5). In particular, techniques that automate and accelerate the synthesis of libraries of 
polymeric nanoparticles and microparticles for use as drug delivery vehicles are of great interest. 
This is because there are many complex interactions between the drug, the delivery vehicle, and 
the cells or tissue interacting with the delivery vehicle (6; 7). High throughput technologies have 
the ability to rapidly screen these interactions to identify and select those that are favorable. 
Previous work from our laboratories and other research groups has utilized these technologies to 
study the effect of polymer composition and polymer geometry on protein release (7-13). The 
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activation of macrophages and the biocompatibility of cells with polyanhydride libraries were 
successfully evaluated (14). These studies demonstrated that polyanhydride formulations have 
excellent properties as drug delivery vehicles owing to their ability to stabilize proteins, to 
provide sustained release of a protein or drug (driven by the surface erosion mechanism of 
polyanhydrides), and to target specific cells (15-18). Additionally, polyanhydride chemistry is 
highly tunable (i.e., by varying copolymer composition), which allows the rate of drug release to 
be modulated. Finally, polyanhydride nanoparticle libraries efficiently activated macrophages 
without inducing any toxicity (14; 19; 20). 
This work builds upon the previous studies via the design of a new and automated high 
throughput system for synthesizing and characterizing both polymer libraries as well as protein-
loaded nanoparticle libraries. The high throughput robot described herein efficiently synthesized 
polymer libraries, synthesized and functionalized nanoparticle libraries, and enabled rapid 
analysis of protein release kinetics from these libraries. The robot was also used to study the 
effect of several other parameters on nanoparticle size and protein release, including sonication 
conditions, use of surfactants, etc. All the high throughout data was validated using conventional 
syntheses and protein release studies. 
7.2 Materials and Methods 
7.2.1 Materials 
Sebacic acid monomer was purchased from Sigma Aldrich (St. Louis, MO). 4-p-
hydroxybenzoic acid, 1-methyl-2-pyrrolidinone, 1,6-dibromohexane, and triethylene glycol were 
also purchased from Sigma Aldrich and they were used for CPTEG and CPH monomer 
synthesis. Monomer and polymer synthesis utilized dimethyl formamide, sulfuric acid, 
acetonitrile, toluene, potassium carbonate, and acetic anhydride, all of which were obtained from 
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Fisher Scientific (Fairlawn, NJ). Apollo Scientific (Cheshire, UK) was the source for 4-p-
fluorobenzonitrile used in monomer synthesis. Nanoparticle synthesis required pentane and 
methylene chloride from Fisher Scientific as well as the surfactant Span 80 from Sigma Aldrich. 
Deuterated chloroform from Cambridge Isotope Laboratories (Andover, MA) was purchased for 
1
H NMR analysis. Ovalbumin (Ova) was purchased from Sigma-Aldrich passed through a 
Thermo Scientific Detoxi-Gel Endotoxin removing column before use to ensure that the 
endotoxin was removed. 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N-
hydroxysuccinimide (NHS) from Fisher Scientific, ethylenediamine from Sigma Aldrich, and 
glycolic acid from Acros Organics (Geel, Belgium) were used for nanoparticle functionalization. 
7.2.2 Automated high throughput robot 
In these studies, a custom built robot called the Nanoprep 24 (OMNI International, 
Kennesaw, GA) was used that allows for automated and facile preparation of polymers and 
nanoparticle libraries (Figure 7.1). The robot has three syringe pumps, permitting individual 
stock solutions of monomers or polymers to be pumped without contaminating each other 
(Figure 7.1C). Two of the syringe pumps lead to stationary dispensing nozzles, and the third 
syringe pump is connected to a stainless steel pipette nozzle to either handle liquid dispensing or 
for programmed liquid transfers. The robot is equipped with a 20 kHz ultrasonic probe that can 
range in amplitude from 0-100%. There are 24 sampling locations in each of its two racks. The 
first rack is able to hold glass test tubes up to 15 mm in diameter and 10 mL in volume (Figure 
7.1D). It is removable and is capable of withstanding the higher temperatures typically used in 
polymer synthesis (Figure 7.1E). The second rack is fitted to hold 50 mL conical polypropylene 
tubes. It is also removable and is designed to be placed in a -80°C freezer. It can accommodate a 
dry ice payload to maintain cool temperatures during nanoparticle synthesis. Finally, there is a 
waste and rinse rack, where the robot can dispose of supernatants and rinse itself to prevent 
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contamination with other samples in the rack. The robot is connected to a computer through a 
USB port which serves as the main user interface. Spreadsheets allow for inputting process 
variables, such as liquid volumes, into each sample rack or sonication duration and amplitude of 
each sample. 
7.2.3 Polymer library synthesis 
1,6-bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-carboxyphenoxy)-3,6-
dioxaoctane (CPTEG) diacids were synthesized as described previously (16; 21-23). In 
conventional synthesis protocols, these diacids were added to a round bottom flask at appropriate 
molar ratios of CPTEG and CPH. Excess acetic anhydride was added and the flask was 
submerged in an oil bath at 125°C for 30 min to acetylate the monomers. The acetic anhydride 
was removed by rotary evaporation and the round bottom flask was re-submerged into an oil 
bath at 140°C to begin polymerization. A vacuum (<0.3 torr) was applied for five hours to carry 
out the polymerization. At the end of polymerization, the round bottom flask was brought to 
standard temperature and pressure, and methylene chloride was added to dissolve the polymer. 
The polymer was precipitated by adding the methylene chloride solution dropwise to excess 
hexane. This hexane solution was kept chilled by a dry ice bath. The polymer was allowed to 
settle to the bottom of the hexane solution allowing the hexane to be poured off. The remaining 
polymer was dried under vacuum. The CPH and SA monomers were acetylated separately as 
described previously (23; 24). Conventional synthesis of CPH:SA copolymers was nearly 
identical to that of CPTEG:CPH copolymer synthesis except the oil bath was at 180°C and the 
reaction proceeded for 30 min. Precipitation was carried out at room temperature in hexane.  
High-throughput synthesis of CPTEG:CPH and CPH:SA libraries was carried out 
simultaneously by creating 15 mg/mL stock solutions of CPH diacid, CPTEG diacid, and SA 
diacid in acetic anhydride. The diacids were acetylated by incubating in a 125°C mineral oil bath 
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for 30 min. Each solution was connected to its own 1/8” diameter tubing on the robot and the 
robot was programmed to individually add specific amounts of acetylated monomer to 10 mL 
glass test tubes (VWR International, Radnor, PA). The test tubes were removed from the robot 
and placed in a 180°C vacuum for 3 h for CPH:SA copolymers and 5 h for CPTEG:CPH 
copolymers. The acetic anhydride gradually evaporated into a chilled bump trap and the 
acetylated monomers were allowed to copolymerize.  
Polymer structure, molecular weight, and purity were verified using 
1
H NMR 
spectroscopy on a Varian VXR 300 MHz spectrometer. Differential scanning calorimetry (DSC, 
Q2000, TA Instruments, New Castle, DE) was used to determine thermal properties (i.e., glass 
transition temperature and melting point).   
7.2.4 Nanoparticle library synthesis 
Conventional synthesis of protein-loaded nanoparticles was carried out as described 
previously (19). Briefly, polymer and 1% (w/w) Ova were weighed into a scintillation vial and 
dissolved in methylene chloride at a concentration of 25 mg/mL. A surfactant, Span 80, was 
added to the polymer solution in varying amounts depending on the copolymer chemistry. The 
polymer solution was then sonicated at 40% amplitude for 30 s and precipitated into a non-
solvent, pentane, at an anti-solvent:solvent ratio of 80:1. The synthesis of CPH:SA nanoparticles 
was carried out at room temperature, while that of CPTEG:CPH nanoparticles was carried out in 
a 4°C cold room with a pentane bath chilled to -20°C. Nanoparticles were collected through 
vacuum filtration.  
For high throughput nanoparticle library synthesis, methylene chloride containing 1% 
(w/w) Ova and the correct amount of Span 80 was added via one of the syringe pumps to each 
polymer containing test tube. The robot sonicated each test tube at 40% amplitude for 30 s to 
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facilitate polymer dissolution and disperse the protein. The polymer solution in each test tube 
was then transferred to its corresponding 50 mL conical tube filled with 45 mL of pentane using 
the stainless steel pipette nozzle. The polymer concentration in the methylene chloride solution 
was 25 mg/mL and the nanoprecipitation maintained a solvent: anti-solvent ratio of 1:80. Since 
the formation of CPTEG:CPH nanoparticles required low temperatures, the pentane was 
previously chilled in the -80°C freezer. In addition, dry ice and liquid nitrogen were added to the 
holding rack to help keep the polymer at -20°C during nanoparticle synthesis. Conical tubes of 
identical treatment groups were combined and particles were collected by vacuum filtration to 
acquire enough particles for release studies. The nanoparticles were characterized by scanning 
electron microscopy (SEM, FEI Quanta 250, Hillsboro, OR) and an average size distribution was 
generated using ImageJ image analysis software from the National Institutes of Health 
(Bethesda, MD) with 200 nanoparticles per image. 
7.2.5 Nanoparticle library functionalization 
The particles were functionalized with a modified lactose, a modified galactose, or 
glycolic acid using an ethylenediamine linker. The modified sugars contained a carboxylic acid 
group to link the sugar to the ethylenediamine through an amide bond (25). Mercury(II)-
catalyzed allylation of penta-O-acetyl-lactosyl bromide was used to prepare β-1-O-allylated 
lactose (26; 27). This was oxidized with excess NaIO4 in the presence of RuCl3 to generate the 
acid (28). Deprotection of the acetyl protecting groups occurred with K2CO3 to yield the final 
product. Similarly, β-1-O-allylated galactose was derived from β-penta-O-acetylated galactose in 
the presence of allyl alcohol and BF3OEt2 (18; 26). The carboxylic acid was generated from 
oxidation of the allyl handle with NaIO4 and RuCl3 and the acetyl deprotecting groups were 
removed using K2CO3. 
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The robot was used to perform surface functionalization of the nanoparticle libraries. For 
these studies, 10 mg of nanoparticles were added to 1.5 mL centrifuge tubes and loaded into the 
test tube holder of the robot. A 45 mg/mL stock solution of EDC and a 62 mg/mL stock solution 
of NHS was prepared and connected to the robot. Functionalization was carried out using a two-
step reaction. The first reaction involved pumping 10 mole equivalents of EDC and 12 mole 
equivalents of NHS into each test tube of the nanoparticle library. The robot sonicated each 
suspension for 30 s at 30% amplitude. As the robot progressed through the sonication step, 10 
mole equivalents of ethylenediamine were added manually. The library was then removed and 
placed on a tube rotor at 4°C for 1 h. Centrifugation for 10 min at 10,000 g pelleted the 
nanoparticles and the test tubes were placed back on the robot to extract the supernatant. The 
robot then added fresh nanopure water to wash the particles and sonicated the suspension for 30 s 
at 30% amplitude. The nanoparticle library was centrifuged for another 10 min at 10,000 g.  The 
robot performed the second step of the reaction by extracting the supernatant followed by adding 
10 mole equivalents of EDC and 12 mole equivalents of NHS into each test tube of the library. 
Sonication for 30 s at 30% amplitude then continued, followed by manual addition of 10 
equivalents of the sugar. The library was then removed from the robot and placed on the tube 
rotor for 1 h at 4°C. The nanoparticles were washed using the robot as previously described 
before being placed in a vacuum oven to dry for an additional one hour. 
7.2.6 Characterization of functionalized nanoparticle libraries 
A phenol-sulfuric acid assay was performed to quantify the sugar density on the surface 
of the nanoparticle library using flat bottom 96-well plates (29; 30). The assay proceeded for 30 
min at 95 °C at which time the reaction induced a color change in the solution. The absorbance 
of each well was measured at a wavelength of 490 nm using a SpectraMax M3 
spectrophotometer (Molecular Devices, Sunnyvale, CA). This was compared against soluble 
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galactose and lactose standards, while non-functionalized nanoparticles were used as a negative 
control. Energy dispersive X-ray spectroscopy (EDS) was performed to assay for nitrogen 
content from the ethylenediamine. 
To track the zeta potential of the functionalized particles as a function of time, five mg of 
the functionalized nanoparticles and 1 mL of PBS were placed in a 1.5 mL centrifuge tube, 
sonicated, and incubated at 37°C in a 100 rpm rotator. 40 μL of particle suspension was removed 
at each time point and diluted in 960 μL of cold nanopure water for a final concentration of 200 
μg/mL. The zeta potential was then measured using a ZetaSizer Nano (Malvern, Worchester, 
UK).  
7.2.7 Protein release kinetics 
Eight mg of Ova-loaded nanoparticles were placed in 1.5 mL microcentrifuge tubes and 
suspended in 1 mL of 0.1 M PBS solution (pH = 7.4). Sonication was used to disperse the 
particles in the solution, after which the particles were placed in a 37°C incubator agitating at 
100 rpm. At selected time points the nanoparticles were pelleted by centrifugation and the 
supernatants were extracted for protein quantification using a microBCA assay (ThermoFisher). 
Fresh PBS was added to replace the removed supernatant maintaining a perfect sink. The Ova 
release kinetics are presented as a cumulative mass fraction as a function of time, which was 
determined by normalizing protein release for each time point with the total protein 
encapsulated, which was determined using a base extraction as described previously (31). 
7.3 Results & Discussion 
7.3.1 Polymer and nanoparticle characterization 
This work described the design and validation of a novel high throughput automated 
robot for efficient synthesis of libraries of polymers and protein-loaded nanoparticles for rapid 
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screening for properties that optimize their use as drug delivery vehicles. The robot enabled 
synthesis of polymer libraries whose properties were consistent with that of conventionally 
synthesized polymers, but with much more ease and with significant time savings. For example, 
in conventional synthesis, the reacted polymer is dissolved in methylene chloride so that it can be 
removed from the round bottom flask and is precipitated in hexanes. The polymer is filtered, 
dried and stored until it is used for nanoparticle synthesis. In the high throughput method, the 
number of steps required to convert monomer or prepolymer to nanoparticles are drastically 
reduced and produce significant time savings. Herein, the monomer or prepolymer and its 
solvent are pumped directly to its corresponding test tube. This test tube is then baked under 
vacuum where the solvent evaporates away into a chilled dewar collection flask to enable 
polymerization to proceed. This test tube is then stored until it is used for nanoparticle synthesis 
avoiding the need for a precipitation step in hexanes. Moreover, the high throughput protocol 
does not utilize the rotary evaporator during conventional synthesis resulting in further time 
savings. It is estimated that synthesizing a single CPTEG:CPH copolymer using conventional 
procedures requires approximately 2-3 h of laboratory time with an additional 18-20 h required 
for the monomers to polymerize, for the copolymer to dissolve in methylene chloride, and for the 
precipitated copolymer to dry. In contrast, the high throughput robot can synthesize an entire 
library of copolymers ranging in composition within 1-2 h of laboratory time and an additional 5 
h for the monomers to polymerize with no time spent on precipitating the polymer. As a result, 
the high throughput synthesis process is more efficient relative to the conventional procedure as 
more copolymers compositions are synthesized simultaneously.   
Representative copolymers were synthesized with the high throughput method and were 
characterized using 
1
H NMR and DSC (Table 7.1). It was observed that Tg gradually increased 
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as the CPH content within the CPTEG:CPH copolymer increased. No defined melting point was 
observed for any of these copolymers, in agreement with previous studies that showed that these 
copolymers were amorphous (21). Additionally, increasing the CPH composition generally 
increased the molecular weight of the CPTEG:CPH copolymers. This suggests that the CPH 
monomer is more reactive than the CPTEG monomer. The semi-crystalline CPH:SA copolymers 
showed well-defined Tg’s and Tm’s. Both the Tg and Tm increased as the SA content increased 
within the copolymer.  
In order to validate the high throughput method, nanoparticles were synthesized using 
both methods for only the 20:80 CPH:SA and 20:80 CPTEG:CPH copolymers. Different 
amounts of the surfactant, Span80, were incorporated into the synthesis procedures in order to 
investigate the effect of a surfactant on nanoparticle morphology. Both methods utilized a 
solid/oil/oil double emulsion technique to synthesize the nanoparticles. In both synthesis 
methods, as the amount of Span 80 was increased from 0% to 1%, the 20:80 CPH:SA 
nanoparticles became smaller and more monodisperse (Table 7.2, Figure 7.2). In contrast, the 
average diameter of the 20:80 CPTEG:CPH nanoparticles did not significantly change with the 
amount of Span 80 used. This is because increasing the amount of surfactant tended to induce 
aggregation in these nanoparticles. The CPH:SA polymers generally have much higher Tg’s (21; 
32), resulting in precipitated nanoparticles that are not aggregated allowing it to withstand higher 
concentrations of surfactant. The 20:80 CPTEG:CPH nanoparticles synthesized using both 
methods had comparable sizes. However, the 20:80 CPH:SA nanoparticles synthesized by 
conventional methods were slightly larger than equivalent nanoparticles synthesized by the high 
throughput method (Table 7.2). The high-throughput 20:80 CPH:SA nanoparticles were smaller 
than the conventional nanoparticles, because the nozzle on the robot helps reduce solvent droplet 
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size preventing polymer from aggregating as it is exposed to the anti-solvent. However, particle 
size can be controlled by adjusting the nozzle velocity as shown by Figure 7.4. 
Additionally, when using the high throughput method to synthesize the nanoparticles, it 
was observed that the nanoparticle size was affected by the transfer rate of the polymer solution 
to the anti-solvent during nanoprecipitation. As the transfer rate was increased, the nanoparticles 
became smaller. Operating the pump at its maximum nozzle velocity of 1200 μL/s resulted in 
nanoparticles that were on average 80 nm smaller than nanoparticles synthesized by much lower 
pump speeds (Figure 7.3). These observations indicate that the pump rate can be easily varied in 
the high throughput synthesis method, providing another tunable parameter to optimize 
nanoparticle size.  
7.3.2 Protein release from polyanhydride nanoparticles 
The release kinetics of protein antigen from a delivery vehicle can greatly influence the 
immune response (33-36).  In these studies, 1% (w/w) Ova was encapsulated into 20:80 
CPTEG:CPH and 20:80 CPH:SA nanoparticles and the encapsulation efficiency and release 
kinetics were investigated as a function of surfactant concentration. Nanoparticles of the same 
compositions were compared to those synthesized using conventional methods in order to 
validate the high throughput process. Consistent with previous studies, polymer chemistry 
dictated the protein release rate from the nanoparticle library (37; 38). The hydrophobic 20:80 
CPTEG:CPH nanoparticles displayed the slowest protein release rate, taking over 80 days to 
completely release the protein (ascertained by not detecting any protein in the supernatant using 
the microBCA assay). At early time points, the 20:80 CPTEG:CPH nanoparticles also had the 
smallest protein burst with only about 20-25% of the protein being released initially. These 
observations were consistent when using particles synthesized by both conventional and high 
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throughput methods. In contrast, the less hydrophobic 20:80 CPH:SA nanoparticles had 
significantly faster release rates and >90% of the encapsulated protein was released in the first 
several days from the particles synthesized by both methods. This formulation also had the 
largest protein burst as 70-80% of the protein was released in the first few time points. With its 
backbone consisting of aromatic rings and hexane, CPH is more hydrophobic relative to SA or 
CPTEG. As a result polymer chemistries rich in CPH are more hydrophobic and have the slowest 
protein release rates (15). Polymer chemistry also significantly affected protein encapsulation 
efficiency (Table 7.3). Regardless of surfactant incorporation, the 20:80 CPTEG:CPH 
nanoparticles consistently had higher encapsulation efficiencies when compared to that of the 
20:80 CPH:SA nanoparticles. This is likely due to the presence of the less hydrophobic CPTEG 
monomer, which contains hydrophilic ethylene glycol moieties, and has been shown to stabilize 
proteins  in previous studies (16).  
Incorporating the surfactant into the nanoparticles had a weak effect on protein release. 
The protein burst was slightly increased when 0.2% Span 80 was used to synthesize 20:80 
CPTEG:CPH nanoparticles, but the slope of the release rate was nearly identical compared to 
20:80 CPTEG:CPH nanoparticles synthesized in the absence of any surfactant (Figure 7.4). The 
protein burst and the protein release rate was nearly unchanged when incorporating 0.2% Span 
80 or 1% Span 80 into 20:80 CPH:SA nanoparticles. Incorporating surfactant into the 
nanoparticles did affect the protein encapsulation efficiency. As expected, adding surfactant 
increased the amount of protein encapsulated within the nanoparticles for both polymer 
chemistries (Table 7.3). This is because the surfactant enhances the stability of the insoluble 
protein as it is dispersed in the methylene chloride oil phase just prior to nanoprecipitation. Span 
based surfactants have been extensively used for stabilization of emulsions (39). Surfactant 
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function is quantified by its hydrophilic-lipophilic balance (HLB) value. Generally, surfactants 
with an HLB <10 tend to be soluble in oil phases, and an HLB between 3-6 is optimal for oil 
emulsifying agents (40). With an HLB of 4.3, Span 80 has been shown to serve as a useful 
emulsifying agent in oil emulsions (41).  
The protein release rate and initial protein burst were comparable for both the high 
throughput and conventional synthesis methods. This validates the high throughput method in 
that it can reproducibly synthesize protein-loaded nanoparticles that have the same release 
kinetics as the conventional method. This agreement between the two methods also indicates that 
the small decrease in nanoparticle size synthesized using the high throughput method did not 
substantially affect protein release rate. The encapsulation efficiencies for both synthesis 
techniques exhibited similar trends in that incorporating Span 80 into the nanoparticles increased 
protein encapsulation efficiency. And finally, the CPTEG-rich formulation had the greatest 
encapsulation efficiencies when using both synthesis techniques. 
7.3.3 Nanoparticle surface functionalization and characterization 
The robot was demonstrated to successfully conjugate modified sugars to the carboxylic 
acid end groups on the surface of the nanoparticle library using the same two-step reaction as in 
the conventional functionalization method. The chemical conjugation step was automated with 
the robot allowing for facile construction of surface-functionalized nanoparticle libraries to 
examine the effect of different sugars.  The surface of 20:80 CPH:SA nanoparticles synthesized 
using the robot was functionalized with different sugars using the high throughput methodology 
(Table 4.4). Nanoparticle libraries were chemically conjugated with glycolic acid (linker) and 
two different sugars (lactose and galactose) and characterized so that comparisons could be made 
to functionalized particles synthesized conventionally. The phenol-sulfuric acid assay revealed 
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that the amounts of lactose and galactose conjugated to 20:80 CPH:SA nanoparticles were 
comparable to the amounts of sugar on these particles when synthesized using conventional 
methods (18; 27; 30; 42). Energy dispersive spectroscopy (EDS) characterization also confirmed 
successful conjugation, as evidenced by the statistically significant nitrogen composition relative 
to that of the non-functionalized nanoparticles due to the ethylenediamine linker that couples the 
sugar to the nanoparticle.  
In order to characterize the duration of time that the linker stays on the particle in 
solution, glycolic acid functionalized 20:80 CPH:SA and 20:80 CPTEG:CPH nanoparticles were 
synthesized using both methods. The time evolution of their surface potentials upon incubation 
in PBS was compared (Figure 7.5). At initial time points the functionalized nanoparticles of both 
chemistries had a positive zeta potential of ~+14 mV. Incubation in aqueous media led to a 
breakdown of the linkage to the surface of the nanoparticles and the zeta potential of both 
formulations became negative after two hours. The nitrogen groups on the ethylenediamine 
linker are responsible for the positive zeta potential of the functionalized nanoparticles at initial 
time points. Once this linker has eroded, the exposed free carboxylic acids on the nanoparticles 
contribute to the negative zeta potential. This zeta potential continued to decrease for about 12 h 
before it reached its saturation value of ~-18-24 mV, which is consistent with previous 
observations as well as with the measured zeta potential of the non-functionalized particles 
indicating that all the sugar from the particles has been removed (27; 30). The zeta potential of 
the 20:80 CPH:SA nanoparticles decreased slightly faster than that of the 20:80 CPTEG:CPH 
nanoparticles in accordance with the increased hydrophobicity of the 20:80 CPTEG:CPH 
formulation, which slowed down its erosion in aqueous solutions (37). Functionalized 
nanoparticles synthesized by both conventional and high throughput methods displayed nearly 
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identical zeta potentials and the kinetics of their surface potential in aqueous solution also 
followed similar trends, validating the high throughput method to synthesize functionalized 
nanoparticles.  
7.4 Conclusion 
This work describes and validates a new automated high throughput robot as a viable tool 
to synthesize libraries of biodegradable polymers, of nanoparticles thereof, and of carbohydrate-
functionalized nanoparticles. The automated process resulted in highly reproducible syntheses 
with significant time savings for the user. The high throughput method was also used to quantify 
the effect of adding surfactants during nanoprecipitation on nanoparticle size and protein 
encapsulation efficiency. With the establishment of standardized methods and protocols, future 
work will focus on utilizing the technique to perform high throughput screening of different 
nanoparticle formulations for drug delivery and cellular interactions.  
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7.7. Figures 
 
Figure 7.1 High throughput setup. A) The robot with its three pumps (left) and its two racks for 
polymer synthesis (right rack) and nanoparticle fabrication (left rack). A sonicator, a stainless 
steel nozzle, and two fixed plastic nozzles move along a guide for filling and transferring liquid 
into individual tubes within a rack. B) User interface allowing the user to select a program to 
operate and monitor the process. C) Three syringe pumps. D) Filling the glass test tubes in rack 
1. E) The rack can be easily removed and inserted into a vacuum oven enabling polymer 
synthesis.   
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Figure 7.2 SEM images of 1% Ova loaded nanoparticles synthesized using conventional and 
high throughput methods. Scale bar is 4μm. 
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Figure 7.3 Nanoparticle size is influenced by nozzle velocity during anti-solvent 
nanoprecipitation with the high throughput robot. Slower velocities resulted in larger 
nanoparticles while larger velocities decreased nanoparticle size. Scale bar is 5μm. 
 
Figure 7.4 Cumulative mass fraction of Ova released from the nanoparticles for one month in 
PBS (pH=7.4) using the microBCA assay. Error bars represent standard deviation. Experiments 
were performed in triplicate. 
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Figure 7.5 Zeta potential of linker-functionalized nanoparticles as a function of time in PBS 
(pH=7.4). The ethylenediamine results in nanoparticles with positive zeta potential. As the 
particles erode, ethylenediamine is cleaved and the carboxylic acids contribute to a negative zeta 
potential. Error bars represent standard deviation. Experiments were performed in triplicate. 
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7.8 Tables 
Table 7.1 Characterization of polyanhydride copolymers synthesized using high throughput method. 
Copolymer Actual Molar Ratio Molecular Weight (Da) T
g
 (°C) T
m
 (°C) 
100:0 CPTEG:CPH 100:0 5400 19.2 - 
80:20 CPTEG:CPH 73:27 5900 20.8 - 
50:50 CPTEG:CPH 45:55 8500 22.3 - 
20:80 CPTEG:CPH 22:78 7600 34.7 - 
0:100 CPTEG:CPH 0:100 10500 40.4 - 
80:20 CPH:SA 83:17 16400 35.1 53.2 
50:50 CPH:SA 48:52 12900 40 59.9 
20:80 CPH:SA 16:84 12200 54.9 68 
0:100 CPH:SA 0:100 9800 61.4 79.6 
 
Table 7.2 Nanoparticle size by conventional and high throughput syntheses. 
Conventional Synthesis High Throughput Synthesis 
Span wt% 20:80 CPH:SA 
Diameter (nm) 
20:80 CPTEG:CPH 
Diameter (nm) 
Span wt% 
 
20:80 CPH:SA 
Diameter (nm) 
20:80 CPTEG:CPH 
Diameter (nm) 
0% 708 ± 322 148 ± 50 0%  359 ± 105 171 ± 53 
0.2% 483 ± 102 142 ± 44 0.2%  298 ± 72 170 ± 48 
1% 408 ± 119 N/A 1%  230 ± 47 N/A 
 
 
 
  
 
2
2
3
 
 
Table 7.3 Protein encapsulation efficiency of nanoparticles synthesized by conventional and high throughput techniques. 
High Throughput Synthesis Conventional Synthesis 
0 Span 20:80 CPH:SA 52.3% 0 Span 20:80 CPH:SA 71.7% 
0.2% Span 20:80 CPH:SA 79.3% 0.2% Span 20:80 CPH:SA 84.3% 
1% Span 20:80 CPH:SA 76.5% 1% Span 20:80 CPH:SA 99.2% 
0% Span 20:80 CPTEG:CPH 98.3% 0% Span 20:80 CPTEG:CPH 74.5% 
0.2% Span 20:80 CPTEG:CPH 110.8% 0.2% Span 20:80 CPTEG:CPH 108.1% 
 
Table 7.4 Surface characterization of functionalized nanoparticles synthesized using high throughput method. 
 
Polymer composition 
Sugar Amount  
(µg/mg) 
EDS Weight % Composition of Nanoparticle Surface 
Average C (%) Average N (%) Average O (%) 
NF 20:80 CPH:SA  - 88.5 ± 1.3 0.01 ± 0.03 11.4 ± 1.3 
Glycolic Acid 20:80 CPH:SA - 83.0 ± 2.1 4.9 ± 1.4 11.8 ± 1.1 
Lactose 20:80 CPH:SA 11.4 ± 2.7 81.3 ± 3.2 5.6 ± 1.4 13.2 ± 2.0 
Galactose 20:80 CPH:SA 4.2 ± 3.2 80.0 ± 2.7 6.3 ± 2.1 13.7 ± 1.4 
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8.1 Abstract 
Developing more efficacious vaccines against H1N1 influenza virus would be a 
significant milestone that could reduce the detrimental effects of seasonal influenza epidemics 
and lower the risk of an influenza pandemic. In these studies, recombinant hemagglutinin (HA) 
and nucleoprotein (NP) antigens were encapsulated into nanovaccine formulations based on 
polyanhydride nanoparticles and/or pentablock copolymer hydrogels and their ability to protect 
animals against H1N1 infection was evaluated. Upon subcutaneous administration, all the 
nanovaccine formulations studied induced robust antibody titers relative to formulations 
containing soluble antigens (i.e., no adjuvants). The combination nanovaccine formulation, 
consisting of both nanoparticles and pentablock copolymer hydrogel, stimulated the strongest 
cell-mediated immune response six days after immunization, characterized by enhanced T cell 
circulation that readily produced IFN-γ and TNF-α upon stimulation. These responses correlated 
with desirable clinical outcomes in mice as evidenced by low viral titer in the lungs post-
infection and no weight loss post-infection. In contrast, control mice that received saline lost 
nearly 20% of their body weight after infection. The lungs of these mice contained CD4
+ 
and 
CD8
+
 T cells that produced large amounts of pro-inflammatory cytokines. These results support 
the development of combination nanovaccine formulations against the influenza A virus.  
8.2 Introduction 
Influenza is a potent respiratory virus that infects mammals and birds. It is responsible for 
an estimated 250,000-500,000 deaths each year even though there are numerous vaccines and 
antivirals commercially available (1). The virus is extremely successful at avoiding the immune 
system because of the effects of antigenic shift or antigenic drift whereby the virus undergoes 
point mutations or genetic recombination during its replication cycle (2). The former results in 
reoccurring influenza epidemics that occur every winter in the northern hemisphere (3). During 
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this time, the most susceptible individuals are the elderly, young children, and those who are 
immunocompromised. Most influenza infections are caused by viral strains with the H1 and H3 
subtypes (4). In addition to the annual epidemics there exists the possibility of an influenza 
pandemic, which occurs when a new strain of the virus is transmitted to humans. There is very 
little immunological memory against new strain(s), resulting in high levels of mortality and a 
large proportion of the population being infected by the virus (5). Many of the pandemics that 
occurred in the 20th and 21st centuries have been attributed to new or mutated H1 influenza 
strains. Notable H1 influenza outbreaks include the Spanish flu pandemic of 1918, the Fort Dix 
outbreak in 1976, the Russian flu epidemic of 1977, and the 2009 swine flu pandemic (5; 6). 
Current subunit and inactivated vaccines protect humans by inducing a large neutralizing 
antibody response against the hemagglutinin (HA) protein (7). HA makes up over 80% of the 
protein on the viral envelope and is an easy target for antibodies (8). The main function of the 
HA protein is to bind to sialic acid on cells in the respiratory system and then later serve as the 
fusion protein to fuse the viral envelope to the cell’s endosome (8). Previous studies have shown 
that vaccines inducing strong cell-mediated immune responses can lessen the severity of disease 
and provide long-lived protection (9; 10). This is because most antibodies are directed against 
the head region of HA, which can vary in structure between subtype and is readily susceptible to 
antigenic drift (4). This greatly contrasts with epitopes that activate T cells which tend to be 
directed towards internal proteins that are more conserved and consistent across strains. 
Specifically, dominant T cell responses tend to have epitopes originating from the matrix protein 
(M1) or the nucleoprotein (NP) (11; 12). These proteins have shown little mutation over 
generations of viral evolution (11). 
227 
 
 
 
It is hypothesized that recombinant protein-based nanovaccines which utilize both the 
HA and the NP antigens can induce protective cell-mediated and humoral immune responses. 
Recombinant antigens are inherently optimal because they can be easily scaled up for mass 
production compared to egg-based vaccines (13-15). This reduces cost and production time 
making it easier for researchers to design vaccines that antigenically match circulating strains 
(16). The potential drawback is that recombinant proteins are often weak immunogens and 
require higher doses (16). In these studies, it is demonstrated that the reduced immunogenicity of 
the individual proteins is overcome by formulating the HA and NP antigens with polyanhydride 
nanoparticles and/or pentablock copolymer hydrogels. These adjuvants/delivery systems have 
been shown to serve as effective vaccine adjuvants that stimulate a strong antibody-mediated 
immune response and a cell-mediated immune response (17-21). Both platforms have been 
shown to exhibit high biocompatibility, and provide a dose sparing effect where less antigen is 
needed to induce a potent immune response relative to solubly administered antigens (20; 22-27).   
8.3. Materials and Methods 
8.2.1 Monomer, polymer, hydrogel and nanoparticle synthesis 
1,6-bis(p-carboxyphenoxy)hexane (CPH) diacid was synthesized using sodium 
hydroxide, hydroxybenzoic acid, dibromohexane, 1-methyl-2-pyrrolidinone (Sigma-Aldrich, St. 
Louis, MO); sulfuric acid, and acetone (Fisher Scientific, Waltham, MA)  as described 
previously (28). 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) diacid was synthesized 
using triethylene glycol, N,N-dimethylacetamide  (Sigma-Aldrich); potassium carbonate, 
dimethyl formamide, toluene, acetonitrile, acetic acid, sulfuric acid (Fisher Scientific); and 4-p-
fluorobenzonitrile (Apollo Scientific, Cheshire, UK) using previously described methods (29). 
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These diacids were copolymerized into a molar ratio of 20:80 CPTEG:CPH using a melt 
polycondensation reaction (30). Chemical structure, purity, and molecular weight of the 
copolymer were determined by dissolving the polymer into deuterated chloroform (Cambridge 
Isotope Laboratories, Andover, MA) and analyzing the 
1
H NMR spectrum generated from a 
Varian VXR 300 MHz spectrometer. Differential scanning calorimetry (DSC, TA Instruments, 
New Castle, DE) was conducted to determine the copolymer glass transition temperature. 
From
1
H NMR measurements the 20:80 CPTEG:CPH copolymer had a molecular weight of 7700 
kDa, which is consistent with previous work (31; 32). Similarly NMR analysis showed that the 
actual molar ratio was 22:78 CPTEG:CPH, and DSC measurements indicated that the glass 
transition temperature was 34°C. 
Monomeric hemagglutinin (HA, ~60kDA) and the nucleoprotein (NP, 57kDa) derived 
from Influenza A H1N1 (A/Puerto Rico/8/34) were purchased from Sino Biological Inc. 
(Beijing, China). Both are recombinant proteins with the HA being produced in Human 
Embryonic Kidney (HEK) 293 cells, while the NP was produced through baculovirus infection 
of insect cells. 1 wt.% of each lyophilized protein were encapsulated into 20:80 CPTEG:CPH 
nanoparticles which were synthesized using anti-solvent nanoprecipitation with a solid-oil-oil 
(S/O/O) double emulsion (33). Polymer was dissolved in methylene chloride at a concentration 
of 20 mg/mL and both proteins were dispersed in the solution through vigorous sonication. In a 
4°C cold room, the solution was poured into a -20°C pentane bath so that the ratio of solvent to 
anti-solvent was 1:250. Particles were collected by vacuum filtration and their morphology was 
analyzed with a FEI Quanta 250 scanning electron microscope (SEM, Kyoto, Japan) after a 
Quorum Q150TS sputter coater (Lewes, UK)  coated them with 2 nm of iridium. The diameter of 
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200 nanoparticles was measured using ImageJ image analysis software (National Institutes of 
Health, Bethesda, MD).  
The hydrogel was composed of 15 wt.% poly(vinyl alcohol) (PVA), 5.9 wt.% Pluronic 
F127 and 4.1 wt.% PDEAEM pentablock copolymer. The pentablock copolymer was 
synthesized using cuprous oxide nanoparticles, a pluronic macroinitiator, N-propyl-pyridynyl 
methanimine (NPPM) ligand, and polyvinylpyrrolidone (DEAEM) as previously described (20). 
Pluronic macroinitiator (10 g, 0.78mmol) and cuprous oxide nanoparticles (0.24 g, 1.68 mmol) 
were added to toluene in a 50 mL round bottom flask. The reaction flask was degassed by 
vacuum-argon before 3.4 mmol NPPM ligand and 2.53 mmol DEAEM monomer were added. 
Oxygen was further removed with freeze-pump-thaw cycles. The reaction proceeded for 20 h at 
70°C rotating at 300 rcf. Pentablock copolymer was precipitated in chilled n-heptane and 
collected with a Buchner funnel. To create the hydrogel, 30 wt.% PVA was heated in PBS to 
80°C and was pipetted into a solution of the pentablock copolymer to form a temperature 
dependent hydrogel. This hydrogel was stored at 4°C until immunization. At this time, protein 
was dissolved in PBS and mixed into the hydrogel using vigorous sonication over ice. 
8.2.2 Animals 
Female BALB/c mice (6-8 weeks old) were purchased from Harlan Laboratories 
(Indianapolis, IN). Bedding, caging, water, and feed were all sterilized and all mice were housed 
in specific pathogen-free conditions. Animal procedures were approved by the Iowa State 
University Institutional Animal Care and Use Committee. 
8.2.3 Immunizations 
Mice were immunized at day 0 and then boosted with a second immunization on day 21 
of the experiment. There were six treatment groups with 12 mice per group and each mouse was 
administered 100 μL of total volume subcutaneously at the nape of the neck. Mice from the first 
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group served as a negative control and only received sterile phosphate saline buffer (PBS). The 
next group of mice received a soluble dose of 10 μg each of HA and NP. The nanoparticle 
treatment group received 5 μg each of HA and NP encapsulated in 500 μg of 20:80 CPTEG:CPH 
nanoparticles with the remaining 5 μg of each protein was administered as a soluble dose. The 
hydrogel treatment group received 25 mg of hydrogel loaded with 10 μg each of HA and NP 
protein. Another group of mice were treated with a combination nanovaccine formulation 
containing 500 μg of nanoparticles loaded with 5 μg each of HA and NP as well as 25 mg of 
hydrogel containing the remaining 5 μg each of HA and NP. The last treatment group consisted 
of a multi-site immunization where mice were immunized with the combination adjuvant. In 
these animals, 50 μL of the combination adjuvant were administered at the nape of the neck and 
the remaining 50 μL were given at the base of the tail. Nanoparticle and hydrogel formulations 
were sonicated over ice for one minute to disperse any aggregates prior to immunization. 
Additionally, there were six remaining mice that received 100 μL of saline. These mice were 
never infected and served as a naïve positive control for the other treatment groups that were 
challenged with the H1N1 virus. 
8.2.4 T cell analysis and flow cytometry 
Six days following each immunization, 100 μL of blood was collected from the 
saphenous vein of each mouse into heparinized capillary tubes. The blood was dispensed into 
cell-culture media (CTCM) containing 500 units/mL heparin (Fresenius Kabi, Germany) to 
prevent clotting. CTCM was composed of β-mercaptoethanol (Sigma-Aldrich), heat inactivated 
fetal bovine serum (Atlanta Biologicals, Atlanta, GA), RPMI 1640, penicillin/streptomycin, and 
L-glutamine (Mediatech, Manassas, VA). 2 mL of Ammonium-Chloride-Potassium (ACK) 
lysing buffer was added to the blood to lyse the red blood cells. ACK buffer consisted of 
ammonium chloride, potassium bicarbonate, and ethylenediaminetetraacetic acid (Fisher 
231 
 
 
 
Scientific). After 3 min of lysing, the solution was neutralized with 3 mL of CTCM media. The 
suspension was centrifuged for 10 min at 250 rcf at 4°C and the supernatant was poured off. The 
remaining cell pellet was dispersed in 250 μL of CTCM media. A small sample was used to 
count the cells on a Beckman Coulter Z2 counter. 5 x 10
5
 cells were added to their own well in a 
round-bottom 96 well plate. The cells were stimulated with a media solution containing 50 
ng/mL phorbol myristate acetate (PMA), 500 ng/mL ionomycin, and 10 μg/mL brefeldin A for 5 
h in a 37°C, 5% CO2 incubator. Following incubation, the cells were fixed and lysed in their 
wells for 15 min at room temperature using 100 μL BD Lysing Solution (Becton-Dickinson, East 
Rutherford, NJ). The cells were kept overnight in a 4°C refrigerator. In the morning, a cocktail of 
fluorescent antibodies was prepared in 0.5 mg/mL saponin solution and 100 μL was allowed to 
incubate with the cells at 4°C for 30 min. The antibody cocktail consisted of 0.1 mg/mL Rat IgG 
(Sigma-Aldrich), 10 μg/mL anti-mouse CD16/32, 0.2 μg/well eFluor 450 anti-mouse CD8b, 
0.125 μg/well PE anti-mouse Granzyme B (eBioscience, San Diego, CA), 0.2 μg/well PE-Cy7, 
0.2 μg/well anti-mouse IFN-γ, 0.2 μg/well APC anti-mouse TNF-α, 0.2 μg/well PerCP/Cy5.5  
anti-mouse CD4 (Biolegend, San Diego, CA). Following antibody staining, the cells were fixed 
once more with BD lysing solution, were washed in Fluorescence Activated Cell Sorter (FACS) 
buffer and analyzed on a BD FACSCanto flow cytometer.  
At day 50, eight days after viral infection, half the mice in each treatment group were 
euthanized. Their lungs were extracted with half the lung being saved for histopathology and the 
other half processed so that homogenate could be analyzed for T cells and activation. The same 
antibody staining procedure used for analyzing cells in the peripheral blood was utilized for cells 
derived from lung homogenate. However, now 1 x 10
6
 cells were used during incubations instead 
of 5 x 10
5
 cells. In addition to stimulating the cells with a PMA/Ionomycin/Brefeldin A cocktail, 
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a separate set of cells were plated and stimulated with 64 ng/mL recombinant mouse IL-2 from 
Biolegend, 4 μM nucleoprotein peptide (NP147-155), and 10 μg/mL Brefeldin A. These cells were 
stimulated for 6 h in a 37°C, 5% CO2 incubator. All other processing and antibody staining was 
identical to cells extracted from the peripheral blood.  
8.2.5 Antibody titer 
100 μL of blood was collected from the saphenous vein of each mouse. The serum was 
separated from the blood by centrifugation at 10,000 rcf for 10 min and stored at 4°C for analysis 
by ELISA. Each well of a flat-bottomed, high-binding 96 well plate was coated with 100 μL of 
0.5 μg/mL HA and allowed to incubate overnight at 4°C. On Day 2, the wells were emptied and 
2% (w/v) gelatin was added for two hours at room temperature to block the plates and reduce 
nonspecific binding to the adsorbed proteins. The gelatin was removed and the plates were 
washed with PBS-Tween (PBST). Serum was added to the wells and 1:2 dilutions were made 
across the plate in a solution of PBS and 1% (v/v) goat serum. The plates were incubated 
overnight at 4°C. On Day 3, the plates were emptied and washed with PBST. 100 μL of 1:000 
Alkaline Phosphatase (AP) conjugated anti-mouse IgG H&L (Jackson ImmunoResearch, West 
Grove, PA) was added to each well and incubated for 2 h. The plates were emptied and then 
washed with PBST before adding 100 μL of AP substrate buffer containing 1 mg/mL p-
nitrophenylphosphate. Thirty minutes later the plates were read on a spectrophotometer at 
wavelength of 405 nm. The same procedure was repeated for specific subclasses of IgG except 
AP conjugated anti-mouse IgG1 and IgG2a were used. 
8.2.6 Viral challenge 
At 42 days following the first immunization, mice from all treatment groups were 
infected with a 50 μL dose of 0.5 Hemagglutinin Units (HAU) Influenza A H1N1 (A/Puerto 
Rico/8/34) obtained from Dr. Yoon at Iowa State’s Veterinary Medical Research Institute. Mice 
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were anesthetized in a chamber with 3% isoflurane in 100% O2 with a flow rate of 2.5 L/min. A 
naïve control group of six mice were only immunized with 100 μL of saline solution and they 
were not challenged with the virus. All the mice were monitored twice a day for the remaining 
duration of the experiment. 
8.2.7 Viral load quantification and clinical evaluation 
Three days after challenge, half of the mice were euthanized. Their lungs were extracted, 
put into a cryogen tube and held in a 4°C refrigerator overnight for viral load quantification the 
following day using quantitative reverse-transcription polymerase chain reaction (qRT-PCR) as 
previously described (34; 35). Viral RNA was extracted from 100μL of homogenized lung tissue 
using the Ambion MagMAX Viral RNA Isolation Kit (Applied Biosystems, Foster City, CA) 
and the KingFisher 96 magnetic particle processor (Thermo Scientific). qRT-PCR was 
performed on a ABI 7900HT Sequence Detection System from Applied Biosystems using the 
QuantiTect Probe RT-PCR Kit from Qiagen (Hilden, Germany). Primers were at a concentration 
of 0.4 μM and were synthesized by Integrated DNA Technologies (Coralville, IA) using 
sequences from the Influenza Sequence Database. The fluorescent probe, from Applied 
Biosystems, was at a concentration of 0.2 μM. Samples that were positive for the virus had a 
threshold count (Ct) below 38. The viral load (TCID50 equivalent/mL) was determined using a 
standard curve built from positive samples with known viral titer allowing Ct to be converted to 
TCID50.  
The remaining half of the mice was monitored for weight loss for eight days. Each mouse 
was weighed individually every day and the body weight was averaged across the entire 
treatment group. After eight days the mice were euthanized, their lungs were extracted, and half 
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the lung was fixed in formalin solution. The other half of the lung was homogenized for flow 
cytometry using the aforementioned methods. 
8.2.8 Statistical analysis 
Statistical significance from the treatment groups was performed with a one-way 
Analysis of Variance (ANOVA) model followed by a post-hoc Tukey’s t-test. P-values less than 
0.05 were considered significant. 
8.3 Results 
8.3.1 Combination nanovaccine induced T cell expansion 
BALB/c mice were immunized subcutaneously with the treatment groups described in 
the Methods section at days 0 and 21. Each treatment group contained 10 μg of NP and 10 μg of 
HA antigens except for the saline negative control. Six days following each immunization, 100 
μL of peripheral blood was collected from each mouse for T cell proliferation. 
White blood cell populations were stained for CD4, CD8, and the cytokines IFN-γ and 
TNF-α. The number of cells from each sample was counted in order to assess T cell 
proliferation. Of the total cell count from the peripheral blood, roughly 10-15% were CD8
+
 T 
cells while approximately 30-40% were CD4
+
 T cells. Peripheral blood from animals immunized 
with nearly all of the treatment groups contained a larger number of CD4
+
 T cells than the blood 
from animals treated with saline, but the number of CD4
+
 T cells was significantly larger in the 
animals immunized with the combination nanovaccine (Figure 8.1A). In addition, peripheral 
blood from animals immunized with several of the treatment groups contained larger numbers of 
CD8
+
 T cell relative to the animals that received saline (Figure 8.1B). Cells originating from the 
peripheral blood of mice treated with the combination nanovaccine had the largest number of 
CD8
+
 T cells. Cells originating from mice that received the soluble antigens were also 
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statistically different compared to cells from mice treated with saline. The number of CD8
+
 T 
cells from mice treated with the nanoparticles was higher, but not statistically significant 
compared to CD8
+
 T cells from mice treated with saline.  
The ability of these T cells to become activated was analyzed by performing intracellular 
cytokine staining on the cells upon in vitro stimulation. The CD4
+
 T cells from mice treated with 
the soluble antigens produced the largest amounts of TNF-α and IFN-γ (Figure 8.1C). The CD4+ 
T cells from animals that were immunized with the nanoparticles and the combination 
nanovaccine formulation were able to produce some TNF-α and IFN-γ, but this was not 
statistically significant compared to the negative control. In contrast, the number of TNF-α and 
IFN-γ producing CD8+ T cells from animals immunized with the combination nanovaccine 
formulation was significantly greater number compared to CD8
+
 T cells from mice that received 
saline (Figure 8.1D). Finally, the number of TNF-α and IFN-γ producing CD8+ T cells from 
animals immunized with the combination nanovaccine delivered at multiple sites were fewer 
than that from animals immunized with the combination nanovaccine at a single site. 
The T cell responses were reevaluated in the peripheral blood at day 27, which was six 
days after the second immunization. At this time point, the animals immunized with the 
pentablock copolymer hydrogel formulation had largest number of CD4
+
 T cells, while the 
largest number of CD8
+
 T cells was observed in the animals that received the soluble antigens 
(Figure 8.2A & 8.2B). The peripheral blood samples from animals that received the hydrogel, 
nanoparticle, and soluble treatment groups showed some upregulation of TNF-α and IFN-γ in 
CD4
+
 T cells, but these were not statistically significant from the cells in the peripheral blood of 
animals treated with saline (Figure 8.2C). None of the treatment groups were able to induce a 
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statistically significant proinflammatory cytokine production in the CD8
+
 T cell population 
(Figure 8.2D).  
8.3.2 Nanovaccine formulations induced robust antibody titers 
At days 21 and 35, peripheral blood was collected from the immunized mice and an 
ELISA was performed to quantify antibody titers against the HA antigen. Total IgG as well as 
IgG1 and IgG2a subclasses were analyzed. At day 21, the total IgG antibody titer was fairly low 
(Figure 8.3A). Nonetheless, the animals immunized with the nanovaccine groups showed 
significantly greater antibody production relative to that in the animals that received the saline 
and soluble antigen groups. At this time point, the average IgG titer in the animals that received 
the soluble antigens was 350, while the animals that received the nanoparticle and hydrogel 
groups had titers in excess of 1100. The animals immunized with the combination nanovaccine 
had the highest IgG titer at nearly 3800. The animals immunized with the combination adjuvant 
administered at multiple sites had an average titer of 1900. Almost all of the total IgG titer was 
of subclass IgG1 (Figure 8.3B & 8.3C). 
Two weeks after the second immunization, the antibody titers for all treatment groups 
increased dramatically. The animals immunized with the combination nanovaccine had the 
largest antibody production with an average antibody titer of nearly 1.8 x 10
5
 (Figure 8.3A). This 
was a 9-fold higher than the antibody titer in the animals that received the soluble antigens. 
Antibody titers from mice that were immunized with the nanoparticle and hydrogel formulations 
were also statistically higher compared to the titers of animals that were immunized with the 
soluble antigens, with the animals immunized with the hydrogel formulation inducing antibody 
production nearly as well as the combination nanovaccine. The titers in the mice immunized with 
the multi-site combination nanovaccine were statistically equivalent to that of the mice 
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immunized with the single site combination nanovaccine. At day 35, once again, most of the 
antibody was of IgG1 subclass but the titers in the animals immunized with the nanoparticle, 
hydrogel, and both combination nanovaccine formulations contained statistically significant 
IgG2a components (Figure 8.3B & 8.3C).  
8.3.3 Mice immunized with nanovaccine formulations had reduced viral titer upon challenge 
Three days post-infection, ½ of the mice in each group (6 mice/group) were euthanized 
and their lungs were harvested for viral quantification using real-time PCR. The lungs of all of 
the mice treated with saline and soluble antigens were positive for the virus. The average TCID50 
in the lungs of mice treated with saline was 1.3 x 10
8
, while the average TCID50 in the lungs of 
mice that were immunized with the soluble antigen was nearly 1 x 10
7 
(Figure 8.4). The lungs of 
mice immunized with all the other nanovaccine formulations exhibited TCID50 values that were 
several orders of magnitude lower. The average viral titer in the lungs of mice immunized with 
the nanoparticle or hydrogel formulations was of the order of 1 x 10
5
, while the viral titer in the 
lungs of mice immunized with the combination nanovaccine formulation (both single and multi-
site) had an average TCID50 of around 10. Significantly, the Ct value for all of the mice receiving 
both forms of the combination nanovaccine was above the cut-off Ct indicating that none of these 
mice were positive for the influenza A virus.    
8.3.4 Immunized mice lost less weight following viral challenge 
For eight days after administration of the virus, the weight of each mouse was recorded 
individually and then averaged with the other mice in its treatment group. Most mice receiving 
antigen did not experience a statistically significant amount of weight loss (Figure 8.5). Mice 
treated with saline began losing weight at day 3 post-infection and continued losing weight for 
the duration of the experiment.  On average, mice treated with saline lost about 20% of their 
original body weight, which was statistically significant from the weight loss in the other 
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treatment groups. Mice immunized with soluble proteins started losing weight at day 5 and 
reached a minimum at day 6. By day 8, these animals started to recover. At each time point, the 
average weight loss in the mice receiving the soluble antigens was not significantly different 
from the weight loss in the mice receiving the nanovaccine formulations. However, at no time 
point did mice receiving the nanoparticle, hydrogel, or either combination nanovaccine 
formulation show any weight loss. Some of these mice in fact gained weight over the eight day 
period and were nearly indistinguishable from naïve mice not receiving any virus.    
8.3.5 T cell expansion in the lung following viral challenge 
Mice were euthanized on the 8
th
 day post-infection. One million cells from lung 
homogenate were stimulated with an intracellular stimulation cocktail that induced nonspecific 
cytokine production (PMA/Ionomycin/Brefeldin A) or induced only antigen specific cytokine 
production (IL-2/NP147-155/Brefeldin A) from T cells within the homogenate. CD4
+
 and CD8
+
 T 
cells derived from saline- and soluble antigen-treated mice produced the largest amounts of IFN-
γ and TNF-α following nonspecific T cell stimulation (Figure 8.6A, 8.6E). There were 
essentially no cells positive for these cytokines in the lungs of mice that received any of the 
nanovaccine formulations when compared to the lungs of the uninfected naive animals.  
The CD4
+
 T cells showed very little antigen specific cytokine production when incubated 
with the NP147-155 peptide as the overall number of responding cells were greatly reduced 
compared to those that were nonspecifically stimulated (Figure 8.6B). CD8
+
 cells from mice 
receiving saline had significant antigen specific cytokine production, which was nearly 
equivalent in number to the CD8
+
 T cells that had been nonspecifically stimulated to produce 
cytokines (Figure 8.6D). Finally, many of the CD8
+
 T cells were positive for granzyme B, 
particularly cells from the mice that received saline and soluble antigens (Figure 8.6E & 8.6F). 
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Relative to cells from naïve mice, there was significant granzyme B in the mice treated with 
saline upon both nonspecific and antigen specific T cell stimulation.  
8.4 Discussion 
According to the Centers for Disease Control and Prevention (CDC) the best strategy to 
prevent influenza and control its spread is through annual vaccination (36). Two types of 
vaccines are currently available to consumers to meet this need. The first is the trivalent 
inactivated influenza vaccine (TIV) and the second is the live attenuated influenza vaccine 
(LAIV) (37). In the TIV vaccine, virions from three or four different strains are inactivated for 
intramuscular administration (38). TIV vaccines with purified virion surface antigens are known 
as subunit vaccines (38). The LAIV contains the same three or four viruses used to formulate the 
TIV vaccine, but it is administered intranasally as a live vaccine that can only replicate in the 
nasal mucosa (39). The composition of these vaccines varies across manufacturer, but most 
influenza vaccines are derived from viral infection of chicken eggs (40). Although these vaccines 
can be effective, there are significant limitations. The first is that these vaccines provide 
protection mostly through an antibody-mediated immune response (7; 41). A more robust cell-
mediated response in conjunction with a strong antibody response could help infected individuals 
recover faster and provide enhanced protection (7). Additionally, there have been influenza 
seasons recently where vaccine shortages have existed (42; 43). Utilizing recombinant antigens 
that can be scaled up more easily along with incorporating adjuvants that can provide a dose-
sparing effect could reduce the potential for a vaccine shortage (44). Thirdly, egg based vaccines 
can have residual egg protein in the vaccine, which could be hazardous to those that are 
hypersensitive or allergic to eggs (45). Recombinant antigens that are incorporated into 
biodegradable nanoparticles and/or hydrogels avoid this problem altogether.  
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The combination nanovaccines described in this work have the potential to overcome 
many of these limitations in the current influenza vaccines. Our data indicates that nanovaccine 
formulations containing recombinant HA and NP protein can effectively adjuvant the immune 
response and protect animals against a live influenza A virus challenge. These nanovaccine 
formulations effectively stimulated T cells and generated an antibody response that was several 
orders of magnitude greater than vaccine formulations consisting of soluble antigens. In turn, this 
resulted in a more favorable clinical outcome following viral challenge. The enhanced 
immunological response demonstrated herein reinforces the concept that nanovaccines have dose 
sparing capabilities. An influenza vaccine that can minimize dosage would be a significant 
breakthrough given that current vaccine production capacity is inadequate to combat a potential 
pandemic (46).  
The data in Figure 8.1A and 8.1B showed that the combination nanovaccine induced 
significantly larger numbers of CD4
+
 and CD8
+
 T cells. The number of CD8
+
 T cells in the 
animals vaccinated with the soluble antigens was also significantly larger. The early endogenous 
T cell data indicated that the soluble antigen formulation and the combination nanovaccine 
performed the best. This is likely because the animals immunized with the soluble antigens 
resulted in CD4
+ 
T cells that produced a large amount of pro-inflammatory cytokines, which is 
attributed to the immediate availability of the entire amount of antigen for processing by antigen 
presenting cells (Figure 8.1C). Similarly, animals immunized with the combination nanovaccine 
resulted in CD8
+
 T cells that produced large amounts of pro-inflammatory cytokines (Figure 
8.1D). Previous studies have shown that it can take up to a month for 20:80 CPTEG:CPH 
nanoparticles to release their payload and up to a week for some hydrogel formulations (15; 20). 
As a result much of the antigen in the nanovaccine formulations is not available to stimulate a 
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strong T cell response immediately, which could explain why the nanoparticle and hydrogel 
treatment groups did not perform as well as the soluble antigen formulation. Nonetheless, it 
appears that combining the nanoparticles and the hydrogel together provided a strong enough 
signal that adjuvants the immune response to induce an increased number of T cells even though 
much of the HA and NP antigen is still encapsulated within the formulation.  
The endogenous T cell data following the boost immunization indicated that animals 
immunized with the hydrogel formulation showed a strong CD4
+
 T cell immune response, 
including production of pro-inflammatory cytokines (Figure 8.2A & 8.2C). Animals immunized 
with the soluble antigens showed large numbers of cytokine-producing CD8
+
 T cells. It is 
interesting that the combination nanovaccine did not induce a strong T cell response in the 
periphery as was observed after the primary immunization. It is known that the kinetics of T cell 
responses peak at 5-7 days following immunization, however, T cell responses upon secondary 
immunizations may reach their peak at earlier times (47; 48). 
The animals immunized with the nanovaccine formulations significantly outperformed 
their counterparts that were immunized with soluble antigens and saline in terms of their serum 
antibody titers. In particular, the animals immunized with the combination nanovaccine showed 
the highest antibody titers 35 days after the first immunization, with titers nearly reaching 1.8 x 
10
5
 using a total of only 20 μg of HA. Most of these titers were IgG1 subclass, but at day 35, 
animals immunized with each of the nanovaccine formulations demonstrated some class 
switching and also induced IgG2a specific antibodies. The nanovaccines clearly showed a dose 
sparing effect, which is consistent with previous studies (17; 24). Additionally, animals 
immunized with the hydrogel resulted in antibody titers that were nearly equal to that induced in 
animals immunized with the combination nanovaccine. The hydrogels are known to form an 
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antigen depot providing a sustained release of antigen, which in turn augments the immune 
response (20). Antigen persistence has been shown to induce better germinal center formation 
and long-lived plasma cells (49; 50). 
Mice receiving the multi-site combination nanovaccine formulation had strong antibody 
titers that were statistically equivalent to titers in animals immunized with the combination 
nanovaccine at one site. It was hypothesized that antigen may drain to multiple lymph nodes by 
administering the formulation at multiple sites, thus enhancing the immune response. However, 
the CD4
+
 and CD8
+
 T cell responses, particularly at day six, were the lowest in the animals 
immunized with the multi-site combination nanovaccine in contrast with the animals immunized 
with the single site combination nanovaccine.  
Even though the animals immunized with the multi-site combination nanovaccine 
formulation did not show strong T cell responses, mice receiving this formulation had an 
excellent clinical outcome in terms of low viral titer and no weight loss after challenge. This 
reinforces the concept that an efficacious antibody response is the primary means to preventing 
influenza infection (7). Viral titers were lowest in the lungs of mice immunized with the single 
site and multi-site combination nanovaccine because none of the mice in either of these groups 
were positive for the virus. qRT-PCR reveled that viral titers were four orders of magnitude 
higher in the lungs of mice receiving the nanoparticle and hydrogel formulations. This is 
consistent with the antibody titer data where antibody titers were slightly lower in the sera of 
animals immunized with the nanoparticle and hydrogel formulations. Of all the immunized 
animals, the cohort immunized with the soluble antigens had the highest viral titer in their lungs. 
This was also the only cohort of immunized animals to exhibit any weight loss, which occurred 
between days 5 and 7. It has been shown that mice with viral titers of 10
8
 or higher exhibit 
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significant weight loss (35). As anticipated, mice receiving saline had viral titers above 10
8
 eight 
days after infection and showed significant weight loss relative to the other immunization 
groups. 
These clinical symptoms and viral titers were reflected in the T cell analysis of the lungs 
of mice eight days after viral infection. Proinflammatory cytokine production by CD4
+
 and CD8
+
 
T cells was highest in the animals that received the saline treatment. This group of animals had 
approximately 4-fold greater CD4
+
 T cells producing proinflammatory cytokines when 
stimulated with the PMA/Ionomycin/Brefeldin A cocktail compared to animals that received the 
nanovaccine formulations. Similarly, mice receiving the saline treatment had over 150-fold 
greater CD8
+
 T cells producing proinflammatory cytokines compared with mice immunized with 
the nanovaccines. Given that the mice immunized with the nanovaccine formulations by 
themselves don’t induce more cytokines than the naive animals, it is clear that these mice have 
effectively resolved the infection. This is true for animals that received the single site and multi-
site combination nanovaccine formulations, because there was no detectable viral titer within the 
lungs of these mice. However, it is interesting to observe that the proinflammatory cytokine 
producing T cell responses in the animals immunized with the hydrogel and nanoparticle 
formulations was not significantly higher relative to that in naïve mice. This is because there is a 
detectable viral titer within the lungs of these mice. Taken together all this data suggests that the 
infection is waning and would likely be cleared shortly in these mice. It is evident that the saline 
treated mice are still dealing with the infection. It is possible that this drastic increase in cytokine 
production as well as granzyme B production could be induce significant histological damage 
within the lung tissue.  
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Cells from the lung homogenate were stimulated with the NP147-155 peptide, a known 
CD8
+
 T cell epitope, to ascertain T cell antigen specificity. There was no statistical difference 
between the CD4
+
 T cell groups, which makes sense as the NP147-155 peptide should only 
stimulate CD8
+
 T cells. It is interesting to note that nearly the same number of CD8
+
 T cells in 
the lungs of mice that received the soluble antigen formulation or saline produced pro-
inflammatory cytokines in the presence of the NP147-155 peptide as the PMA/Ionomycin/Brefeldin 
A cocktail. This indicates that nearly all of the CD8
+
 T cells infiltrating the lung are antigen-
specific. 
8.5 Conclusions 
This work demonstrates that vaccine formulations containing influenza HA and NP 
together with a combination of polyanhydride nanoparticles and pentablock copolymer hydrogels 
generated a robust antibody response against HA and provided an enhanced cell-mediated 
immune response. Animals immunized with the combination nanovaccine generally showed the 
best immune responses and were protected from influenza virus challenge, but strong antibody 
titers and cell-mediated responses were also measured in the animals immunized with the 
nanoparticle and hydrogel only formulations. The animals immunized with the nanovaccine 
formulations (alone or in combination) were effectively protected from an H1N1 influenza virus 
infection compared to animals that received soluble antigens (i.e., without any nanoadjuvants). 
Mice receiving the nanovaccine formulations had lower viral titers, did not experience any 
weight loss after infection, and had proinflammatory cytokine induction within the lung that was 
comparable to that in naïve unchallenged mice. Together, these results demonstrate the promise 
of pursuing the design and development of efficacious influenza vaccines based on these 
combination nanovaccines. 
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8.8 Figures 
 
Figure 8.1 CD4
+
 and CD8
+
 T cell expansion in the peripheral blood six days after immunization. 
A) Animals immunized with the combination nanovaccine had the largest number of CD4
+
 T 
cells. B) Animals immunized with the combination nanovaccine or soluble antigens had the 
largest number of CD8
+
 T cells. C) & D) Proinflammatory cytokine production by CD4
+
 T cells 
is strongest in animals immunized with the soluble antigens and that in CD8
+
 T cells is greatest 
in the animals immunized with the combination nanovaccine. Error bars represent standard error 
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of mean. N = 12 mice per group. * represents statistical significance (p < 0.05) compared with 
the saline treatment group.   
 
Figure 8.2 CD4
+
 and CD8
+
 T cell expansion in the peripheral blood on day 27, which is 6 days 
after the boost immunization. A) Animals immunized with the hydrogel formulation had the 
largest number of CD4
+
 T cells. B) Animals immunized with the soluble antigens had the largest 
number of CD8
+
 T cells. C) Proinflammatory cytokine production by CD4
+
 T cells in animals 
immunized with the nanoparticle and hydrogel treatment groups is high, but not statistically 
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significant compared to that in animals that received saline. D) CD8
+
 T cells from all the animals 
exhibited little cytokine production at this time point. Error bars represent standard error of 
mean. N = 12 mice per group. * represents statistical significance (p < 0.05) compared with the 
saline treatment group.   
 
Figure 8.3 Antibody titers from immunized animals at days 21 and 35 post-immunization. A) 
Nanovaccine formulations induced significant total IgG production, with the combination 
nanovaccine leading the way. B) Most of the antibody titers in animals immunized by the various 
vaccine formulations is specific to IgG1. C) Nanovaccine formulations induce statistically 
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significant class switching to IgG2a at Day 35. N = 12 mice per group. P values less than 0.05 
are significant from each other.  Groups that have different letters are statistically significant at 
that time point. 
 
Figure 8.4 Viral titers are highest in mice treated only with saline solution and nearly 
undetectable in mice receiving the combination nanovaccine. N = 6 mice per group. P values less 
than 0.05 are significant from each other as represented by the different letters. 
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Figure 8.5 Average body weight loss in each treatment group following infection with the H1N1 
virus. Mice treated with saline lost nearly 20% of their body weight eight days after infection, 
which mice receiving the nanovaccine formulations on average never lost weight. Saline is 
statistically significant from every other group starting at Day 4. N = 6 mice per group. 
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Figure 8.6 Non-specific and antigen-specific CD4
+
 and CD8
+
 cytokine production in the lungs 
of mice immunized with various formulations eight days after viral infection. A) CD4
+
 T cells 
from mice receiving saline exhibit the largest cytokine production upon non-specific stimulation. 
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B) None of the mice immunized with various formulations showed antigen-specific cytokine 
production in CD4
+
 T cells. C) & D) Mice receiving saline produced overwhelming amounts of 
pro-inflammatory cytokines in CD8
+
 T cells upon both non-specific and antigen specific 
stimulation. E) & F) The CD8
+
 T cells from mice receiving saline also produced granzyme B 
upon both non-specific and antigen specific stimulation. In contrast, there is no CD4
+
 or CD8
+
 
cytokine production upon stimulation in the lungs of mice immunized with the nanovaccine 
formulations. N = 6 mice per group. P values less than 0.05 are significant from each other as 
represented by the different letters.  
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CHAPTER 9: CONCLUSIONS AND ONGOING/FUTURE WORK 
9.1 Conclusions 
A significant component of this thesis has been dedicated to the rational design of 
nanovaccines that are capable of targeting their payloads to specific receptors on antigen 
presenting cells (APCs). There is evidence in the literature on the use of functionalized vaccines 
to augment the immunogenicity of an antigen by stimulating its uptake and processing as well as 
triggering proinflammatory transcription factors through intracellular signaling (1-3). Chapters 4, 
5, and 6 investigated a specific class of receptors, known as C-type Lectin receptors (CLRs) that 
are present on APCs such as dendritic cells. Nanoparticles were functionalized with di-mannose 
in order to target the macrophage mannose receptor. Early results conducted on primary dendritic 
cells in vitro suggested that these di-mannose modified nanoparticles were readily internalized 
by the cells, induced elevated cytokine secretion, and stimulated surface marker expression (4). 
In vivo studies in Chapter 5 showed that both functionalized and non-functionalized 
polyanhydride nanoparticles were safe for subcutaneous and intranasal administration. There was 
no histological damage in kidney, liver, or lung tissue of mice upon administration of these 
nanoparticles and no significant upregulation of serum biomarkers that would indicate tissue 
damage was observed (5). The efficacy of the carbohydrate-functionalized nanoparticles was 
tested with additional in vivo studies in Chapter 6. In these studies, it was observed that 
carbohydrate-functionalized nanoparticles encapsulated with ovalbumin did not stimulate a 
robust CD8
+
 T cell response in mice and induced similar long-lived antibody titers as those 
induced in animals receiving non-functionalized nanoparticles.  
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Another core component of this thesis evaluated the ability of polyanhydride 
nanoparticles to protect mice against influenza A virus. In Chapter 8, nanoparticles were loaded 
with the hemagglutinin (HA) and nucleoprotein (NP) antigens. Protection against influenza is 
known to depend strongly on the antibody response against HA, but the NP was added in order 
to help stimulate a stronger cell-mediated immune response (6). Pentablock copolymer hydrogels 
were used as adjuvants in combination with the nanoparticles to replace the carbohydrate-
functionalized nanoparticles because previous results have suggested that this combination 
induced synergistic in vivo immune responses against influenza (7). HA- and NP-based 
nanovaccine formulations consisted of nanoparticles alone, hydrogel alone, and a combination 
formulation in which nanoparticles were combined with hydrogels. The combination 
nanovaccine induced the best cell-mediated immune response as evidenced by the increased 
number of activated T cells. In addition, all nanovaccine formulations generated strong antibody 
titers. Mice treated with the nanovaccines had reduced clinical morbidity after viral infection, 
which was exemplified by almost no weight loss and lower viral titer in their lungs post-
infection. All the mice immunized with the combination nanovaccine completely cleared the 
virus, while all the mice receiving saline and soluble antigens had significantly higher viral 
nucleic acids in their lungs. 
Overall, this thesis demonstrates the enhanced properties of polyanhydride nanoparticles 
as nano-adjuvants that can induce both antibody- and cell-mediated immune responses against 
viral pathogens such as influenza A. This work also developed a new high throughput 
methodology for efficient synthesis and functionalization of these nanoparticles. Although the 
carbohydrate-functionalized nanoparticles performed similarly to the non-functionalized 
nanoparticles in terms of inducing in vivo adaptive immune responses, insightful information 
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was still obtained from these studies that provides some new directions for using functionalized 
polyanhydrides as an adjuvant/delivery platform. Targeting CLRs for drug delivery is still a 
nascent field. The concept of lectins recognizing specific glycan moieties was discovered in the 
1980s and the structure and function of many lectins are still unknown (8). Future research will 
undoubtedly illuminate the targeting capabilities of this class of receptors. The in vivo influenza 
challenge studies in Chapter 8 showed that polyanhydride nanoparticles provide an enhanced 
immune response and when used in combination with the pentablock copolymer hydrogels, they 
provide synergistically enhanced immune responses, which significantly reduced clinical 
morbidity. All of these studies with the nanovaccines have motivated several ongoing research 
directions and future studies, which are described below.  
9.2 Ongoing Research and Future Studies 
There are several ongoing studies with our collaborators that are further evaluating the 
efficacy of polyanhydride nanoparticles as vaccine delivery vehicles, particularly against 
influenza A virus. These studies illustrate the potential breadth of the advantages provided by the 
polyanhydride nanoparticles for the development of influenza vaccines. For example, 
preliminary data generated together with our collaborators, Drs. Legge and Waldschmidt, at the 
University of Iowa has indicated that nanovaccine formulations based on polyanhydride 
nanoparticles have the ability to provide heterosubtypic protection. Ongoing studies with our 
collaborator, Dr. Kohut in the Department of Kinesiology at Iowa State University, show that 
nanovaccines may induce efficacious immune responses in aged mice in addition to young adult 
mice. Finally, ongoing studies with our collaborator, Dr. Gourapura, at Ohio State University are 
evaluating whether polyanhydride nanoparticles can protect pigs from influenza viral challenge. 
All of these studies are described below. 
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In our collaborative studies with researchers at the University of Iowa, 20:80 
CPTEG:CPH nanoparticles were synthesized with 1 wt.% HA, 1 wt.% NP, and 1.67 wt.% CpG 
ODN 1668 in the presence of 0.2 wt.% Span 80 as a surfactant. CpG is a TLR 9 agonist known 
for stimulating the NF-κB transcription factor triggering a release of proinflammatory cytokines 
and kick starting the adaptive immune response (9; 10). The NP antigen contains several 
conserved epitopes recognized by T cells (11). The hypothesis here is that the presence of the NP 
will stimulate a cell-mediated immune response and help protect the mice from heterologous 
challenge as these epitopes tend to be more conserved across strains (12). Collaborators at the 
University of Iowa intranasally immunized BALB/c mice with 500 μg of nanoparticles 
containing 2.5 μg each of HA and NP along with 2.5 μg of soluble HA and NP. The mice were 
boosted with the same dose on day 14, and at day 46 they were challenged with either the 
homologous H1N1 A/PR/8/34 or the heterologous H3N2 A/HK/68 virus. All the mice receiving 
the nanovaccine immunization survived the homologous challenge, losing approximately 10% of 
their body weight before recovering (Figure 9.1A & 9.1B). In contrast, naïve control mice that 
were infected but not vaccinated on average lost over 25% of their body weight and after 18 days 
post-infection resulted in 100% death. Heterologous challenge resulted in the immunized mice 
losing about 20% of their body weight, and 80% of the mice survived the challenge (Figure 9.1C 
& 9.1D). Again, the naïve control mice lost over 25% of their body weight with only 20% 
survival post-challenge. Future studies are underway to demonstrate reproducibility as well as to 
probe the mechanisms of the role of CD8
+
 T cells and the kinetics of the B cell response in 
inducing protection following nanovaccine immunization.  
Other collaborative studies here at ISU are analyzing the ability of polyanhydride 
nanovaccines to induce an efficacious immune response in aged mice. It is known that the 
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strength of the immune response to a new antigen is strongly correlated with age (13). The 
elderly generally have a reduced adaptive immune response when immunized with a new antigen 
(14). It has been shown that the elderly on average have higher basal levels of proinflammatory 
cytokines and need more antigen than a healthy young adult to stimulate cytokine production 
against that antigen (15). Our collaborative studies with Dr. Kohut analyzed the ability of 
polyanhydride nanoparticles to stimulate an efficacious cell-mediated immune response against 
ovalbumin (Ova). In these studies, 2 wt.% of Ova was encapsulated into 20:80 CPTEG:CPH 
nanoparticles using a solid/oil/oil double emulsion. Pentablock copolymer hydrogels with a 
composition of 15 wt.% poly(vinyl alcohol) (PVA), 5.9 wt.% Pluronic F127 and 4.1 wt.% 
PDEAEM pentablock copolymer were prepared by the Mallapragada laboratory. 17 month-old 
and 2-month young mice were immunized subcutaneously at the nape of the neck with 100 μg of 
soluble protein or the combination nanovaccine consisting of 10 μg protein in the nanoparticles 
and 90 μg protein in the hydrogels. After six days, draining lymph nodes were collected and 
homogenized. Cells were stimulated with a PMA/Ionomycin/Brefledin A cocktail and analyzed 
via flow cytometry.  
The combination nanovaccine induced greater numbers of CD4
+
 and CD8
+
 T cells in the 
draining lymph nodes of both young and aged mice, although this result was only significant in 
young mice (Figure 8.2A & 8.2B). In contrast, the mice receiving soluble Ova had numbers of T 
cells similar to saline administered mice. All formulations resulted in greater numbers of CD4
+
 
IFN-γ+ TNF-α+ T cells in aged mice in comparison to young mice, but there were no differences 
between formulations of the same age group (Figure 8.2C). The enhanced immune response 
provided by the combination nanovaccine was statistically significant in the young mice. 
Although there was not a statistically significant upregulation in aged mice, trends in the data 
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suggest that the combination vaccine could elevate the immune response in aged mice. As a 
result future studies will continue to optimize the combination nanovaccine formulation to 
produce a more efficacious immune response in aged mice. These studies will utilize the HA and 
NP antigen. 
Finally, ongoing studies with our collaborators at Ohio State University are analyzing the 
immune response of intranasally administered polyanhydride nanoparticles loaded with whole 
inactivated H1N2 swine antigen. The swine influenza virus is highly contagious in pigs and is of 
great interest to the swine industry due to the economic losses that it can potentially inflict on 
livestock (16). Additionally, pigs are considered “mixing vessels” where different subtypes of 
the influenza virus can easily recombine and be translated to humans (17; 18). As a result an 
efficacious influenza vaccine for swine is urgently needed. In these studies, 20:80 CPTEG:CPH 
nanoparticles were synthesized using a solid/oil/oil emulsion in the presence of 0.2 wt.% Span 80 
surfactant encapsulating 4 wt.% of H1N2 antigen. 4-5 week old piglets were immunized with an 
equivalent dose of 1 x 10
7
 TCID50. Three weeks following initial immunization, the piglets were 
boosted and after a total of five weeks following the first immunization, the piglets were 
intranasally and intratracheally challenged with heterologous H1N1-OH7 (6 x 10
6
 TCID50/pig).  
Compared to whole inactivated antigen administered in soluble form, the polyanhydride 
nanoparticle formulation stimulated similar numbers of helper T cells, cytotoxic T cells or γδ T 
cells within isolated peripheral blood mononuclear cells at 35 days post-vaccination (Figure 
9.3A). Lung lesions from the piglets were scored at six days post-infection (Figure 9.3B). All 
infected pigs had significant lung lesions. The lungs of the piglets immunized with the 
nanoparticle formulation showed reduced lesions, but this was not statistically significant from 
the lesions observed in the lugs of the piglets that received the other formulations. The body 
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temperature of the piglets was monitored for six days post-infection (Figure 9.3C). With the 
exception of the 1
st
 day, piglets immunized with the nanoparticle formulation maintained a body 
temperature that were close to the mock unchallenged piglets compared to the temperatures of 
the piglets that were immunized with the soluble antigen formulation. Future studies need to 
focus on better delivery techniques because the nanoparticles currently cannot be delivered 
through a misting device that would allow deep penetration of the vaccine into the nasal cavity. 
Instead nanoparticles are administered using a nasal dropper. It is hypothesized that optimizing 
the nanoparticles for use with the misting device would induce more robust immune responses 
because deeper penetration of the vaccine would prevent it from being wasted.  
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9.4 Figures 
 
Figure 9.1 Mice vaccinated intranasally with HA and NP loaded nanoparticles survive 
homologous and heterologous influenza challenge. A) Weight loss following H1N1 viral 
challenge of vaccinated and unvaccinated mice. B) Survival curve following H1N1 viral 
challenge of vaccinated and unvaccinated mice. C) Weight loss following H3N2 viral challenge 
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of vaccinated and unvaccinated mice. D) Survival curve following H3N2 viral challenge of 
vaccinated and unvaccinated mice. N = 5 mice per group. 
 
Figure 9.2 Combination nanovaccine enhanced the number of activated T cells in BALB/c mice. 
A) Greater numbers of CD4
+
 T cells are present in the peripheral blood of aged and young mice 
immunized with the combination nanovaccine. B) More CD8
+
 T cells are present in the 
peripheral blood of young mice immunized with the combination nanovaccine. C) CD4
+
 T cells 
in aged mice express more proinflammatory cytokines across all treatment groups in comparison 
to that in young mice. D) The combination nanovaccine showed higher levels of cytokine 
expression by CD8
+
 T cells even though it was not statistically significant. N = 8 mice per group. 
Statistical significance determined by p values less than 0.05. * compares significance for mice 
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of equivalent age but different vaccine treatment group. # compares significance of a given 
treatment group across age groups.  
 
 
Figure 9.3 Immune response in pigs upon immunization with the nanovaccine. A) The 
nanovaccine induces T cell expression similarly to that induced by soluble antigen 35 days 
following vaccination. B) Post-infection analysis of lung lesions indicates that the lesions in the 
lungs of pigs immunized with the nanovaccines performed were similar to the lesions in the 
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lungs of the mock vaccinated pigs. C) Post-infection the body temperature of pigs immunized 
with the nanovaccine vaccine is slightly lower than that of unvaccinated pigs and pigs receiving 
the soluble vaccine. N = 7-8 pigs per group. 
 
